unsd_region,unsd_subregion,countryname,iso2,iso3,unsd_ldc,unsd_lld,unsd_sids,unsd_dev,Entity,covax,incomegroup,wb_region,wb_gdp2021,y2021GGXWDG_NGDP,y2021NGDPDPC,numericcode,latitudeaverage,longitudeaverage,hdirank,hdi,hdi_cat,m49code,un_population2020,pop_total,vaccinesdelivered,req70,deliveredpopulation,vaccinesdelivered_lag,informcovid19risk,covid19riskclass,gap_percapita,gap_gghe,uhc,che,h7_vaccinationpolicy,e4_internationalsupport,h5_investmentinvaccines,h5_dummyinvestment,date,stringencyindex,governmentresponseindex,containmenthealthindex,economicsupportindex,h7_name,who_region,data_source,date_updated,total_vaccinations,persons_vaccinated_1plus_dose,total_vaccinations_per100,persons_vaccinated_1plus_dose_pe,persons_fully_vaccinated,persons_fully_vaccinated_per100,vaccines_used,number_vaccines_types_used,first_vaccine_date,date_reported,new_cases,cumulative_cases,new_deaths,cumulative_deaths,whoregion,casescumulativetotal,casescumulativetotalper100000pop,casesnewlyreportedinlast7days,casesnewlyreportedinlast7daysper,casesnewlyreportedinlast24hours,deathscumulativetotal,deathscumulativetotalper100000po,deathsnewlyreportedinlast7days,deathsnewlyreportedinlast7dayspe,deathsnewlyreportedinlast24hours,vac_willingness_date,vac_willingness_errormargin,vaccine_willingness_monthly,v3_vaccinefinancialsupportsummar,v3_name,total_cases,new_cases_smoothed,total_deaths,new_deaths_smoothed,total_cases_per_million,new_cases_per_million,new_cases_smoothed_per_million,total_deaths_per_million,new_deaths_per_million,new_deaths_smoothed_per_million,reproduction_rate,icu_patients,icu_patients_per_million,hosp_patients,hosp_patients_per_million,weekly_icu_admissions,weekly_icu_admissions_per_millio,new_vaccinations_smoothed_per_mi,stringency_index,population,population_density,median_age,aged_65_older,aged_70_older,gdp_per_capita,extreme_poverty,cardiovasc_death_rate,diabetes_prevalence,female_smokers,male_smokers,handwashing_facilities,hospital_beds_per_thousand,life_expectancy,human_development_index,excess_mortality,time,weekly_hosp_admissions,weekly_hosp_admissions_per_milli,total_boosters,total_boosters_per_hundred,people_vaccinated,people_fully_vaccinated,new_vaccinations,new_vaccinations_smoothed,total_vaccinations_per_hundred,people_vaccinated_per_hundred,people_fully_vaccinated_per_hund,continent,dec40target,dec40target_name,securedvaccineofpopulation,total_donations,cost_gdp_income70,cost_gdp_income40,pricebracket_che,pricebracket_che70,pricebracket_che40,utilrate_current,utilrate_lag,donationsoftotal
Americas,Latin America and the Caribbean,Aruba,AW,ABW,,,x,Developing,Aruba,0,High Income Economies,Latin America and the Caribben,2569000000,117.468,25700.87,,,,,,,533,106.766,106766,184836,150073,172.43,180784,,,,,,,5,0,0,0,20220224,25,34.900002,36.310001,25,Universal availability,AMRO,REPORTING,2022-02-25,167759,87350,157.12801,81.814003,80409,75.313004,"Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty",2,17Feb2021,2022-03-08,48,33732,1,212,Americas,33732,31594.328,48,44.958,48,212,198.565,1,0.93699998,1,,,,5,All eligible groups are fully government-funded,33732,6.8569999,212,0.14300001,314678.84,0,63.969002,1977.704,0,1.3329999,,,,,,,,280,25,107195,584.79999,41.200001,13.085,7.4520001,35973.781,,,11.62,,,,,76.290001,,80.199997,08Mar2022,,,,,87511,80582,5076,2679,156.81,81.639999,75.169998,North America,1,Target reached,,,0.072122075,0.041212611,,,,90.761002,92.795273,
Asia,Southern Asia,Afghanistan,AF,AFG,x,x,,Developing,Afghanistan,1,Low Income Economies,South Asia,19692000000,,,4,33,65,169,0.511,Low human development,4,38928.341,38928340,,55769599,27.95,,6.8,Very High,1.05,43.5,37,65.80603027,1,152400000,113000000,1,20220307,19.440001,16.879999,19.290001,0,Availability for ONE or TWO of following: key workers/clinically vulnerable groups (non elderly)/elderly groups,EMRO,REPORTING,2022-03-06,5597130,4952744,14.378,12.723,4281934,11,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",4,22Feb2021,2022-03-08,418,175000,3,7626,Eastern Mediterranean,175000,449.54401,1341,3.4449999,418,7626,19.59,28,0.071999997,3,2021-10-01,7.50%,68,5,All eligible groups are fully government-funded,175353,210.571,7630,3,4401.936,8.8610001,5.2859998,191.53799,0.1,0.075000003,0.76999998,,,,,,,222,19.440001,39835428,54.422001,18.6,2.5810001,1.337,1803.9871,,597.02899,9.5900002,,,37.745998,0.5,64.830002,0.51099998,,08Mar2022,,,,,4952744,4281934,6868,70761,14.05,12.43,10.75,Asia,0,Target not reached,66.40133667,3700000,,,17.44521,12.211647,6.9780841,,,
Africa,Sub-Saharan Africa,Angola,AO,AGO,x,,,Developing,Angola,1,Lower Middle Income Economies,Sub-Saharan Africa,68072000000,103.713,2200.68,24,-12.5,18.5,148,0.581,Medium human development,24,32866.268,32866268,37744357,47507055,111.23,37744357,5.6,High,,,40,71.32600403,5,0,88000000,1,20220307,60.189999,59.900002,68.449997,0,Universal availability,AFRO,REPORTING,2022-03-02,16633167,10780927,50.609001,32.801998,5609044,17.066,SII - Covishield,1,10Mar2021,2022-03-08,0,98806,0,1900,Africa,98806,300.63,65,0.198,0,1900,5.7810001,0,0,0,2022-01-01,2.50%,96.4,5,All eligible groups are fully government-funded,98829,11.857,1900,0,2912.4221,0.67799997,0.34900001,55.992001,0,0,0.97000003,,,,,,,1376,60.189999,33933611,23.889999,16.799999,2.405,1.362,5819.4951,,276.04501,3.9400001,,,26.664,,61.150002,0.58099997,,08Mar2022,,,227810,0.67000002,10780927,5609044,,183173,49.02,31.77,16.530001,Africa,0,Target not reached,96.25269318,1520000,0.43831906,0.25046805,19.319742,13.523819,7.7278967,44.067959,44.067959,4.027092
Americas,Latin America and the Caribbean,Anguilla,AI,AIA,,,x,Developing,Anguilla,0,Unclassified Economies,Unclassified,,,,,,,,,,660,15.002,15002,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,22165,10370,147.74699,69.124001,9531,63.532001,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty",2,05Feb2021,2022-03-08,0,2555,0,9,Americas,2555,17031.063,27,179.976,0,9,59.992001,0,0,0,,,,,,2574,2.714,9,0,170181.81,0,179.457,595.04102,0,0,,,,,,,,2446,,15125,,,,,,,,,,,,,81.879997,,,08Mar2022,,,2389,15.8,10439,9549,1421,331,147.95,69.019997,63.130001,North America,1,Target reached,,,,,,,,,,
Europe,Northern Europe,Åland Islands,AX,ALA,,,,Developed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Europe,Southern Europe,Albania,AL,ALB,,,,Developed,Albania,0,Upper Middle Income Economies,Europe and Central Asia,14763000000,81.475,5837.18,8,41,20,69,0.795,High human development,8,2877.8,2877800,2979520,4022108,103.71,2686193,4.2,Medium,1.24,0.8,59,,5,0,6900000,1,20220305,35.189999,37.5,42.860001,0,Universal availability,EURO,REPORTING,2022-02-20,2707658,1284034,94.099998,45.118,1192155,41.889,"AstraZeneca - Vaxzevria,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",5,13Jan2021,2022-03-08,40,272250,1,3483,Europe,272250,9460.3516,687,23.872,40,3483,121.03,14,0.486,1,2022-01-01,2.50%,85.6,5,All eligible groups are fully government-funded,272337,90.713997,3483,1.571,94794.031,30.283001,31.575001,1212.349,0,0.54699999,0.51999998,,,,,,,967,35.189999,2872934,104.871,38,13.188,8.6429996,11803.431,1.1,304.19501,10.08,7.0999999,51.200001,,2.8900001,78.57,0.79500002,36.790001,08Mar2022,,,239070,8.3199997,1270745,1198759,23655,17565,94.279999,44.23,41.73,Europe,1,Target reached,62.05459213,360975,0.24799646,0.14171226,,,,90.875641,100.79909,12.115207
Europe,Southern Europe,Andorra,AD,AND,,,,Developed,Andorra,0,High Income Economies,Europe and Central Asia,,51.562,40417.27,20,42.5,1.6,36,0.868,High human development,20,77.265,77265,,,,,,,,,,2744.194336,5,473499125,0,0,20220307,23.15,46.349998,42.259998,75,Universal availability,EURO,REPORTING,2022-02-13,142420,57797,184.3,75.872002,53250,69.903,"AstraZeneca - Vaxzevria,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,20Jan2021,2022-03-08,186,38620,0,151,Europe,38620,49983.82,621,803.72699,186,151,195.431,0,0,0,2022-01-01,3.90%,85.9,5,All eligible groups are fully government-funded,38710,77.857002,152,0.14300001,500426.63,1163.4821,1006.504,1964.9919,12.928,1.847,0.88999999,,,,,,,840,23.15,77354,163.755,,,,,,109.135,7.9699998,29,37.799999,,,83.730003,0.86799997,31.41,08Mar2022,,,24732,31.969999,57797,53250,2829,1762,184.11,74.720001,68.839996,Europe,1,Target reached,101.2630234,,0.045861583,0.026206618,0.96494621,0.67546237,0.38597849,,,
Asia,Western Asia,United Arab Emirates,AE,ARE,,,,Developing,United Arab Emirates,0,High Income Economies,Middle East and North Africa,373145000000,37.32,43537.69,784,24,54,31,0.89,High human development,784,9890.4,9890400,26621242,13987516,266.45,25185522,2.5,Low,,,76,1842.694458,5,0,5000000,1,20220228,21.299999,31.77,36.310001,0,Universal availability,EMRO,REPORTING,2022-03-03,24247279,9991089,245.16,101.018,9618421,97.25,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty,SII - Covishield",5,14Dec2020,2022-03-08,386,883270,1,2302,Eastern Mediterranean,883270,8930.5771,3297,33.334999,386,2302,23.275,1,0.0099999998,1,2022-01-01,2.50%,97.7,5,All eligible groups are fully government-funded,883593,448.85699,2302,0.14300001,88438.156,32.328999,44.925999,230.405,0,0.014,0.66000003,,,,,,,1626,21.299999,9991083,112.442,34,1.1440001,0.52600002,67293.484,,317.84,17.26,1.2,37.400002,,1.2,77.970001,0.88999999,,08Mar2022,,,4817674,48.220001,9890523,9524573,220000,155312,242.53999,98.989998,95.330002,Asia,1,Target reached,132.9156494,,0.042574607,0.024328345,1.437026,1.0059183,0.57481045,91.082451,96.274673,
Americas,Latin America and the Caribbean,Argentina,AR,ARG,,,,Developing,Argentina,0,Upper Middle Income Economies,Latin America and the Caribben,416938000000,,9929.15,32,-34,-64,46,0.845,High human development,32,45195.777,45195776,103488733,63848152,226.92,99589433,3.4,Low,,,76,945.9919434,5,0,100000000,1,20220221,37.040001,48.959999,48.810001,50,Universal availability,AMRO,REPORTING,2022-02-25,93008081,40572052,205.789,89.769997,36237826,80.18,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,CanSino - Convidecia,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",7,29Dec2020,2022-03-08,6286,8942888,74,126842,Americas,8942888,19787,42232,93.442001,6286,126842,280.64999,690,1.527,74,2022-01-01,2.50%,96,5,All eligible groups are fully government-funded,8949362,6455.1431,126901,92,196232.88,141.95599,141.54201,2782.561,1.294,2.017,0.61000001,1076,23.593,,,,,2084,37.040001,45605823,16.177,31.9,11.198,7.441,18933.906,0.60000002,191.032,5.5,16.200001,27.700001,,5,76.669998,0.84500003,28.58,08Mar2022,,,17279249,37.889999,40412075,36228146,1297018,440583,206.58,88.610001,79.440002,South America,1,Target reached,148.3648224,3900000,0.14579295,0.083310254,2.1860652,1.5302455,0.87442607,89.872665,93.391518,3.7685261
Asia,Western Asia,Armenia,AM,ARM,,x,,Developing,Armenia,0,Upper Middle Income Economies,Europe and Central Asia,13146000000,62.15,4594.91,51,40,45,81,0.776,High human development,51,2963.234,2963234,2261417,4155379,76.19,2043853,3.6,Medium,1.04,2,69,523.9990845,,,,,,,,,,,EURO,REPORTING,2022-02-13,1971565,1080404,66.5,36.459999,872336,29.438999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Sinovac - CoronaVac",5,16Jun2021,2022-03-08,0,421401,0,8548,Europe,421401,14220.983,1245,42.014999,0,8548,288.46899,70,2.362,0,2022-01-01,3.10%,82.2,,,421541,197.85699,8552,10.571,142022.52,47.167999,66.661003,2881.2771,1.348,3.562,0.28999999,,,,,,,1870,,2968128,102.931,35.700001,11.232,7.5710001,8787.5801,1.8,341.01001,7.1100001,1.5,52.099998,94.042999,4.1999998,75.089996,0.77600002,13.99,08Mar2022,,,23230,0.77999997,1087524,920978,,17910,68.449997,36.639999,31.030001,Asia,0,Target not reached,56.43961334,883200,0.31504425,0.18002529,3.9465718,2.7626002,1.5786287,87.182724,96.46315,39.055161
Oceania,Polynesia,American Samoa,AS,ASM,,,x,Developing,American Samoa,0,Upper Middle Income Economies,East Asia and Pacific,,,,,,,,,,16,55.197,55197,,,,,,,,,,,,,,,,,,,,,WPRO,REPORTING,2022-02-16,85050,42212,154.084,76.474998,37805,68.490997,"Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,21Dec2020,2022-03-08,12,304,0,0,Western Pacific,304,550.755,220,398.57199,12,0,0,0,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,Antarctica,AQ,ATA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Africa,Sub-Saharan Africa,French Southern Territories,TF,ATF,,,,Developing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Americas,Latin America and the Caribbean,Antigua and Barbuda,AG,ATG,,,x,Developing,Antigua and Barbuda,0,High Income Economies,Latin America and the Caribben,1468000000,105.219,14117.84,28,17.05,-61.8,78,0.778,High human development,28,97.928,97928,212354,138219,215.09,212354,3.6,Medium,,,73,760.2649536,,,,,,,,,,,AMRO,REPORTING,2022-02-25,124726,63582,127.364,64.927002,61144,62.437,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",6,01Mar2021,2022-03-08,0,7455,0,135,Americas,7455,7612.6582,18,18.381001,0,135,137.855,0,0,0,2021-08-01,10.00%,81.9,,,7455,1.143,135,0,75510.492,0,11.576,1367.3929,0,0,0.34999999,,,,,,,658,,98728,231.845,32.099998,6.9330001,4.631,21490.943,,191.511,13.17,,,,3.8,77.019997,0.778,-20.16,08Mar2022,,,,,63704,61327,2221,1278,126.64,64.519997,62.119999,North America,1,Target reached,108.8596954,113950,0.13129488,0.07502564,3.4829962,2.4380975,1.3931985,58.734943,58.734943,53.660397
Oceania,Australia and New Zealand,Australia,AU,AUS,,,,Developed,Australia,0,High Income Economies,East Asia and Pacific,1480360000000,62.06,62618.59,36,-27,133,8,0.944,High human development,36,25499.881,25499880,64032144,36103504,248.3,57677927,2.1,Low,,,87,5427.462402,5,773231831,4703229758,1,20220304,43.98,46.610001,53.27,0,Universal availability,WPRO,REPORTING,2022-02-27,54043583,22047151,211.937,86.459999,20475638,80.296997,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Novavax - Covavax,Pfizer BioNTech - Comirnaty",5,21Feb2021,2022-03-08,23849,3010761,32,5448,Western Pacific,3010761,11806.96,168944,662.52899,23849,5448,21.365,277,1.086,32,2022-01-01,2.50%,94.4,5,All eligible groups are fully government-funded,3459870,29014,5495,32.285999,134164.77,1190.1169,1125.087,213.082,1.202,1.252,1.05,116,4.4980001,1787,69.294998,,,2365,43.98,25788217,3.2019999,37.900002,15.504,10.129,44648.711,0.5,107.791,5.0700002,13,16.5,,3.8399999,83.440002,0.94400001,-3.0699999,08Mar2022,,,11874570,46.049999,22093332,20524493,351226,295848,211.31,85.669998,79.589996,Oceania,1,Target reached,495.019928,,0.029601432,0.016915105,0.48788914,0.3415224,0.19515567,84.400711,93.698898,
Europe,Western Europe,Austria,AT,AUT,,,,Developed,Austria,0,High Income Economies,Europe and Central Asia,490395000000,84.202,53793.37,40,47.3333,13.3333,18,0.922,High human development,40,9006.4,9006400,31249239,12660301,345.56,29040018,3,Low,,,79,5242.183105,5,5227200,1085695,1,20220307,43.52,65.099998,60.119999,100,Universal availability,EURO,REPORTING,2022-02-20,17855030,6791963,200.60001,76.305,6547061,73.554001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,26652,2919373,27,14444,Europe,2919373,32798.023,220870,2481.3889,26652,14444,162.27299,231,2.595,27,2022-01-01,2.50%,83.2,5,All eligible groups are fully government-funded,2924852,31474.57,15071,32.856998,323435.66,3421.293,3480.5181,1666.58,4.9759998,3.6329999,1.03,190,21.011,2655,293.595,,,540,43.52,9043072,106.749,44.400002,19.202,13.748,45436.688,0.69999999,145.183,6.3499999,28.4,30.9,,7.3699999,81.540001,0.92199999,2.4000001,08Mar2022,,,5034911,55.68,6803599,6572038,,112548,199.72,75.239998,72.669998,Europe,1,Target reached,314.4679871,,0.034457777,0.01969016,0.50513303,0.35359314,0.20205322,57.137489,61.484226,
Asia,Western Asia,Azerbaijan,AZ,AZE,,x,,Developing,Azerbaijan,0,Upper Middle Income Economies,Europe and Central Asia,45018000000,28.88,5167.38,31,40.5,47.5,88,0.756,High human development,31,10139.175,10139175,13992690,14312682,136.87,12924351,4,Medium,0.54,1.3,65,193.1088409,5,10000000,0,0,20220222,46.299999,54.169998,51.189999,75,Universal availability,EURO,REPORTING,2022-02-20,12659541,5309691,124.9,52.368,4779944,47.143002,"AstraZeneca - Vaxzevria,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",4,20Jan2021,2022-03-08,149,789481,13,9531,Europe,789481,7786.4419,3811,37.587002,149,9531,94.001999,114,1.124,13,2022-01-01,2.50%,88.7,,No availability,789757,465,9547,15.571,77250.359,26.997,45.484001,933.84302,1.5650001,1.523,0.33000001,,,,,,,2168,46.299999,10223344,119.309,32.400002,6.0180001,3.8710001,15847.419,,559.81201,7.1100001,0.30000001,42.5,83.240997,4.6999998,73,0.75599998,48.779999,08Mar2022,,,2842070,27.799999,5308772,4795324,116709,85991,128.72,51.93,46.91,Asia,1,Target reached,68.43283081,150000,0.28014198,0.16008112,10.708986,7.4962907,4.2835946,90.472534,97.95108,1.0719883
Africa,Sub-Saharan Africa,Burundi,BI,BDI,x,x,,Developing,Burundi,1,Low Income Economies,Sub-Saharan Africa,3266000000,72.433,261.053,108,-3.5,30,185,0.433,Low human development,108,11890.781,11890781,802731,17157601,6.55,802731,6.5,Very High,1.82,33.9,42,20.56754112,3,0,0,0,20220307,25,25.1,28.690001,0,Availability for ALL of following: key workers/ clinically vulnerable groups (non elderly)/elderly groups,AFRO,REPORTING,2022-03-04,11502,9738,0.097000003,0.082000002,9181,0.077,Beijing CNBG - BBIBP-CorV,1,18Oct2021,2022-03-08,0,38178,0,15,Africa,38178,321.07199,44,0.37,0,15,0.126,0,0,0,,,,5,All eligible groups are fully government-funded,38178,7.2859998,38,0,3115.1909,0,0.59399998,3.1010001,0,0,0.69999999,,,,,,,4,25,12255429,423.06201,17.5,2.562,1.5039999,702.22498,71.699997,293.06799,6.0500002,,,6.1440001,0.80000001,61.580002,0.433,,08Mar2022,,,,,9738,9181,109,410,0.090000004,0.079999998,0.07,Africa,0,Target not reached,62.03991318,500000,3.0783021,1.7590297,55.816105,39.071274,22.326441,1.4328586,1.4328586,62.287365
Europe,Western Europe,Belgium,BE,BEL,,,,Developed,Belgium,0,High Income Economies,Europe and Central Asia,576768000000,113.416,50412.71,56,50.8333,4,14,0.931,High human development,56,11589.616,11589616,25393385,16285268,218.3,24252254,2.8,Low,,,84,4960.393555,5,0,27427500,1,20220307,46.299999,56.77,61.310001,25,Universal availability,EURO,REPORTING,2022-02-20,24601511,9199837,213.5,79.843002,9038321,78.441002,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,7,3601627,2,30296,Europe,3601627,31257.504,34719,301.31601,7,30296,262.92999,88,0.764,2,2022-01-01,2.50%,90.9,5,All eligible groups are fully government-funded,3609122,6468.7139,30313,16.285999,310266.38,644.32501,556.09802,2605.926,1.461,1.4,0.75999999,206,17.709,2069,177.866,,,749,46.299999,11632334,375.564,41.799999,18.570999,12.849,42658.574,0.2,114.898,4.29,25.1,31.4,,5.6399999,81.629997,0.93099999,0.37,08Mar2022,989,85.022003,7204260,61.93,9221824,9092136,197613,154974,215.7,79.279999,78.160004,Europe,1,Target reached,314.4679871,,0.036768507,0.021010574,0.53382862,0.37368003,0.21353145,96.881577,101.4401,
Africa,Sub-Saharan Africa,Benin,BJ,BEN,x,,,Developing,Benin,1,Lower Middle Income Economies,Sub-Saharan Africa,17489000000,52.26,1446.83,204,9.5,2.25,158,0.545,Low human development,204,12123.198,12123198,3923320,17431443,31.51,3923320,5.8,High,0.84,14.9,40,29.12529182,5,4500000,0,0,20220219,55.560001,54.169998,54.759998,50,Universal availability,AFRO,REPORTING,2022-02-22,2788620,2591583,23.002001,21.377001,2013843,16.611,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",5,29Mar2021,2022-03-08,0,26575,0,163,Africa,26575,219.20799,0,0,0,163,1.345,0,0,0,2022-01-01,4.10%,85.3,5,All eligible groups are fully government-funded,26575,1.143,163,0,2134.3611,0,0.092,13.091,0,0,0.38999999,,,,,,,1772,55.560001,12451031,99.110001,18.799999,3.244,1.942,2064.2361,49.599998,235.84801,0.99000001,0.60000002,12.3,11.035,0.5,61.77,0.54500002,,08Mar2022,,,,,2591583,2013843,,60281,22.4,20.809999,16.17,Africa,0,Target not reached,42.2223053,100000,0.66669893,0.38097081,47.312832,33.11898,18.925133,71.078064,71.078064,2.5488617
Americas,Latin America and the Caribbean,Bonaire Sint Eustatius and Saba,BQ,BES,,,x,Developing,Bonaire Sint Eustatius and Saba,0,Unclassified Economies,Unclassified,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2021-04-09,7391,5726,28.441,22.034,2965,11.41,"Moderna - Spikevax,Pfizer BioNTech - Comirnaty",2,22Feb2021,2022-03-08,3,472,0,3,Americas,211,10915.675,3,155.19901,2,0,0,0,0,0,,,,,,7633,5.7140002,31,0,288636.78,415.95801,216.082,1172.244,0,0,,,,,,,,7412,,26445,,,,,,,,,,,,,77.790001,,,08Mar2022,,,,,19109,16736,,196,135.55,72.260002,63.290001,North America,1,Target reached,,,,,,,,,,
Africa,Sub-Saharan Africa,Burkina Faso,BF,BFA,x,x,,Developing,Burkina Faso,1,Low Income Economies,Sub-Saharan Africa,18314000000,48.182,926.2,854,13,-2,182,0.452,Low human development,854,20903.278,20903278,6249206,30095936,29.07,6249206,6.3,High,1.65,10.5,40,42.3445282,5,80000000,0,0,20220227,13.89,23.440001,26.790001,0,Universal availability,AFRO,REPORTING,2022-03-06,2330052,2117997,11.147,10.132,1152574,5.5139999,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,SII - Covishield",3,02Jun2021,2022-03-08,0,20751,0,375,Africa,20751,99.272003,0,0,0,375,1.794,0,0,0,2022-01-01,4.80%,72.5,,No availability,20751,0,375,0,965.29303,0,0,17.444,0,0,0.20999999,,,,,,,64,13.89,21497097,70.151001,17.6,2.4089999,1.358,1703.1021,43.700001,269.048,2.4200001,1.6,23.9,11.877,0.40000001,61.580002,0.45199999,,08Mar2022,,,,,2117997,1152574,,39484,10.84,9.8500004,5.3600001,Africa,0,Target not reached,60.93035889,400000,0.8676312,0.49578926,27.110941,18.977659,10.844377,37.285568,37.285568,6.4008131
Asia,Southern Asia,Bangladesh,BD,BGD,x,,,Developing,Bangladesh,1,Lower Middle Income Economies,South Asia,338385000000,39.937,2138.79,50,24,90,133,0.632,Medium human development,50,164689.383,164689376,457683832,232824892,275.21,419450675,5.2,High,0.32,4.6,48,45.85716248,5,501500000,0,0,20220212,68.519997,65.620003,75,0,Universal availability,SEARO,REPORTING,2022-03-01,213176935,124691912,129.442,75.712997,84611747,51.376999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",8,27Jan2021,2022-03-08,0,1947702,0,29089,South-East Asia,1947702,1182.652,3326,2.02,0,29089,17.663,44,0.027000001,0,2022-01-01,2.50%,98.7,5,All eligible groups are fully government-funded,1948148,538.85699,29096,7.2859998,11714.414,2.6819999,3.24,174.957,0.041999999,0.044,0.34,,,,,,,6296,68.519997,166303494,1265.036,27.5,5.098,3.2620001,3523.9839,14.8,298.00299,8.3800001,1,44.700001,34.807999,0.80000001,72.589996,0.63200003,,08Mar2022,,,4367133,2.6300001,125588721,87310746,6758992,3758404,130.64,75.519997,52.5,Asia,1,Target reached,137.6074829,27758090,0.45100266,0.25771582,30.049831,21.034882,12.019933,46.577335,50.822884,6.0649052
Europe,Eastern Europe,Bulgaria,BG,BGR,,,,Developed,Bulgaria,0,Upper Middle Income Economies,Europe and Central Asia,77971000000,24.964,11331.87,100,43,25,56,0.816,High human development,100,6948.445,6948445,8327711,9655317,120.75,8327711,3.7,Medium,,,66,697.8963623,5,0,79094046.73,1,20220221,44.439999,57.810001,53.57,87.5,Universal availability,EURO,REPORTING,2022-02-20,4275051,2073249,61.5,29.825001,2031747,29.228001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,2462,1103788,91,35923,Europe,1103788,15878.456,12509,179.94701,2462,35923,516.76801,342,4.9200001,91,2022-01-01,2.50%,66.4,5,All eligible groups are fully government-funded,1105968,1721.1429,35964,46.714001,160362.95,316.095,249.562,5214.7021,5.9450002,6.7729998,0.57999998,498,72.209,4233,613.776,,,251,44.439999,6896655,65.18,44.700001,20.801001,13.272,18563.307,1.5,424.68799,5.8099999,30.1,44.400002,,7.454,75.050003,0.81599998,55.130001,08Mar2022,,,695856,10.09,1904143,2049790,38117,27038,62.529999,27.610001,29.719999,Europe,0,Target not reached,314.4679871,,0.12774591,0.072997659,2.9631908,2.0742335,1.1852763,51.335247,51.335247,
Asia,Western Asia,Bahrain,BH,BHR,,,,Developing,Bahrain,0,High Income Economies,Middle East and North Africa,36602000000,123.35,26293.95,48,26,50.55,42,0.852,High human development,48,1701.583,1701583,3712854,2447613,212.37,3613901,3.9,Medium,,,77,940.3956909,5,0,0,0,20220221,38.889999,51.040001,58.330002,0,Universal availability,EMRO,REPORTING,2022-03-06,3410306,1231321,200.42101,72.363998,1212914,71.281998,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Gamaleya - Sputnik-Light,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",8,04Nov2020,2022-03-08,1699,528834,1,1459,Eastern Mediterranean,528834,31079.088,13951,819.88702,1699,1459,85.744003,5,0.294,1,2022-01-01,9.00%,89.8,5,All eligible groups are fully government-funded,530730,1870.714,1461,0.85699999,303570.06,1084.485,1070.022,835.67102,1.1440001,0.49000001,0.69999999,,,,,,,1117,38.889999,1748295,1935.907,32.400002,2.372,1.387,43290.703,,151.689,16.52,5.8000002,37.599998,,2,77.290001,0.852,,08Mar2022,,,950713,54.380001,1227305,1197343,81811,22003,193.07001,70.199997,68.489998,Asia,1,Target reached,106.1862259,100000,0.070495307,0.040283032,2.815836,1.9710852,1.1263344,91.851334,94.366341,2.6933458
Americas,Latin America and the Caribbean,Bahamas,BS,BHS,,,x,Developing,Bahamas,0,High Income Economies,Latin America and the Caribben,12275000000,102.546,27437.2,44,24.25,-76,58,0.814,High human development,44,393.248,393248,545280,555680,137.38,512853,3.9,Medium,,,75,2004.616333,5,0,1600000,1,20220307,62.959999,58.849998,67.260002,0,Universal availability,AMRO,REPORTING,2022-02-25,327515,163061,83.285004,41.466,153878,39.130001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",4,14Mar2021,2022-03-08,0,33172,0,771,Americas,33172,8435.4746,37,9.4090004,0,771,196.061,0,0,0,2022-01-01,8.70%,83.7,5,All eligible groups are fully government-funded,33180,4.8569999,771,0,83594.938,10.078,12.237,1942.486,0,0,0.63,,,,,,,655,62.959999,396914,39.497002,34.299999,8.9960003,5.1999998,27717.848,,235.95399,13.17,3.0999999,20.4,,2.9000001,73.919998,0.81400001,,08Mar2022,,,22009,5.5500002,163061,153878,6771,3473,82.519997,41.080002,38.77,North America,0,Target not reached,81.91069031,318350,0.067557916,0.038604524,1.320951,0.92466569,0.52838039,60.063637,63.861378,58.382851
Europe,Southern Europe,Bosnia and Herzegovina,BA,BIH,,,,Developed,Bosnia and Herzegovina,0,Upper Middle Income Economies,Europe and Central Asia,21328000000,38.927,6647.83,70,44,18,73,0.78,High human development,70,3280.815,3280815,2781120,4568843,85.22,2781120,4.2,Medium,0.65,0.2,61,553.822937,5,0,9190000,1,20220307,36.110001,39.580002,45.240002,0,Universal availability,EURO,REPORTING,2022-01-29,1924950,943394,58.700001,28.754999,846080,25.789,"AstraZeneca - AZD1222, Pfizer BioNTech - Comirnaty, Sinovac - CoronaVac, Gamaleya - Sputnik V",4,,2022-03-08,96,372478,14,15575,Europe,372478,11353.216,1276,38.893002,96,15575,474.73001,116,3.536,14,2022-01-01,2.50%,77.1,5,All eligible groups are fully government-funded,372645,180.571,15590,17.143,114187.13,51.173,55.331001,4777.1401,4.5960002,5.2529998,0.56,,,,,,,1322,36.110001,3263459,68.496002,42.5,16.569,10.711,11713.895,0.2,329.63501,10.08,30.200001,47.700001,97.164001,3.5,77.400002,0.77999997,42.59,08Mar2022,,,120530,3.6900001,943394,846080,66884,17247,58.98,28.91,25.93,Europe,0,Target not reached,62.11323547,2316440,0.21775527,0.12443158,3.7340455,2.6138318,1.4936181,69.21492,69.21492,83.291626
Americas,Latin America and the Caribbean,Saint Barthélemy,BL,BLM,,,,Developing,Saint Barthélemy,0,Unclassified Economies,Unclassified,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2022-03-08,0,3726,0,4,Americas,3726,37693.477,15,151.745,0,4,40.465,0,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Europe,Eastern Europe,Belarus,BY,BLR,,,,Developed,Belarus,0,Upper Middle Income Economies,Europe and Central Asia,60969000000,44.862,7032.48,112,53,28,53,0.823,High human development,112,9449.321,9449321,11714821,13220014,124.06,11478749,3.8,Medium,1.08,0.4,76,399.3970947,4,0,0,0,20220228,23.15,25.83,29.52,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,EURO,REPORTING,2022-02-20,10649534,5528298,112.7,58.505001,4632574,49.025002,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac",2,03Feb2021,2022-03-08,1205,932207,13,6579,Europe,932207,9865.333,12471,131.978,1205,6579,69.624001,99,1.048,13,2022-01-01,2.50%,70.1,5,All eligible groups are fully government-funded,932949,1669.429,6594,14.429,98799.336,78.578003,176.793,698.30499,1.589,1.528,0.5,,,,,,,3382,23.15,9442867,46.858002,40.299999,14.799,9.7880001,17167.967,,443.129,5.1799998,10.5,46.099998,,11,74.790001,0.82300001,1.61,08Mar2022,,,275734,2.9200001,5528298,4632574,,77113,112.78,58.540001,49.060001,Europe,1,Target reached,62.02823257,3010000,0.20584488,0.11762565,5.1778045,3.6244631,2.0711217,90.906502,92.776085,25.693949
Americas,Latin America and the Caribbean,Belize,BZ,BLZ,,,x,Developing,Belize,0,Lower Middle Income Economies,Latin America and the Caribben,1691000000,117.892,4457.89,84,17.25,-88.75,110,0.716,High human development,84,397.621,397621,814244,566881,201.09,814244,3.8,Medium,,,64,293.4125977,5,12631000,0,0,20220207,77.779999,73.959999,77.379997,50,Universal availability,AMRO,REPORTING,2022-02-25,458351,234370,115.271,58.942001,206583,51.953999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",5,01Mar2021,2022-03-08,0,56876,0,651,Americas,56876,14303.822,279,70.166,0,651,163.72099,1,0.25099999,0,2022-01-01,9.90%,92.9,,No availability,56952,25.570999,652,0.28600001,140651.73,187.694,63.153,1610.214,2.47,0.70599997,0.52999997,,,,,,,882,77.779999,404915,16.426001,25,3.8529999,2.279,7824.3618,,176.957,17.110001,,,90.083,1.3,74.620003,0.71600002,51.099998,08Mar2022,,,39225,9.6899996,234810,207253,10917,4569,113.81,57.990002,51.18,North America,1,Target reached,120.4979706,506150,0.2163804,0.12364594,4.6964583,3.2875206,1.8785833,56.291603,56.291603,62.161957
Americas,Northern America,Bermuda,BM,BMU,,,,Developed,Bermuda,0,High Income Economies,North America,,,,,,,,,,60,62.273,62273,137596,86929,221.6,125668,,,,,,,5,0,0,0,20220219,44.439999,59.900002,57.740002,75,Universal availability,AMRO,REPORTING,2022-02-25,124342,46961,199.672,75.411003,46119,74.058998,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty",2,11Jan2021,2022-03-08,0,11634,0,123,Americas,11634,18682.254,121,194.306,0,123,197.517,0,0,0,,,,5,All eligible groups are fully government-funded,11743,26,123,0,189122.59,1755.46,418.733,1980.932,0,0,,,,,,,,1707,44.439999,62092,1308.8199,,,,50669.316,,139.547,13,,,,,82.589996,,-1.1,08Mar2022,,,31502,50.73,47336,46247,,1224,201.45,76.239998,74.480003,North America,1,Target reached,,,,,,,,90.367455,98.944839,
Americas,Latin America and the Caribbean,Bolivia (Plurinational State of),BO,BOL,,x,,Developing,Bolivia,1,Lower Middle Income Economies,Latin America and the Caribben,43039000000,82.748,3266.69,68,-17,-65,107,0.718,High human development,68,11673.029,11673029,22834017,16566110,192.97,22834017,4.9,Medium,0.78,0.5,68,245.9234772,5,0,0,0,20220307,50,46.880001,53.57,0,Universal availability,AMRO,REPORTING,2022-02-25,12606278,6944412,107.995,59.491001,5614579,48.098999,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",6,30Jan2021,2022-03-08,0,895098,0,21463,Americas,895098,7668.0918,1586,13.587,0,21463,183.868,22,0.18799999,0,2022-01-01,2.50%,94.4,5,All eligible groups are fully government-funded,895424,273.14301,21469,4,75672.172,27.549999,23.083,1814.343,0.50700003,0.338,0.44,41,3.4649999,251,21.212,,,1187,50,11832936,10.202,25.4,6.704,4.3930001,6885.8291,7.0999999,204.299,6.8899999,,,25.382999,1.1,71.510002,0.71799999,43.990002,08Mar2022,,,1048818,8.8599997,6930515,5604495,146827,107780,106.39,58.57,47.360001,South America,1,Target reached,107.1544724,3650000,0.29528362,0.16873349,5.6033692,3.9223583,2.2413476,55.208324,55.208324,15.984922
Americas,Latin America and the Caribbean,Brazil,BR,BRA,,,,Developing,Brazil,0,Upper Middle Income Economies,Latin America and the Caribben,1431620000000,90.55,7741.15,76,-10,-55,84,0.765,High human development,76,212559.409,212559408,519511886,299590817,242.77,518399111,3.5,Medium,0.09,0,79,853.3879395,5,0,148930783,1,20220307,69.910004,62.759998,68.150002,25,Universal availability,AMRO,REPORTING,2022-02-25,369527744,172334091,173.847,81.075996,148777530,69.992996,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",5,17Jan2021,2022-03-08,15961,29049013,216,652143,Americas,29049013,13666.303,280909,132.15601,15961,652143,306.80499,3009,1.416,216,2022-01-01,2.50%,96.4,5,All eligible groups are fully government-funded,29152318,47638.285,653134,458.85699,136229.95,348.08099,222.616,3052.1221,2.2709999,2.1440001,0.56999999,,,,,,,2519,69.910004,213993441,25.040001,33.5,8.552,5.0599999,14103.452,3.4000001,177.961,8.1099997,10.1,17.9,,2.2,75.879997,0.76499999,37.349998,08Mar2022,,,67303447,31.450001,178366451,155930535,3976605,1941268,185.3,83.349998,72.870003,South America,1,Target reached,170.0657196,5216600,0.18700063,0.10685751,2.4232824,1.6962976,0.96931297,71.129799,71.282478,1.0041349
Americas,Latin America and the Caribbean,Barbados,BB,BRB,,,x,Developing,Barbados,0,High Income Economies,Latin America and the Caribben,5043000000,138.259,16105.13,52,13.1667,-59.5333,58,0.814,High human development,52,287.371,287371,512235,402791,178.04,512235,4,Medium,,,77,1143.322021,5,15000,0,0,20220304,42.59,50.52,54.169998,25,Universal availability,AMRO,REPORTING,2022-02-25,309125,159958,107.569,55.661999,149167,51.907001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",5,08Jan2021,2022-03-08,111,56124,0,319,Americas,56124,19529.883,959,333.70999,111,319,111.005,3,1.044,0,2021-07-01,13.60%,89.1,5,All eligible groups are fully government-funded,56376,141.571,323,1,195948.67,542.216,492.06601,1122.666,3.4760001,3.4760001,0.75999999,,,,,,,501,42.59,287708,664.46301,39.799999,14.952,9.4729996,16978.068,,170.05,13.57,1.9,14.5,88.469002,5.8000002,79.190002,0.81400001,-3.28,08Mar2022,,,,,160485,150017,16939,4526,107.92,55.779999,52.139999,North America,1,Target reached,89.02081299,367400,0.11509376,0.065767862,2.3160579,1.6212405,0.92642313,60.348278,60.348278,71.724892
Asia,South-eastern Asia,Brunei Darussalam,BN,BRN,,,,Developing,Brunei,0,High Income Economies,East Asia and Pacific,12128000000,2.257,33979.37,96,4.5,114.6667,47,0.838,High human development,96,437.483,437483,1129527,618145,255.82,988237,3.1,Low,,,81,671.5626831,5,0,0,0,20220224,57.41,59.369999,67.860001,0,Universal availability,WPRO,REPORTING,2022-02-25,1041610,407674,238.09399,93.186996,404502,92.461998,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",5,03Apr2021,2022-03-08,4185,93034,4,98,Western Pacific,93034,21265.936,29492,6741.3521,4185,98,22.400999,22,5.0289998,4,2021-08-01,12.20%,74.1,5,All eligible groups are fully government-funded,97018,4179.4292,151,3.4289999,219730.39,9023.1289,9465.7432,341.991,9.059,7.7649999,1.58,,,,,,,4779,57.41,441532,81.347,32.400002,4.5910001,2.382,71809.25,,201.285,12.79,2,30.9,,2.7,75.860001,0.838,-7.4099998,08Mar2022,,,118331,26.799999,407674,404502,8701,7901,235.91,92.330002,91.610001,Asia,1,Target reached,127.9099808,352000,0.054550748,0.031171855,3.9430423,2.7601295,1.5772169,92.216476,105.40083,31.163486
Asia,Southern Asia,Bhutan,BT,BTN,x,x,,Developing,Bhutan,1,Lower Middle Income Economies,South Asia,2630000000,123.352,3296.11,64,27.5,90.5,129,0.654,Medium human development,64,771.612,771612,1742920,1091860,223.48,1737227,4.2,Medium,,,62,115.9807587,5,100000,0,0,20220305,73.610001,77.080002,77.379997,75,Universal availability,SEARO,REPORTING,2022-02-27,1592652,596568,206.407,77.315002,574736,74.485001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",5,27Mar2021,2022-03-08,441,15560,0,7,South-East Asia,15560,2016.568,2423,314.01999,441,7,0.90700001,1,0.13,0,,,,5,All eligible groups are fully government-funded,15560,346.14301,7,0.14300001,19951.275,565.45697,443.82999,8.9759998,0,0.183,1.2,,,,,,,1500,73.610001,779900,21.188,28.6,4.8850002,2.977,8708.5967,1.5,217.06599,9.75,,,79.806999,1.7,71.779999,0.65399998,,08Mar2022,,,351962,45.130001,596568,574736,97322,91636,204.21001,76.489998,73.690002,Asia,1,Target reached,118.946022,1032500,0.29264799,0.16722743,11.881281,8.3168964,4.7525125,91.37838,91.677826,59.239666
Americas,Latin America and the Caribbean,Bouvet Island,BV,BVT,,,,Developing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Africa,Sub-Saharan Africa,Botswana,BW,BWA,,x,,Developing,Botswana,0,Upper Middle Income Economies,Sub-Saharan Africa,17344000000,22.77,7349.88,72,-22,24,100,0.735,High human development,72,2351.625,2351625,2854394,3356136,119.07,2854394,4.7,Medium,0.4,0.1,61,481.5330505,5,0,0,0,20220228,13.89,31.25,35.709999,0,Universal availability,AFRO,REPORTING,2022-03-06,1438728,1438728,61.18,61.18,1228164,52.226002,"Bharat - Covaxin,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",6,26Mar2021,2022-03-08,0,263950,0,2619,Africa,263950,11224.144,0,0,0,2619,111.37,0,0,0,2022-01-01,13.90%,45,5,All eligible groups are fully government-funded,263950,0,2619,0,110105.79,0,0,1092.506,0,0,0.75,,,,,,,751,13.89,2397240,4.0440001,25.799999,3.941,2.2420001,15807.374,,237.37199,4.8099999,5.6999998,34.400002,,1.8,69.589996,0.73500001,,08Mar2022,,,158470,6.6100001,1438728,1228164,10435,15933,60.02,60.02,51.23,Africa,1,Target reached,120.7483215,280400,0.19695559,0.11254606,4.2946172,3.0062318,1.7178468,50.403973,50.403973,9.823451
Africa,Sub-Saharan Africa,Central African Republic,CF,CAF,x,x,,Developing,Central African Republic,1,Low Income Economies,Sub-Saharan Africa,2567000000,46.482,525.914,140,7,21,188,0.397,Low human development,140,4829.764,4829764,1419416,6887982,28.85,1419416,7.6,Very High,2.36,,33,37.19958115,4,0,0,0,20220221,18.52,28.440001,32.5,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-03-04,900298,819313,18.641001,16.964001,780030,16.15,"Bharat - Covaxin,SII - Covishield",2,19Mar2021,2022-03-08,0,14320,0,113,Africa,14320,296.495,0,0,0,113,2.3399999,0,0,0,2021-11-01,7.50%,69,5,All eligible groups are fully government-funded,14320,13.571,113,0,2910.5769,0,2.7579999,22.968,0,0,0.28,,,,,,,1294,18.52,4919987,7.4790001,18.299999,3.655,2.2509999,661.23999,,435.72699,6.0999999,,,16.603001,1,53.279999,0.39700001,,08Mar2022,,,,,819313,780030,12887,18602,18.299999,16.65,15.85,Africa,0,Target not reached,61.52439499,150000,1.5280064,0.87314653,30.860563,21.602394,12.344225,63.427353,63.427353,10.567726
Americas,Northern America,Canada,CA,CAN,,,,Developed,Canada,0,High Income Economies,North America,1763050000000,109.88,52791.23,124,60,-95,16,0.929,High human development,124,37742.157,37742156,99197363,53295078,260.58,99197363,2,Low,,,89,5048.372559,5,1179611478,10015395121,1,20220307,68.980003,64.059998,67.860001,37.5,Universal availability,AMRO,REPORTING,2022-02-25,80233844,32365984,212.584,85.755997,30693702,81.324997,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",5,14Dec2020,2022-03-08,2697,3323338,30,36986,Americas,3323338,8805.374,39801,105.455,2697,36986,97.997002,449,1.1900001,30,2022-01-01,2.50%,92.4,5,All eligible groups are fully government-funded,3349164,6002.8569,37148,63.143002,87978.664,127.719,157.688,975.83502,1.786,1.659,0.98000002,552,14.5,4453,116.975,,,1038,68.980003,38067913,4.0370002,41.400002,16.983999,10.797,44017.59,0.5,105.599,7.3699999,12,16.6,,2.5,82.43,0.92900002,-7.9000001,08Mar2022,,,17909832,47.049999,32604053,30982761,879472,545411,214.08,85.650002,81.389999,North America,1,Target reached,417.9803467,1000000,0.035111893,0.020063939,0.52452546,0.36716783,0.20981018,80.883041,80.883041,1.0080913
Oceania,Australia and New Zealand,Cocos (Keeling) Islands,CC,CCK,,,,Developed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Europe,Western Europe,Switzerland,CH,CHE,,,,Developed,Switzerland,0,High Income Economies,Europe and Central Asia,790655000000,42.694,93515.48,756,47,8,2,0.955,High human development,756,8654.618,8654618,19335324,12201692,221.85,15415094,1.9,Very Low,,,83,9666.337891,5,324650000,389260460,1,20220307,26.85,42.189999,41.07,50,Universal availability,EURO,REPORTING,2022-02-20,11821090,6076088,136.60001,70.602997,5802688,67.426003,"Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,23Dec2020,2022-03-08,26,2935467,0,12726,Europe,2935467,33917.926,118595,1370.309,26,12726,147.043,23,0.266,0,2022-01-01,2.50%,84.3,5,All eligible groups are fully government-funded,2974778,22294,13203,9.4289999,341320.66,2993.405,2557.9729,1514.8879,1.147,1.082,1.0700001,138,15.834,1430,164.076,,,309,26.85,8715494,214.243,43.099998,18.436001,12.644,57410.164,,99.738998,5.5900002,22.6,28.9,,4.5300002,83.779999,0.95499998,-8.3699999,08Mar2022,448,51.403,3604915,41.360001,6078075,5988546,113657,92652,178.78,69.739998,68.709999,Europe,1,Target reached,378.3491821,,0.019821318,0.011326467,0.27394035,0.19175825,0.10957614,61.137276,76.685165,
Americas,Latin America and the Caribbean,Chile,CL,CHL,,,,Developing,Chile,0,High Income Economies,Latin America and the Caribben,280167000000,34.404,16799.37,152,-30,-71,43,0.851,High human development,152,19116.209,19116208,53967524,26897307,280.9,50153869,3.1,Low,,,70,1375.802979,5,12000000000,3435342491,1,20220306,32.869999,41.93,47.919998,0,Universal availability,AMRO,REPORTING,2022-02-25,48356547,17759193,252.961,92.901001,17183623,89.889999,"AstraZeneca - Vaxzevria,CanSino - Convidecia,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",4,21Dec2020,2022-03-08,14114,3202562,149,43226,Americas,3202562,16753.131,141543,740.435,14114,43226,226.12199,873,4.5669999,149,2022-01-01,2.50%,96.9,5,All eligible groups are fully government-funded,3214326,21901,43260,129.571,167305.09,612.31403,1139.943,2251.675,1.77,6.744,0.87,1051,54.703999,,,462,24.047001,4580,32.869999,19212362,24.282,35.400002,11.087,6.9380002,22767.037,1.3,127.993,8.46,34.200001,41.5,,2.1099999,80.18,0.85100001,51.290001,08Mar2022,2769,144.12601,14688271,76.449997,17821767,17272037,430473,298737,256.13,92.760002,89.900002,South America,1,Target reached,223.5742798,,0.11033747,0.063049987,1.9246942,1.347286,0.76987767,89.60305,96.416382,
Asia,Eastern Asia,China,CN,CHN,,,,Developing,China,0,Upper Middle Income Economies,East Asia and Pacific,16492800000000,68.946,11891.2,156,35,105,85,0.761,High human development,156,1439323.774,1439323776,3472617573,2021902543,240.45,3203415701,3.4,Low,,,79,535.1333618,5,334545124.7,2952723948,1,20220301,64.349998,71.089996,72.32,62.5,Universal availability,WPRO,REPORTING,2022-02-27,3138003103,1276556393,213.283,86.764999,1235633241,83.983002,"Anhui ZL - Recombinant,Beijing CNBG - BBIBP-CorV,CanSino - Convidecia,IMB - Covidful,Pfizer BioNTech - Comirnaty,Shenzhen - LV-SMENP-DC,Sinovac - CoronaVac,Wuhan CNBG - Inactivated",8,22Jul2020,2022-03-08,25504,629238,280,7776,Western Pacific,629238,42.768002,293362,19.938999,25504,7776,0.52899998,1543,0.105,280,2021-08-01,2.50%,98,5,All eligible groups are fully government-funded,111857,301,4636,0,77.452003,0.233,0.208,3.21,0,0,2.55,,,,,,,3525,64.349998,1444216102,147.674,38.700001,10.641,5.9289999,15308.712,0.69999999,261.89899,9.7399998,1.9,48.400002,,4.3400002,76.910004,0.76099998,,08Mar2022,,,554728000,38.41,1269302000,1234540000,24741000,22424286,219.17999,87.889999,85.480003,Asia,1,Target reached,118.9756012,,0.12173709,0.069564044,3.8644574,2.7051201,1.5457829,90.364197,97.958038,
Africa,Sub-Saharan Africa,Côte d’Ivoire,CI,CIV,,,,Developing,Cote d'Ivoire,1,Lower Middle Income Economies,Sub-Saharan Africa,71104000000,50.207,2489.1,384,8,-5,162,0.538,Low human development,384,26378.275,26378276,20677089,37875081,76.43,20677089,5.6,High,0.07,0.4,47,75.08779144,5,309921796.2,0,0,20220213,13.89,29.690001,30.360001,25,Universal availability,AFRO,REPORTING,2022-03-05,9970869,6874956,37.799999,26.063,4006643,15.189,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",5,01Mar2021,2022-03-08,0,81556,0,795,Africa,81556,309.17899,73,0.27700001,0,795,3.0139999,2,0.0080000004,0,2022-01-01,2.50%,84.5,5,All eligible groups are fully government-funded,81559,10.857,795,0.28600001,3014.7161,0.111,0.40099999,29.386,0,0.011,0.74000001,,,,,,,1171,13.89,27053629,76.399002,18.700001,2.9330001,1.582,3601.0061,28.200001,303.73999,2.4200001,,,19.351,,57.779999,0.53799999,,08Mar2022,,,,,6874956,4006643,156394,121105,36.860001,25.41,14.81,Africa,0,Target not reached,58.2578125,175000,0.38752964,0.2214455,18.351852,12.846296,7.3407407,48.221821,48.221821,0.84634739
Africa,Sub-Saharan Africa,Cameroon,CM,CMR,,,,Developing,Cameroon,1,Lower Middle Income Economies,Sub-Saharan Africa,44406000000,45.797,1645.81,120,6,12,153,0.563,Medium human development,120,26545.864,26545864,3345862,38113967,12.29,3345862,5.7,High,1.15,38.5,46,53.99584961,5,0,0,0,20220228,22.219999,33.849998,38.689999,0,Universal availability,AFRO,REPORTING,2022-03-01,1272574,1073258,4.7940001,4.0430002,813063,3.063,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",4,12Apr2021,2022-03-08,0,119240,0,1923,Africa,119240,449.185,0,0,0,1923,7.244,0,0,0,2022-01-01,2.80%,58.6,5,All eligible groups are fully government-funded,119322,11.714,1926,0.42899999,4382.9292,0,0.43000001,70.746002,0,0.016000001,0.5,,,,,,,26,22.219999,27224262,50.884998,18.799999,3.165,1.919,3364.926,23.799999,244.661,7.1999998,,,2.7349999,1.3,59.290001,0.56300002,,08Mar2022,,,,,1073258,813063,9890,47269,4.6700001,3.9400001,2.99,Africa,0,Target not reached,60.1625061,200000,0.58609438,0.33491108,25.520479,17.864336,10.208192,38.034264,38.034264,5.9775329
Africa,Sub-Saharan Africa,Democratic Republic of the Congo,CD,COD,x,,,Developing,Democratic Republic of Congo,1,Low Income Economies,Sub-Saharan Africa,49624000000,11.873,593.558,180,0,25,175,0.48,Low human development,180,89561.404,89561408,6549599,129329180,7.09,6549599,6.8,Very High,0.89,35.2,41,20.57073212,4,0,0,0,20220214,33.330002,32.080002,36.669998,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-02-28,850731,754459,0.94999999,0.84200001,442965,0.495,SII - Covishield,1,19Apr2021,2022-03-08,0,86154,0,1335,Africa,86154,96.195,0,0,0,1335,1.4910001,0,0,0,2022-01-01,3.90%,65.9,5,All eligible groups are fully government-funded,86154,16.429001,1335,0,932.625,0,0.178,14.451,0,0,0.86000001,,,,,,,107,33.330002,92377986,35.879002,17,3.02,1.745,808.133,77.099998,318.94901,6.0999999,,,4.4720001,,60.68,0.47999999,,08Mar2022,,,,,754459,442965,42303,25961,0.92000002,0.81999999,0.47999999,Africa,0,Target not reached,74.84567261,850000,1.3538693,0.77363962,55.807446,39.065212,22.322977,12.989055,12.989055,12.977894
Africa,Sub-Saharan Africa,Congo,CG,COG,,,,Developing,Congo,1,Lower Middle Income Economies,Sub-Saharan Africa,10899000000,85.44,2655.72,178,-1,15,149,0.574,Medium human development,178,5518.092,5518092,2753270,7919824,48.67,2753270,5.7,High,0.68,4.2,39,48.55877304,5,0,16800000,1,20220307,48.150002,43.23,49.400002,0,Universal availability,AFRO,REPORTING,2022-02-14,812761,675865,14.729,12.248,635227,11.512,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,SII - Covishield",4,23Mar2021,2022-03-08,0,24020,0,378,Africa,24020,435.29599,0,0,0,378,6.8499999,0,0,0,2022-01-01,16.00%,48.9,5,All eligible groups are fully government-funded,24020,0,378,0,4246.0542,0,0,66.82,0,0,0.77999997,,,,,,,198,48.150002,5657017,15.405,19,3.402,2.063,4881.4058,37,344.09399,7.1999998,1.7,52.299999,47.964001,,64.57,0.574,,08Mar2022,,,,,675865,635227,1486,7088,14.37,11.95,11.23,Africa,0,Target not reached,75.77248383,400000,0.36321601,0.207552,28.377983,19.864588,11.351192,29.519844,29.519844,14.528179
Oceania,Polynesia,Cook Islands,CK,COK,,,x,Developing,Cook Islands,0,High Income Economies,Unclassified,,,,,,,,,,184,17.564,17564,,,,,,,,,,662.2428589,,,,,,,,,,,WPRO,REPORTING,2022-02-19,36399,14571,207.23599,82.959,12773,72.723,Pfizer BioNTech - Comirnaty,1,17May2021,2022-03-08,9,141,0,0,Western Pacific,141,802.77802,116,660.44202,9,0,0,0,0,0,,,,,,2,0,,,113.817,0,0,,,,,,,,,,,2219,,17572,,,,,,,,,,,,,76.25,,,08Mar2022,,,,,14930,12787,,812,157.73,84.959999,72.769997,Oceania,1,Target reached,,,,,3.998533,2.7989731,1.5994133,,,
Americas,Latin America and the Caribbean,Colombia,CO,COL,,,,Developing,Colombia,0,Upper Middle Income Economies,Latin America and the Caribben,280401000000,66.727,5892.14,170,4,-72,83,0.767,High human development,170,50882.884,50882884,85608831,71772177,166.99,73202491,4.3,Medium,0.3,0.1,76,495.3297119,5,31600666,0,0,20220228,59.259998,57.549999,65.769997,0,Universal availability,AMRO,REPORTING,2022-02-25,76733198,41253498,150.804,81.074997,33371543,65.584999,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",5,17Feb2021,2022-03-08,1088,6071704,54,139091,Americas,6071704,11932.702,9003,17.694,1088,139091,273.35501,398,0.78200001,54,2022-01-01,2.50%,96,5,All eligible groups are fully government-funded,6073416,1087.8571,139154,42.856998,118469.06,14.825,21.219999,2714.3611,0.66299999,0.83600003,0.44999999,,,,,,,1999,59.259998,51265841,44.223,32.200001,7.6459999,4.3119998,13254.949,4.5,124.24,7.4400001,4.6999998,13.5,65.386002,1.71,77.290001,0.76700002,61.470001,08Mar2022,,,8715348,17,41409379,33706581,1036209,414465,151.48,80.769997,65.75,South America,1,Target reached,83.49567413,6000000,0.24568324,0.14039041,4.1749969,2.9224977,1.6699988,89.632339,104.8232,7.0086226
Africa,Sub-Saharan Africa,Comoros,KM,COM,x,,x,Developing,Comoros,1,Lower Middle Income Economies,Sub-Saharan Africa,1318000000,26.572,1390.06,174,-12.1667,44.25,156,0.554,Medium human development,174,869.595,869595,1024034,1243838,115.26,1024034,6,High,,,52,72.32379913,0,0,0,0,,,,,,No availability,AFRO,REPORTING,2022-03-04,637961,341102,73.362,39.224998,301218,34.639,"Beijing CNBG - BBIBP-CorV,Bharat - Covaxin,SII - Covishield",3,10Apr2021,2022-03-08,0,8047,0,160,Africa,8047,925.367,12,1.38,0,160,18.399,0,0,0,,,,,,8051,2.5710001,160,0,9061.7881,3.3770001,2.8940001,180.088,0,0,0.63,,,,,,,0,,888456,437.35199,20.4,2.9630001,1.726,1413.89,18.1,261.51599,11.88,4.4000001,23.6,15.574,2.2,64.32,0.55400002,,08Mar2022,,,,,341102,301218,,5633,71.809998,38.389999,33.900002,Africa,0,Target not reached,66.88322449,100000,0.69392687,0.39652964,19.053204,13.337242,7.6212811,62.298809,62.298809,9.7653008
Africa,Sub-Saharan Africa,Cabo Verde,CV,CPV,,,x,Developing,Cape Verde,1,Lower Middle Income Economies,Sub-Saharan Africa,2071000000,160.667,3346.55,132,16,-24,126,0.665,Medium human development,132,555.988,555988,945230,786661,168.22,945230,4.5,Medium,,,69,177.8902741,5,0,40026836.76,1,20220220,52.779999,55.209999,59.52,25,Universal availability,AFRO,REPORTING,2022-03-05,711323,352929,127.939,63.478001,300099,53.976002,"Beijing CNBG - BBIBP-CorV,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",4,18Mar2021,2022-03-08,0,55892,0,401,Africa,55892,10052.753,5,0.89899999,0,401,72.124001,0,0,0,,,,5,All eligible groups are fully government-funded,55903,2.286,401,0,99489.055,8.8979998,4.0679998,713.64899,0,0,0.2,,,,,,,1648,52.779999,561901,135.58,25.700001,4.46,3.437,6222.5542,,182.21899,2.4200001,2.0999999,16.5,,2.0999999,72.980003,0.66500002,,08Mar2022,,,,,352929,300099,4461,6701,126.59,62.810001,53.41,Africa,1,Target reached,95.52127838,560150,0.28823715,0.16470693,7.7463484,5.4224439,3.0985394,75.25396,75.25396,59.260708
Americas,Latin America and the Caribbean,Costa Rica,CR,CRI,,,,Developing,Costa Rica,0,Upper Middle Income Economies,Latin America and the Caribben,61186000000,71.201,11860.22,188,10,-84,62,0.81,High human development,188,5094.114,5094114,10349539,7194674,201.39,9820731,3.4,Low,0.31,0,77,921.5857544,5,1597691.5,40000000,1,20220222,50,53.650002,57.740002,25,Universal availability,AMRO,REPORTING,2022-02-25,8970610,4152664,176.097,81.518997,3787890,74.358002,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty",2,24Dec2020,2022-03-08,0,814583,0,8082,Americas,814583,15990.658,8919,175.084,0,8082,158.65401,51,1.001,0,2022-01-01,2.50%,96.2,5,All eligible groups are fully government-funded,818996,1409.286,8136,12.714,159367.11,283.70999,274.23099,1583.171,2.9189999,2.474,0.76999998,,,,,,,10533,50,5139053,96.079002,33.599998,9.4680004,5.6939998,15524.995,1.3,137.97301,8.7799997,6.4000001,17.4,83.841003,1.13,80.279999,0.81,23.870001,08Mar2022,,,1326215,25.809999,4195968,3827352,,87355,181.92999,81.650002,74.480003,North America,1,Target reached,113.817276,638330,0.12205507,0.069745757,2.2439582,1.5707709,0.89758331,86.676422,91.343605,6.1677141
Americas,Latin America and the Caribbean,Cuba,CU,CUB,,,x,Developing,Cuba,0,Upper Middle Income Economies,Latin America and the Caribben,,,,192,21.5,-80,70,0.783,High human development,192,11326.616,11326616,38534948,15844497,340.49,34859027,3.4,Low,,,83,1031.921753,5,0,0,0,20220307,29.629999,39.580002,38.099998,50,Universal availability,AMRO,REPORTING,2022-02-25,34926539,10604386,308.358,93.624001,9875909,87.192001,"CIGB - CIGB-66,Finlay - Soberana Plus,Finlay - Soberana-02",3,,2022-03-08,548,1073504,1,8501,Americas,1073504,9477.7119,3642,32.153999,548,8501,75.053001,7,0.061999999,1,,,,5,All eligible groups are fully government-funded,1073951,527.57098,8501,0.85699999,94892.969,39.495998,46.616001,751.138,0,0.075999998,0.87,,,,,,,1135,29.629999,11317498,110.408,43.099998,14.738,9.7189999,,,190.968,8.2700005,17.1,53.299999,85.197998,5.1999998,78.800003,0.78299999,14.83,08Mar2022,,,6027115,53.25,10613819,9888591,437983,321878,309.94,93.779999,87.370003,North America,1,Target reached,170.0739441,,,,2.0040278,1.4028195,0.80161119,90.636009,100.19367,
Americas,Latin America and the Caribbean,Curaçao,CW,CUW,,,x,Developing,Curacao,0,High Income Economies,Latin America and the Caribben,,,,,,,,,,531,164.1,164100,,230714,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,244091,106676,148.752,65.009003,98126,59.799,"AstraZeneca - Vaxzevria,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,24Feb2021,2022-03-08,102,39185,3,264,Americas,39185,23879.752,252,153.571,102,264,160.884,3,1.8279999,3,,,,,,39185,32.143002,264,0.42899999,237778.83,315.54199,195.04601,1601.981,0,2.6010001,,,,,,,,431,,164796,362.64401,41.700001,16.367001,10.068,,,,11.62,,,,,78.879997,,,08Mar2022,,,39710,24.1,107061,98268,4693,3452,148.69,64.970001,59.630001,North America,1,Target reached,,,,,,,,,,
Oceania,Australia and New Zealand,Christmas Island,CX,CXR,,,,Developed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Americas,Latin America and the Caribbean,Cayman Islands,KY,CYM,,,,Developing,Cayman Islands,0,High Income Economies,Latin America and the Caribben,,,,,,,,,,136,65.72,65720,157587,93097,236.98,147399,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,143257,61502,217.981,93.582001,59726,90.878998,Pfizer BioNTech - Comirnaty,1,15Jan2021,2022-03-08,438,19811,1,18,Americas,19811,30144.553,438,666.46399,438,18,27.389,1,1.522,1,,,,,,19811,62.570999,18,0.14300001,297918.72,6586.6641,940.95203,270.685,15.038,2.148,,,,,,,,9263,,66498,256.496,,,,49903.027,,,13.22,,,,,83.919998,,,08Mar2022,,,,,61502,59726,1579,1024,215.42999,92.489998,89.82,North America,1,Target reached,,,,,,,,90.906609,97.189941,
Asia,Western Asia,Cyprus,CY,CYP,,,,Developed,Cyprus,0,High Income Economies,Europe and Central Asia,26599000000,111.041,29486.28,196,35,33,33,0.887,High human development,196,1207.361,1207361,2615618,1254407,291.92,2521627,3.3,Low,,,78,1996.458252,5,0,0,0,20220307,36.110001,58.330002,52.380001,100,Universal availability,EURO,REPORTING,2022-02-20,1706147,655735,192.10001,73.844002,652791,73.512001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,1584,334822,1,878,Europe,334822,37704.969,13403,1509.338,1584,878,98.873001,19,2.1400001,1,2022-01-01,11.10%,88.5,5,All eligible groups are fully government-funded,338517,2002.1429,883,3.714,377807.03,4123.8608,2234.522,985.48602,5.5799999,4.145,0.89999998,14,15.625,148,165.17799,9,10.135,1265,36.110001,896005,127.657,37.299999,13.416,8.5629997,32415.133,,141.17101,9.2399998,19.6,52.700001,,3.4000001,80.980003,0.88700002,27.15,08Mar2022,92,102.477,440267,49.139999,687926,645292,15365,12513,197.92999,76.779999,72.019997,Europe,1,Target reached,322.5299072,196000,0.062863134,0.03592179,1.3263488,0.92844415,0.53053951,65.22921,67.660561,7.4934487
Europe,Eastern Europe,Czechia,CZ,CZE,,,,Developed,Czechia,0,High Income Economies,Europe and Central Asia,278889000000,45.007,25806.38,203,49.75,15.5,27,0.9,High human development,203,10708.982,10708982,23609031,15014374,220.14,23659436,3.4,Low,,,76,1844.217773,5,2079966.77,0,0,20220214,41.669998,53.119999,55.360001,37.5,Universal availability,EURO,REPORTING,2022-02-20,17288966,6935621,161.7,64.856003,6830050,63.868,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,10419,3642514,46,38986,Europe,3642514,34061.48,54548,510.08301,10419,38986,364.56201,236,2.207,46,2022-01-01,2.50%,83,5,All eligible groups are fully government-funded,3642514,7806.1431,38986,43,339642.5,971.50897,727.87598,3635.21,4.289,4.0089998,0.69999999,198,18.462,2285,213.062,126,11.749,358,41.669998,10724553,137.17599,43.299999,19.027,11.58,32605.906,,227.485,6.8200002,30.5,38.299999,,6.6300001,79.379997,0.89999998,26.370001,08Mar2022,1926,179.588,4034414,37.619999,6944808,6849087,122088,98378,162.42,64.760002,63.860001,Europe,1,Target reached,315.149353,135620,0.071827203,0.041044112,1.4358391,1.0050874,0.57433563,73.230309,73.074295,0.57444119
Europe,Western Europe,Germany,DE,DEU,,,,Developed,Germany,0,High Income Economies,Europe and Central Asia,4318490000000,72.498,50787.86,276,51,9,6,0.947,High human development,276,83783.945,83783944,210648919,117460659,251.07,208417163,2.2,Low,,,83,5440.251465,5,3763342890,1861521162,1,20220307,80.559998,83.849998,81.550003,100,Universal availability,EURO,REPORTING,2022-02-20,169071638,63380508,203.3,76.209,62500884,75.151001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,156799,16026216,324,124450,Europe,16026216,19269.988,1158998,1393.584,156799,124450,149.63901,1513,1.819,324,2022-01-01,2.50%,91,5,All eligible groups are fully government-funded,16326087,193052.14,124769,249.286,194588.73,3111.5801,2300.9661,1487.1071,3.7539999,2.971,1.05,2157,25.709,,,1568,18.688999,988,80.559998,83900471,237.01601,46.599998,21.452999,15.957,45229.246,,156.13901,8.3100004,28.200001,33.099998,,8,81.330002,0.94700003,-4.3099999,08Mar2022,5118,61.000999,47778595,56.950001,63524805,62863234,1648968,1131098,203.28999,75.709999,74.93,Europe,1,Target reached,332.3463135,,0.036496911,0.020855378,0.4867422,0.34071955,0.19469689,80.262283,81.121742,
Africa,Sub-Saharan Africa,Djibouti,DJ,DJI,x,,,Developing,Djibouti,1,Lower Middle Income Economies,Middle East and North Africa,3732000000,42.289,3645.5,262,11.5,43,166,0.524,Low human development,262,988.002,988002,571252,1403076,57,571252,5.6,High,2.92,8.7,47,61.80943298,5,0,0,0,20220221,58.330002,47.919998,54.759998,0,Universal availability,EMRO,REPORTING,2022-02-26,160742,140287,16.268999,14.199,100289,10.151,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",6,15Mar2021,2022-03-08,0,15550,0,189,Eastern Mediterranean,15550,1573.887,3,0.30399999,0,189,19.129999,0,0,0,2021-02-01,2.70%,73,5,All eligible groups are fully government-funded,15550,0.42899999,189,0,15515.912,0,0.428,188.586,0,0,0.49000001,,,,,,,452,58.330002,1002197,41.285,25.4,4.2129998,2.3800001,2705.406,22.5,258.03699,6.0500002,1.7,24.5,,1.4,67.110001,0.52399999,,08Mar2022,,,,,140287,100289,,802,16.040001,14,10.01,Africa,0,Target not reached,54.96711731,200000,0.26460019,0.15120012,22.294333,15.606032,8.9177322,28.138544,28.138544,35.010818
Americas,Latin America and the Caribbean,Dominica,DM,DMA,,,x,Developing,Dominica,1,Upper Middle Income Economies,Latin America and the Caribben,574000000,107.76,7777.02,212,15.4167,-61.3333,94,0.742,High human development,212,71.991,71991,222117,101041,307.76,222117,4.2,Medium,6.38,2,,440.1698608,5,0,0,0,20220210,37.040001,46.349998,52.98,0,Universal availability,AMRO,REPORTING,2022-02-25,61649,32113,85.634003,44.606998,29536,41.027,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Pfizer BioNTech - Comirnaty,SII - Covishield",4,12Feb2021,2022-03-08,0,11248,0,61,Americas,11248,15624.175,140,194.46899,0,61,84.733002,4,5.5560002,0,2022-01-01,13.40%,85.5,5,All eligible groups are fully government-funded,11248,33.143002,61,0.57099998,155849.91,1385.579,459.22,845.203,0,7.9180002,0.97000003,,,,,,,222,37.040001,72172,98.567001,,,,9673.3672,,227.37601,11.62,,,,3.8,75,0.74199998,,08Mar2022,,,,,32153,29605,1226,901,85.57,44.549999,41.02,North America,1,Target reached,178.199295,120200,0.18613814,0.10636465,4.6981864,3.2887304,1.8792745,27.755192,27.755192,54.115623
Europe,Northern Europe,Denmark,DK,DNK,,,,Developed,Denmark,0,High Income Economies,Europe and Central Asia,370592000000,38.755,67919.59,208,56,10,10,0.94,High human development,208,5792.203,5792203,12146313,8138623,208.94,12068996,2.1,Low,,,81,6003.325195,5,95666655,3000000,1,20220307,16.67,28.120001,32.139999,0,Universal availability,EURO,REPORTING,2022-02-20,13160370,4842238,226,83.160004,4746722,81.519997,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,16Dec2020,2022-03-08,12225,2876288,37,4905,Europe,2876288,49397.305,111450,1914.04,12225,4905,84.237999,293,5.0320001,37,2022-01-01,2.50%,94.5,5,All eligible groups are fully government-funded,2891763,15480.571,4948,42.714001,497438.97,2661.998,2662.957,851.151,7.3969998,7.348,0.70999998,37,6.3649998,1644,282.79999,,,299,16.67,5813302,136.52,42.299999,19.677,12.325,46682.516,0.2,114.767,6.4099998,19.299999,18.799999,,2.5,80.900002,0.94,2.46,08Mar2022,2092,359.86401,3632532,62.490002,4844256,4742292,166825,133718,226.58,83.330002,81.580002,Europe,1,Target reached,314.4679871,,0.027291095,0.015594912,0.44108889,0.30876222,0.17643556,108.34868,109.04279,
Americas,Latin America and the Caribbean,Dominican Republic,DO,DOM,,,x,Developing,Dominican Republic,0,Upper Middle Income Economies,Latin America and the Caribben,81782000000,66.144,8491.62,214,19,-70.6667,88,0.756,High human development,214,10847.904,10847904,16813951,15335200,153.5,15642999,4.3,Medium,0.24,0.1,74,491.0593567,5,0,748800,1,20220306,8.3299999,22.4,25.6,0,Universal availability,AMRO,REPORTING,2022-02-25,15173404,7110411,139.87399,65.545998,5855045,53.973999,"AstraZeneca - Vaxzevria,SII - Covishield,Sinovac - CoronaVac",3,16Feb2021,2022-03-08,54,576003,0,4371,Americas,576003,5309.8062,1447,13.339,54,4371,40.292999,3,0.028000001,0,2022-01-01,2.50%,95.9,5,All eligible groups are fully government-funded,576129,173.85699,4371,0.28600001,52596.68,11.503,15.872,399.043,0,0.026000001,0.60000002,,,,,,,646,8.3299999,10953714,222.873,27.6,6.9809999,4.4190001,14600.861,1.6,266.65302,8.1999998,8.5,19.1,55.181999,1.6,74.080002,0.75599998,-3.23,08Mar2022,,,2233771,20.389999,7139986,5864471,244052,184208,139.69,65.18,53.540001,North America,1,Target reached,143.4271088,80000,0.17047395,0.097413689,4.2113037,2.9479125,1.6845214,90.242943,96.998047,0.47579536
Africa,Northern Africa,Algeria,DZ,DZA,,,,Developing,Algeria,1,Lower Middle Income Economies,Middle East and North Africa,155306000000,58.48,3638.33,12,28,3,91,0.748,High human development,12,43851.043,43851044,33877404,62463276,75.93,33877404,3.9,Medium,1.21,0.8,78,248.2058716,5,0,1642713755,1,20220223,58.330002,50,57.139999,0,Universal availability,AFRO,REPORTING,2022-02-20,13631683,7456361,31.086,17.004,6076272,13.857,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,SII - Covishield,Sinovac - CoronaVac",4,30Jan2021,2022-03-08,32,265297,2,6857,Africa,265297,604.99597,361,0.82300001,32,6857,15.637,22,0.050000001,2,2022-01-01,2.50%,68.1,5,All eligible groups are fully government-funded,265323,44.714001,6858,2.5710001,5946.729,0.583,1.002,153.71001,0.022,0.057999998,0.31,11,0.24699999,,,,,318,58.330002,44616626,17.348,29.1,6.211,3.8570001,13913.839,0.5,278.36401,6.73,0.69999999,30.4,83.740997,1.9,76.879997,0.74800003,29.469999,08Mar2022,,,436274,0.98000002,7456361,6076272,147230,256927,30.549999,16.709999,13.62,Africa,0,Target not reached,57.65037155,200000,0.26512164,0.15149808,5.5518427,3.8862901,2.2207372,40.238274,40.238274,0.59036398
Americas,Latin America and the Caribbean,Ecuador,EC,ECU,,,,Developing,Ecuador,0,Upper Middle Income Economies,Latin America and the Caribben,99247000000,60.954,5884.15,218,-2,-77.5,86,0.759,High human development,218,17643.06,17643060,35197360,25043864,196.76,32764530,3.9,Medium,,,77,486.492157,5,0,0,0,20220307,67.589996,72.919998,72.620003,75,Universal availability,AMRO,REPORTING,2022-02-25,31772830,14761254,180.08701,83.666,13535095,76.716003,"AstraZeneca - Vaxzevria,CanSino - Convidecia,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",4,20Jan2021,2022-03-08,0,836216,0,35264,Americas,836216,4739.6328,3809,21.589001,0,35264,199.875,20,0.113,0,2022-01-01,2.50%,96.7,5,All eligible groups are fully government-funded,841575,1973.571,35309,12.286,47045.656,299.578,110.326,1973.8409,2.516,0.68699998,0.83999997,,,,,,,2238,67.589996,17888474,66.939003,28.1,7.1040001,4.4580002,10581.936,3.5999999,140.448,5.5500002,2,12.3,80.635002,1.5,77.010002,0.759,-28.73,08Mar2022,,,4412659,24.67,14787129,13595355,429786,354692,180.25,82.660004,76,South America,1,Target reached,108.2814636,3614950,0.24601685,0.14058106,4.2508392,2.9755876,1.7003357,90.270493,96.973251,10.270514
Africa,Northern Africa,Egypt,EG,EGY,,,,Developing,Egypt,1,Lower Middle Income Economies,Middle East and North Africa,374892000000,91.36,3851.75,818,27,30,116,0.707,High human development,818,102334.403,102334400,87754232,145961658,84.17,87754232,3.6,Medium,0.8,2.3,68,149.8403168,3,0,0,0,20220228,43.52,52.189999,48.93,75,Availability for ALL of following: key workers/ clinically vulnerable groups (non elderly)/elderly groups,EMRO,REPORTING,2022-03-01,71361630,41192990,69.734001,40.252998,30174310,29.486,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",6,24Jan2021,2022-03-08,923,491892,25,24222,Eastern Mediterranean,491892,480.67099,8121,7.9359999,923,24222,23.669001,148,0.145,25,2022-01-01,2.50%,88.2,5,All eligible groups are fully government-funded,492774,1097.286,24244,19.143,4726.4712,8.46,10.525,232.53799,0.211,0.184,0.75999999,,,,,,,1945,43.52,104258327,97.999001,25.299999,5.1589999,2.891,10550.206,1.3,525.43201,17.309999,0.2,50.099998,89.827003,1.6,71.989998,0.70700002,37.459999,08Mar2022,,,1104196,1.0599999,41192990,30174310,975155,615408,68.449997,39.509998,28.940001,Africa,0,Target not reached,125.0481567,8637600,0.25043163,0.14310378,9.1964569,6.4375196,3.6785827,81.31987,81.31987,9.8429441
Africa,Sub-Saharan Africa,Eritrea,ER,ERI,x,,,Developing,Eritrea,1,Low Income Economies,Sub-Saharan Africa,2277000000,175.106,625.974,232,15,39,180,0.459,Low human development,232,3546.427,3546427,0,5042047,0,0,5.9,High,3.82,107.6,38,25.2679348,0,0,0,0,20220225,56.48,46.880001,53.57,0,No availability,,,,,,,,,,,,,2022-03-08,1,9716,0,103,Africa,9716,273.966,15,0.42300001,1,103,2.904,0,0,0,,,,,No availability,9716,1.714,103,0,2697.793,0,0.47600001,28.599001,0,0,0.57999998,,,,,,,,56.48,3601462,44.304001,19.299999,3.6070001,2.171,1510.459,,311.10999,6.0500002,0.2,11.4,,0.69999999,66.32,0.45899999,,08Mar2022,,,,,,,,,,,,Africa,,Not available,60,,1.2837594,0.73357677,45.433075,31.803154,18.173231,,,
Africa,Northern Africa,Western Sahara,EH,ESH,,,,Developing,Western Sahara,0,Unclassified Economies,Unclassified,,,,,,,,,,732,597.33,597330,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Europe,Southern Europe,Spain,ES,ESP,,,,Developed,Spain,0,High Income Economies,Europe and Central Asia,1450880000000,120.224,30536.86,724,40,-4,25,0.904,High human development,724,46754.783,46754784,139375523,65443295,298.16,135369455,2.8,Low,,,83,2711.192871,5,0,26589481,1,20220306,37.959999,57.290001,52.98,87.5,Universal availability,EURO,REPORTING,2022-02-20,98615715,40929909,208.3,86.473,35998047,76.053001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,14266,11136425,98,100574,Europe,11136425,23528.016,106040,224.032,14266,100574,212.48399,544,1.149,98,2022-01-01,2.50%,95.7,5,All eligible groups are fully government-funded,11159574,17641.285,100859,139.429,238731.92,495.21701,377.392,2157.6331,6.0970001,2.983,0.79000002,810,17.327999,4734,101.272,268,5.7329998,865,37.959999,46745211,93.105003,45.5,19.436001,13.799,34272.359,1,99.403,7.1700001,27.4,31.4,,2.97,83.559998,0.90399998,11.72,08Mar2022,3455,73.911003,24215926,51.799999,41083791,39103590,765399,670109,198.47,87.889999,83.650002,Europe,1,Target reached,314.4679871,,0.060700413,0.034685951,0.97669184,0.68368429,0.39067674,70.755402,72.849312,
Europe,Northern Europe,Estonia,EE,EST,,,,Developed,Estonia,0,High Income Economies,Europe and Central Asia,34973000000,19.961,27100.74,233,59,26,29,0.892,High human development,233,1326.539,1326539,2602007,1855263,196.35,2496257,3,Low,,,75,1598.818848,5,331000,0,0,20220306,46.299999,47.919998,54.759998,0,Universal availability,EURO,REPORTING,2022-02-20,2010403,835907,151.3,62.898998,830030,62.456001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,3305,520407,15,2308,Europe,520407,39158.496,21328,1604.845,3305,2308,173.668,60,4.5149999,15,2022-01-01,12.00%,87.1,5,All eligible groups are fully government-funded,520407,3046.2859,2308,8.2860003,392704.28,2493.9861,2298.7571,1741.64,6.7909999,6.2519999,0.80000001,27,20.374001,655,494.26901,16,12.039,601,46.299999,1325188,31.033001,42.700001,19.452,13.491,29481.252,0.5,255.569,4.02,24.5,39.299999,,4.6900001,78.739998,0.89200002,28.280001,08Mar2022,467,352.151,447434,33.759998,857929,840394,17558,10161,147.89,64.739998,63.419998,Europe,1,Target reached,314.4679871,,0.068396658,0.039083805,1.6562227,1.1593559,0.66248906,77.26355,80.536697,
Africa,Sub-Saharan Africa,Ethiopia,ET,ETH,x,x,,Developing,Ethiopia,1,Low Income Economies,Sub-Saharan Africa,91514000000,57.113,939.511,231,8,38,173,0.485,Low human development,231,114963.583,114963584,42954095,165026716,36.44,42954095,6,High,0.62,11.8,39,26.74220467,5,0,0,0,20220225,40.740002,45.310001,51.790001,0,Universal availability,AFRO,REPORTING,2022-03-06,26178996,21524528,22.771999,18.723,18060829,15.71,"Beijing CNBG - BBIBP-CorV,Bharat - Covaxin,Janssen - Ad26.COV 2-S,SII - Covishield",4,13Mar2021,2022-03-08,41,469007,0,7476,Africa,469007,407.961,280,0.244,41,7476,6.5029998,14,0.012,0,2022-01-01,2.50%,76.9,5,All eligible groups are fully government-funded,469047,39.570999,7477,2,3979.1479,0.33899999,0.336,63.431,0.0080000004,0.017000001,0.54000002,,,,,,,2648,40.740002,117876226,104.957,19.799999,3.526,2.063,1729.927,26.700001,182.634,7.4699998,0.40000001,8.5,7.96,0.30000001,66.599998,0.48500001,,08Mar2022,,,,,21524528,,1866822,1389911,22.209999,18.26,,Africa,,Not available,52.92679977,3900000,0.85533857,0.48876491,42.928398,30.049879,17.17136,60.946449,60.946449,9.0794601
Europe,Northern Europe,Finland,FI,FIN,,,,Developed,Finland,0,High Income Economies,Europe and Central Asia,303278000000,72.224,53522.57,246,64,26,11,0.938,High human development,246,5540.718,5540718,12777320,7767705,230.29,12282406,2.1,Low,,,78,4450.302734,5,9626908,5543828,1,20220307,23.15,43.75,42.860001,50,Universal availability,EURO,REPORTING,2022-02-20,11420891,4468653,206.7,80.875999,4218421,76.347,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,0,694142,0,2571,Europe,694142,12562.992,15212,275.31601,0,2571,46.530998,2,0.035999998,0,2022-01-01,2.50%,91.7,5,All eligible groups are fully government-funded,694142,8055,2571,29.285999,125107.58,4031.6411,1451.78,463.38,33.162998,5.2779999,1.22,35,6.3080001,831,149.774,,,989,23.15,5548361,18.136,42.799999,21.228001,13.264,40585.723,,153.507,5.7600002,18.299999,22.6,,3.28,81.910004,0.93800002,-1.17,08Mar2022,,,2785200,50.200001,4459276,4237004,151516,72110,206.92999,80.370003,76.360001,Europe,1,Target reached,314.4680176,,0.03463212,0.019789781,0.5950157,0.416511,0.23800628,89.384087,92.985779,
Oceania,Melanesia,Fiji,FJ,FJI,,,x,Developing,Fiji,1,Upper Middle Income Economies,East Asia and Pacific,4363000000,86.792,5127.44,242,-18,175,93,0.743,High human development,242,896.444,896444,1750811,1264059,193.91,1750811,4.2,Medium,,,64,235.6750183,5,0,0,0,20220307,61.110001,65.099998,63.689999,75,Universal availability,WPRO,REPORTING,2022-02-28,1288363,667948,143.71899,74.511002,620415,69.208,"AstraZeneca - Vaxzevria,Moderna - Spikevax,SII - Covishield",3,07Mar2021,2022-03-08,15,64034,0,834,Western Pacific,64034,7143.104,104,11.601,15,834,93.033997,0,0,0,2021-07-01,9.30%,79,5,All eligible groups are fully government-funded,64034,14.857,834,0,70920.445,0,16.455,923.69098,0,0,1.0599999,,,,,,,226,61.110001,902899,49.562,28.6,6.224,3.2839999,8702.9746,1.4,412.82001,14.49,10.2,34.799999,,2.3,67.440002,0.74299997,,08Mar2022,,,106232,11.77,668239,620913,28295,14274,142.78,74.010002,68.769997,Oceania,1,Target reached,134.1412048,1249500,0.28232414,0.16132808,8.7747955,6.1423564,3.509918,73.586639,73.586639,71.366928
Americas,Latin America and the Caribbean,Falkland Islands (Malvinas),FK,FLK,,,,Developing,Falkland Islands,0,Unclassified Economies,Unclassified,,,,,,,,,,238,3.483,3483,,,,,,,,,,,,,,,,,,,,,AMRO,OWID,2021-04-14,4407,2632,126.529,75.567001,1775,50.962002,AstraZeneca - AZD1222,1,,2022-03-08,1,116,0,0,Americas,116,3330.4619,6,172.265,1,0,0,0,0,0,,,,,,116,0.85699999,,,32879.82,283.44699,242.95399,,,,,,,,,,,3401,,3528,,,,,,,,,,,,,81.440002,,,08Mar2022,,,,,2632,1775,,189,124.91,74.599998,50.310001,South America,1,Target reached,,,,,,,,,,
Europe,Western Europe,France,FR,FRA,,,,Developed,France,0,High Income Economies,Europe and Central Asia,2917670000000,115.825,45028.27,250,46,2,26,0.901,High human development,250,65273.512,65273512,178822312,94589951,264.67,166653984,3,Low,,,78,4491.735352,5,1311754455,600266651.2,1,20220226,63.889999,64.059998,69.639999,25,Universal availability,EURO,REPORTING,2022-02-20,153013512,54700591,227.3,81.253998,53687279,79.749001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,1295,22383443,157,136323,Europe,22383443,34415.227,350648,539.13202,1295,136323,209.601,1061,1.631,157,2022-01-01,2.50%,89.1,5,All eligible groups are fully government-funded,23217640,54617.145,139687,148.85699,344362.97,1380.113,810.07898,2071.8311,2.477,2.2079999,0.68000001,2089,30.983999,22208,329.388,811,12.029,631,63.889999,67422000,122.578,42,19.718,13.079,38605.672,,86.059998,4.77,30.1,35.599998,,5.98,82.660004,0.90100002,-2.96,08Mar2022,6700,99.374001,35817999,53.130001,53977048,52363217,970062,733686,209.25,80.059998,77.660004,Europe,1,Target reached,314.4679871,,0.041165251,0.023523001,0.58952719,0.412669,0.23581086,85.567352,91.815094,
Europe,Northern Europe,Faroe Islands,FO,FRO,,,,Developed,Faeroe Islands,0,High Income Economies,Europe and Central Asia,,,,,,,,,,234,48.865,48865,,68674,,,,,,,,,5,0,0,0,20220301,13.89,16.15,18.450001,0,Universal availability,EURO,OWID,2022-02-18,103894,41715,212.614,85.367996,40895,83.690002,"Moderna - mRNA-1273, Pfizer BioNTech - Comirnaty",2,,2022-03-08,0,34658,0,28,Europe,34658,70926.023,275,562.77502,0,28,57.300999,0,0,0,,,,5,All eligible groups are fully government-funded,34658,251.286,28,0,706541.88,5606.1812,5122.7388,570.81097,0,0,,,,,,,,530,13.89,49053,35.307999,,,,,,,,,,,,80.669998,,41.709999,08Mar2022,,,21284,43.389999,41715,40895,1442,1001,211.8,85.040001,83.370003,Europe,1,Target reached,,,,,,,,,,
Oceania,Micronesia,Micronesia (Federated States of),FM,FSM,,,x,Developing,Micronesia (country),1,Lower Middle Income Economies,East Asia and Pacific,410000000,15.099,3855.22,583,6.9167,158.25,136,0.62,Medium human development,583,115.021,115021,82402,162757,70.88,82402,5,High,13.81,13,47,415.1982727,,,,,,,,,,,WPRO,REPORTING,2022-02-16,97185,57174,84.491997,49.707001,45863,39.873001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,13Jan2021,2022-03-08,0,0,0,0,Western Pacific,0,0,0,0,0,0,0,0,0,0,,,,,,1,0,,,8.6020002,0,0,,,,,,,,,,,,,116255,150.77699,23,4.8099999,2.392,3299.4641,16,454.34299,12.02,,,,,67.879997,0.62,,08Mar2022,,,,,,,,,,,,Oceania,,Not available,50,,0.2502062,0.14297497,3.3188963,2.3232274,1.3275585,117.9401,117.9401,
Africa,Sub-Saharan Africa,Gabon,GA,GAB,,,,Developing,Gabon,0,Upper Middle Income Economies,Sub-Saharan Africa,16618000000,72.105,8569.22,266,-1,11.75,119,0.703,High human development,266,2225.728,2225728,1630502,3190361,71.55,1630502,4.9,Medium,0.05,0,49,215.0191498,5,0,0,0,20220307,50.93,45.830002,52.380001,0,Universal availability,AFRO,REPORTING,2022-02-09,545642,299993,24.514999,13.478,245649,11.037,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty",3,23Mar2021,2022-03-08,0,47543,0,303,Africa,47543,2136.0591,0,0,0,303,13.613,0,0,0,2022-01-01,16.40%,98.1,5,All eligible groups are fully government-funded,47562,2.714,303,0,20871.246,1.316,1.191,132.963,0,0,0.51999998,,,,,,,848,50.93,2278829,7.8590002,23.1,4.4499998,2.9760001,16562.412,3.4000001,259.96701,7.1999998,,,,6.3000002,66.470001,0.70300001,,08Mar2022,,,841,0.039999999,299993,245649,1486,7131,23.940001,13.16,10.78,Africa,0,Target not reached,56.87602997,620000,0.16893019,0.09653154,9.6177483,6.7324238,3.8470993,33.464664,33.464664,38.025101
Europe,Northern Europe,United Kingdom of Great Britain and Northern Ireland,GB,GBR,,,,Developed,United Kingdom,0,High Income Economies,Europe and Central Asia,2855670000000,108.497,46200.26,826,54,-2,13,0.932,High human development,826,67886.004,67886000,154032127,95489960,225.83,149107572,2.6,Low,,,87,4312.88916,5,1567200601,16471269650,1,20220302,17.59,33.849998,35.119999,25,Universal availability,EURO,REPORTING,2022-02-22,139482283,52573589,205.5,77.246002,48885893,71.828003,"AstraZeneca - Vaxzevria,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,21Dec2020,2022-03-08,32522,19245305,66,162147,Europe,19245305,28349.443,281535,414.71701,32522,162147,238.85201,440,0.648,66,2022-01-01,2.50%,92.9,5,All eligible groups are fully government-funded,19360938,46338.285,162505,104.571,283855.13,914.96301,679.37598,2382.5229,3.1229999,1.533,1.01,257,3.7679999,10702,156.90401,,,662,29.629999,68207114,272.89801,40.799999,18.517,12.527,39753.242,0.2,122.137,4.2800002,20,24.700001,,2.54,81.32,0.93199998,-4.23,08Mar2022,8143,119.386,38377152,56.27,52672968,49106830,1062705,970350,205.49001,77.230003,72,Europe,1,Target reached,334.6713562,,0.040120985,0.022926278,0.61397356,0.4297815,0.24558944,90.554024,93.544731,
Asia,Western Asia,Georgia,GE,GEO,,,,Developing,Georgia,0,Upper Middle Income Economies,Europe and Central Asia,17474000000,54.246,4807.95,268,42,43.5,61,0.812,High human development,268,3989.175,3989175,3592541,5571682,90.27,3592541,4.1,Medium,0.3,0.2,66,291.1220398,5,0,0,0,20220228,50,51.040001,58.330002,0,Universal availability,EURO,REPORTING,2022-02-13,2567028,1255300,64.300003,31.468,1131748,28.370001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",4,17Mar2021,2022-03-08,2783,1629065,32,16430,Europe,1629065,40837.141,16746,419.78601,2783,16430,411.86499,231,5.7909999,32,2022-01-01,11.30%,87.2,5,All eligible groups are fully government-funded,1629065,2392.2859,16430,33,409336.16,699.28601,601.11102,4128.376,8.0410004,8.2919998,0.34999999,,,,,,,256,50,3979773,65.031998,38.700001,14.864,10.244,9745.0791,4.1999998,496.21799,7.1100001,5.3000002,55.5,,2.5999999,73.769997,0.81199998,17.75,08Mar2022,,,80818,2.03,1578207,1249476,58479,29680,71.050003,39.66,31.4,Asia,0,Target not reached,71.06046295,804570,0.30108467,0.17204838,7.10355,4.9724851,2.8414199,71.454384,71.454384,22.395569
Europe,Northern Europe,Guernsey,GG,GGY,,,,Developed,Guernsey,0,Unclassified Economies,Unclassified,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EURO,OWID,2022-02-28,148014,,229.593,,,,"Moderna - mRNA-1273, AstraZeneca - AZD1222, Pfizer BioNTech - Comirnaty",3,,2022-03-08,0,14434,0,31,Europe,14434,22389.402,931,1444.127,0,31,48.085999,0,0,0,,,,,,,,,,,,,,,,,,,,,,,742,,63385,,,,,,,,,,,,,,,,07Mar2022,,,39278,61.970001,54146,51351,1603,1747,234.03999,85.419998,81.010002,Europe,1,Target reached,,,,,,,,,,
Africa,Sub-Saharan Africa,Ghana,GH,GHA,,,,Developing,Ghana,1,Lower Middle Income Economies,Sub-Saharan Africa,71946000000,83.541,2413.1,288,8,-2,138,0.611,Medium human development,288,31072.945,31072944,27413385,44424979,86.39,27413385,4.8,Medium,0.92,3.2,47,75.28166199,5,0,200000000,1,20220227,43.52,47.400002,54.169998,0,Universal availability,AFRO,REPORTING,2022-02-25,12511697,7721716,40.265999,24.85,4789981,15.415,"Gamaleya - Gam-Covid-Vac,SII - Covishield",2,02Mar2021,2022-03-08,0,160028,0,1442,Africa,160028,515.008,0,0,0,1442,4.6409998,0,0,0,2022-01-01,2.50%,89.8,5,All eligible groups are fully government-funded,160640,107,1442,0,5062.377,19.285999,3.372,45.443001,0,0,1.11,,,,,,,983,43.52,31732128,126.719,21.1,3.385,1.948,4227.6299,12,298.245,4.9699998,0.30000001,7.6999998,41.047001,0.89999998,64.07,0.611,,08Mar2022,,,127214,0.40000001,7721716,4789981,60270,442283,39.43,24.33,15.1,Africa,0,Target not reached,71.33377838,2665000,0.3997348,0.22841987,18.30459,12.813213,7.321836,45.640831,45.640831,9.7215281
Europe,Southern Europe,Gibraltar,GI,GIB,,,,Developed,Gibraltar,0,High Income Economies,Europe and Central Asia,,,,,,,,,,292,33.691,33691,124455,47167,369.4,119809,,,,,,,,,,,,,,,,,EURO,OWID,2022-03-01,113138,41968,335.811,124.567,40917,121.448,Pfizer BioNTech - Comirnaty,1,,2022-03-08,198,15807,0,101,Europe,15807,46917.574,379,1124.9301,198,101,299.78299,0,0,0,,,,,,15807,52.285999,101,0,469175.75,3858.5969,1551.9189,2997.833,0,0,,,,,,,,1187,,33691,3457.1001,,,,,,,,,,,,79.93,,157.23,08Mar2022,,,30317,89.989998,41995,40943,1330,1068,336.16,124.65,121.53,Europe,1,Target reached,,,,,,,,90.906754,94.431969,
Africa,Sub-Saharan Africa,Guinea,GN,GIN,x,,,Developing,Guinea,1,Low Income Economies,Sub-Saharan Africa,15273000000,47.467,1168.18,324,11,-10,178,0.477,Low human development,324,13132.792,13132792,7710972,18896132,57.13,7710972,6,High,0.48,8.3,37,43.03782272,4,0,0,0,20220307,54.630001,49.790001,56.900002,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-03-03,5159979,3067446,39.291,23.357,2092533,15.934,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",6,05Mar2021,2022-03-08,0,36397,0,440,Africa,36397,277.146,0,0,0,440,3.3499999,0,0,0,2022-01-01,4.40%,94.3,5,All eligible groups are fully government-funded,36427,4.2859998,440,0,2698.8491,0,0.31799999,32.598999,0,0,0.46000001,,,,,,,1273,54.630001,13497237,51.755001,19,3.135,1.733,1998.926,35.299999,336.71701,2.4200001,,,17.450001,0.30000001,61.599998,0.477,,08Mar2022,,,,,3531742,1875830,298940,172447,36.779999,26.17,13.9,Africa,0,Target not reached,74.76309204,418000,0.6879077,0.3930901,26.674212,18.671947,10.669684,66.917358,66.917358,5.4208469
Americas,Latin America and the Caribbean,Guadeloupe,GP,GLP,,,,Developing,Guadeloupe,0,Unclassified Economies,Unclassified,,,,,,,,,,312,400.127,400127,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,362639,146572,90.632004,36.632,140020,34.993999,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",6,08Jan2021,2022-03-08,0,126256,0,919,Americas,126256,31554.219,1728,431.866,0,919,229.679,1,0.25,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Africa,Sub-Saharan Africa,Gambia,GM,GMB,x,,,Developing,Gambia,1,Low Income Economies,Sub-Saharan Africa,2015000000,82.313,819.22,270,13.4667,-16.5667,172,0.496,Low human development,270,2416.664,2416664,441183,3481712,17.74,441183,5.8,High,3.08,49.5,44,29.72580338,5,0,0,0,20220308,13.89,31.25,35.709999,0,Universal availability,AFRO,REPORTING,2022-02-16,362079,330027,14.983,13.656,316887,13.113,"Beijing CNBG - BBIBP-CorV,SII - Covishield",2,10Mar2021,2022-03-08,15,11963,0,365,Africa,11963,495.01999,24,0.99299997,15,365,15.103,0,0,0,,,,,No availability,11963,3.4289999,365,0,4810.335,6.0320001,1.3789999,146.767,0,0,0.34,,,,,,,189,13.89,2486937,207.56599,17.5,2.339,1.4170001,1561.767,10.1,331.42999,1.91,0.69999999,31.200001,7.8759999,1.1,62.049999,0.49599999,,08Mar2022,,,,,330027,316887,429,3615,14.56,13.27,12.74,Africa,0,Target not reached,65.36135101,10000,0.98093307,0.56053317,38.619644,27.033752,15.447859,82.070023,82.070023,2.266633
Africa,Sub-Saharan Africa,Guinea-Bissau,GW,GNB,x,,x,Developing,Guinea-Bissau,1,Low Income Economies,Sub-Saharan Africa,1565000000,79.137,858.04,624,12,-15,175,0.48,Low human development,624,1967.998,1967998,1004520,2821686,49.84,1004520,6.2,High,3.66,80.7,40,62.57557678,,,,,,,,,,,AFRO,REPORTING,2022-03-06,558351,515764,28.371,26.208,339123,17.232,"Beijing CNBG - BBIBP-CorV,SII - Covishield",2,02Apr2021,2022-03-08,0,8027,0,167,Africa,8027,407.87601,5,0.25400001,0,167,8.4860001,0,0,0,,,,,,8038,2.286,168,0.14300001,3988.1121,2.4809999,1.1339999,83.353996,0.49599999,0.071000002,0.79000002,,,,,,,119,,2015490,66.191002,19.4,3.0020001,1.5650001,1548.675,67.099998,382.474,2.4200001,,,6.4029999,,58.32,0.47999999,,08Mar2022,,,,,515764,339123,1658,17553,27.700001,25.59,16.83,Africa,0,Target not reached,80.16879272,488000,0.93655306,0.53517318,18.345816,12.842071,7.3383265,55.583862,55.583862,48.580418
Africa,Sub-Saharan Africa,Equatorial Guinea,GQ,GNQ,,,,Developing,Equatorial Guinea,0,Upper Middle Income Economies,Sub-Saharan Africa,11619000000,42.703,8625.76,226,2,10,145,0.592,Medium human development,226,1402.985,1402985,820058,2029847,56.56,820058,5.9,High,1.35,2.4,45,254.891098,,,,,,,,,,,AFRO,REPORTING,2022-02-14,455655,251474,32.478001,17.924,204181,14.553,"Beijing CNBG - BBIBP-CorV,Sinovac - CoronaVac",2,12Feb2021,2022-03-08,0,15885,0,183,Africa,15885,1132.229,1,0.071000002,0,183,13.044,1,0.071000002,0,,,,,,15894,1.429,183,0.14300001,10962.203,0,0.98500001,126.216,0,0.098999999,0.50999999,,,,,,,390,,1449891,45.194,22.4,2.846,1.752,22604.873,,202.812,7.7800002,,,24.639999,2.0999999,58.740002,0.59200001,,08Mar2022,,,,,259685,207819,639,5013,32.240002,17.91,14.33,Africa,0,Target not reached,27.58828163,300000,0.1678229,0.0958988,8.1132689,5.6792884,3.2453074,55.563751,55.563751,36.582779
Europe,Southern Europe,Greece,GR,GRC,,,,Developed,Greece,0,High Income Economies,Europe and Central Asia,219012000000,206.688,19827.16,300,39,22,32,0.888,High human development,300,10423.056,10423056,26012945,14519046,250.83,24918831,3.3,Low,,,75,1500.594971,5,0,3242505,1,20220222,72.220001,80.730003,77.980003,100,Universal availability,EURO,REPORTING,2022-02-20,19946219,7828777,186.10001,73.039001,7543277,70.375999,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,8639,2517111,52,26246,Europe,2517111,23483.656,95447,890.48297,8639,26246,244.86501,386,3.6010001,52,2022-01-01,2.50%,91.5,5,All eligible groups are fully government-funded,2538168,14185.143,26303,55.570999,244743.03,2030.423,1367.803,2536.269,5.4959998,5.3579998,0.93000001,,,,,118,11.382,1185,72.220001,10370747,83.478996,45.299999,20.396,14.524,24574.383,1.5,175.69501,4.5500002,35.299999,52,,4.21,82.239998,0.88800001,23.91,08Mar2022,2120,204.412,5395838,52.029999,7869761,7552026,120023,109105,195.10001,75.879997,72.82,Europe,1,Target reached,314.4679871,,0.093487926,0.053421669,1.7646334,1.2352433,0.70585334,76.678047,80.044762,
Americas,Latin America and the Caribbean,Grenada,GD,GRD,,,x,Developing,Grenada,1,Upper Middle Income Economies,Latin America and the Caribben,1121000000,70.19,9575.34,308,12.1167,-61.6667,74,0.779,High human development,308,112.519,112519,181977,158221,161.02,181977,3.6,Medium,6.15,3.4,72,534.2744141,,,,,,,,,,,AMRO,REPORTING,2022-02-25,85891,42971,76.332001,38.188999,37460,33.291,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",4,15Feb2021,2022-03-08,0,13690,0,216,Americas,13690,12166.402,0,0,0,216,191.961,0,0,0,,,,,,13690,0,216,0,121134.36,0,0,1911.251,0,0,0.19,,,,,,,398,,113015,317.13199,29.4,7.3039999,5.0209999,13593.877,,243.964,10.71,,,,3.7,72.400002,0.77899998,,08Mar2022,,,5502,4.8699999,43005,37504,694,579,76.110001,38.049999,33.18,North America,0,Target not reached,85.62580109,58750,0.15118001,0.086388581,3.8706701,2.7094691,1.5482681,47.198822,47.198822,32.284298
Americas,Northern America,Greenland,GL,GRL,,,,Developed,Greenland,0,High Income Economies,Europe and Central Asia,,,,,,,,,,304,56.772,56772,,,,,,,,,,,5,0,19012.2,1,20220307,25,34.900002,39.880001,0,Universal availability,EURO,OWID,2022-02-14,79703,41229,140.39101,72.622002,38474,67.768997,Moderna - mRNA-1273,1,,2022-03-08,15,11825,0,20,Europe,11825,20828.93,78,137.392,15,20,35.229,2,3.523,0,,,,5,All eligible groups are fully government-funded,11825,11.143,20,0.42899999,207937.69,263.76901,195.942,351.69199,0,7.5359998,,,,,,,,35,25,56868,0.13699999,,,,,,199.94099,2.1600001,,,,,71.699997,,5.2600002,08Mar2022,,,,,41243,38502,2780,1128,140.23,72.519997,67.699997,North America,1,Target reached,,,,,,,,,,
Americas,Latin America and the Caribbean,Guatemala,GT,GTM,,,,Developing,Guatemala,0,Upper Middle Income Economies,Latin America and the Caribben,80402000000,32.059,4542.25,320,15.5,-90.25,127,0.663,Medium human development,320,17915.567,17915568,19189736,25549815,105.15,19189736,4.8,Medium,0.52,0.6,55,271.0212708,5,0,0,0,20220225,53.240002,58.07,57.439999,62.5,Universal availability,AMRO,REPORTING,2022-02-25,14535479,7184896,81.133003,40.104,5608096,31.302999,"AstraZeneca - Vaxzevria,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",5,25Feb2021,2022-03-08,1017,792961,10,17083,Americas,792961,4426.1001,15970,89.139999,1017,17083,95.352997,112,0.625,10,2022-01-01,2.50%,95.2,5,All eligible groups are fully government-funded,795808,2141.8569,17106,13.714,43606.234,156.00101,117.363,937.32202,1.26,0.75099999,0.87,,,,,,,2857,53.240002,18249868,157.834,22.9,4.6939998,3.016,7423.8081,8.6999998,155.89799,10.18,,,76.665001,0.60000002,74.300003,0.66299999,130.64999,08Mar2022,,,1908653,10.46,7275131,5716727,132785,96711,81.650002,39.860001,31.32,North America,0,Target not reached,66.84031677,9159000,0.31869668,0.1821124,7.6303973,5.3412781,3.0521591,75.746109,75.746109,47.728642
Americas,Latin America and the Caribbean,French Guiana,GF,GUF,,,,Developing,French Guiana,0,Unclassified Economies,Unclassified,,,,,,,,,,254,298.682,298682,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,219105,95896,73.357002,32.105999,86248,28.875999,"Moderna - Spikevax,Pfizer BioNTech - Comirnaty",2,13Jan2021,2022-03-08,84,77866,1,394,Americas,77866,26069.867,214,71.648003,84,394,131.91299,3,1.0039999,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Oceania,Micronesia,Guam,GU,GUM,,,x,Developing,Guam,0,High Income Economies,East Asia and Pacific,,,,,,,,,,316,168.783,168783,,,,,,,,,,,5,0,0,0,20220207,52.779999,51.040001,58.330002,0,Universal availability,WPRO,REPORTING,2022-02-16,317874,147421,188.342,87.348,133367,79.021004,"Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,04Jan2021,2022-03-08,0,38362,0,331,Western Pacific,38362,22729.67,1062,629.23999,0,331,196.119,9,5.3330002,0,,,,5,All eligible groups are fully government-funded,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Americas,Latin America and the Caribbean,Guyana,GY,GUY,,,x,Developing,Guyana,1,Upper Middle Income Economies,Latin America and the Caribben,7824000000,47.027,9369.01,328,5,-59,122,0.682,Medium human development,328,786.559,786559,1067339,1106461,135.05,1067339,3.6,Medium,0.12,0.1,72,325.8851624,5,0,3589867.22,1,20220208,77.779999,75.519997,79.169998,50,Universal availability,AMRO,REPORTING,2022-02-25,863110,464288,109.733,59.028,349754,44.466999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",6,11Feb2021,2022-03-08,15,63055,0,1223,Americas,63055,8016.6348,152,19.325001,15,1223,155.489,3,0.38100001,0,,,,5,All eligible groups are fully government-funded,63076,18.570999,1223,0.42899999,79809.805,17.714001,23.497999,1547.457,0,0.542,0.47999999,,,,,,,1493,77.779999,790329,3.9519999,26.299999,5.3049998,2.8369999,7435.0469,,373.159,11.62,,,77.158997,1.6,69.910004,0.68199998,,08Mar2022,,,51925,6.5700002,433497,330026,6844,5226,103.18,54.849998,41.759998,South America,1,Target reached,120.1293793,334050,0.15450938,0.088291079,6.3457937,4.4420557,2.5383174,80.865593,80.865593,31.297461
Asia,Eastern Asia,"China, Hong Kong Special Administrative Region",HK,HKG,,,,Developing,Hong Kong,0,High Income Economies,East Asia and Pacific,364682000000,2.132,49485.08,344,22.25,114.1667,4,0.949,High human development,344,7496.988,7496988,14331438,10573920,189.75,13749117,,,,,,,5,0,14322225,1,20220215,65.739998,76.040001,76.190002,75,Universal availability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5,All eligible groups are fully government-funded,525242,40980.715,2578,226.85699,69542.688,3770.125,5425.897,341.32999,38.528999,30.035999,,,,,,,,10257,65.739998,7552800,7039.7139,44.799999,16.302999,10.158,56054.922,,,8.3299999,,,,,84.860001,0.949,12.16,08Mar2022,,,1989909,26.35,6306417,5274800,102018,86319,179.67999,83.5,69.839996,Asia,1,Target reached,105.9209824,,0.037457757,0.021404432,,,,,,
Oceania,Australia and New Zealand,Heard Island and McDonald Islands,HM,HMD,,,,Developed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Americas,Latin America and the Caribbean,Honduras,HN,HND,,,,Developing,Honduras,1,Lower Middle Income Economies,Latin America and the Caribben,26230000000,58.853,2602.17,340,15,-86.5,132,0.634,Medium human development,340,9904.608,9904608,12717612,14088192,126.38,10858977,4.9,Medium,,,65,187.5543366,5,309023.49,0,0,20220305,34.259998,49.48,47.619999,62.5,Universal availability,AMRO,REPORTING,2022-02-25,11561083,5414940,116.724,54.671001,4563441,46.074001,"AstraZeneca - Vaxzevria,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",6,26Feb2021,2022-03-08,0,414311,0,10799,Americas,414311,4183.0132,1578,15.932,0,10799,109.03,24,0.242,0,2022-01-01,2.50%,96.9,5,All eligible groups are fully government-funded,414714,283,10812,4.8569999,41211.789,100.865,28.122999,1074.432,2.6830001,0.48300001,0.43000001,,,,,,,7905,34.259998,10062994,82.805,24.9,4.652,2.8829999,4541.7949,16,240.20799,7.21,2,,84.168999,0.69999999,75.269997,0.634,,08Mar2022,,,1053810,10.47,5414940,4563441,81065,156407,114.89,53.810001,45.349998,North America,1,Target reached,105.0606613,389100,0.37069061,0.21182321,7.3472042,5.143043,2.9388816,90.906082,106.46568,3.0595367
Europe,Southern Europe,Croatia,HR,HRV,,,,Developed,Croatia,0,High Income Economies,Europe and Central Asia,65839000000,87.022,15807.7,191,45.1667,15.5,43,0.851,High human development,191,4105.268,4105268,6962899,5714320,170.59,6837183,3.5,Medium,,,71,1040.085693,5,0,3292815,1,20220228,43.52,45.310001,51.790001,0,Universal availability,EURO,REPORTING,2022-02-20,5179921,2303242,127.6,56.789001,2221948,54.752998,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,157,1063985,20,15234,Europe,1063985,26218.377,9191,226.48199,157,15234,375.39099,165,4.066,20,2022-01-01,2.50%,76.1,5,All eligible groups are fully government-funded,1065001,1294,15250,21.285999,260923.69,248.91901,317.02802,3736.228,3.9200001,5.2150002,0.56,,,1720,421.397,,,278,43.52,4081657,73.725998,44,19.724001,13.053,22669.797,0.69999999,253.782,5.5900002,34.299999,39.900002,,5.54,78.489998,0.85100001,24.290001,08Mar2022,1156,283.133,594785,14.57,2307645,2232194,53059,35538,127.45,56.540001,54.689999,Europe,1,Target reached,314.4679871,,0.11725931,0.067005321,2.545944,1.7821609,1.0183777,74.393166,75.76104,
Americas,Latin America and the Caribbean,Haiti,HT,HTI,x,,x,Developing,Haiti,1,Lower Middle Income Economies,Latin America and the Caribben,8050000000,24.947,1691.83,332,19,-72.4167,170,0.51,Low human development,332,11402.533,11402533,795222,16158356,6.89,795222,6.6,Very High,1.89,25.4,49,56.99440002,5,0,0,0,20220227,37.959999,44.790001,51.189999,0,Universal availability,AMRO,REPORTING,2022-02-25,234119,151962,2.053,1.3329999,101391,0.889,"Janssen - Ad26.COV 2-S,Moderna - Spikevax",2,,2022-03-08,0,30400,0,825,Americas,30400,266.608,47,0.412,0,825,7.2350001,5,0.044,0,2022-01-01,3.60%,62.4,,No availability,30400,8.2860003,825,0.71399999,2633.9309,1.3,0.71799999,71.480003,0.17299999,0.061999999,0.75,,,,,,,65,37.959999,11541683,398.448,24.299999,4.8000002,2.954,1653.173,23.5,430.548,6.6500001,2.9000001,23.1,22.863001,0.69999999,64,0.50999999,,08Mar2022,,,,,156166,105573,14852,5695,2.0699999,1.35,0.91000003,North America,0,Target not reached,50,,0.57015187,0.32580104,24.177814,16.924469,9.6711254,29.44071,29.44071,
Europe,Eastern Europe,Hungary,HU,HUN,,,,Developed,Hungary,0,High Income Economies,Europe and Central Asia,171751000000,76.584,18527.59,348,47,20,40,0.854,High human development,348,9660.35,9660350,30732977,13487827,319,30625075,3.4,Low,,,74,1062.394165,5,0,19959700,1,20220228,51.849998,60.419998,56.549999,87.5,Universal availability,EURO,REPORTING,2022-02-20,15916521,6326391,162.89999,64.755997,6102186,62.460999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",7,23Dec2020,2022-03-08,1387,1807285,59,44495,Europe,1807285,18499.209,17704,181.217,1387,44495,455.44699,444,4.5450001,59,2022-01-01,2.50%,84.1,5,All eligible groups are fully government-funded,1807285,2529.1431,44495,63.429001,187591.3,143.967,262.51801,4618.4609,6.1240001,6.5840001,0.63,,,3997,414.87799,,,506,51.849998,9634162,108.043,43.400002,18.577,11.976,26777.561,0.5,278.29599,7.5500002,26.799999,34.799999,,7.02,76.879997,0.85399997,-4.1100001,08Mar2022,,,4048407,42.02,6397623,6176191,187488,125911,167.57001,66.410004,64.110001,Europe,1,Target reached,350.7970581,,0.10004539,0.057168797,2.4924836,1.7447385,0.99699342,51.789715,51.972187,
Asia,South-eastern Asia,Indonesia,ID,IDN,,,,Developing,Indonesia,1,Lower Middle Income Economies,East Asia and Pacific,1167180000000,41.396,4224.98,360,-5,120,107,0.718,High human development,360,273523.621,273523616,387486882,386906503,140.21,341251545,4.5,Medium,,,57,120.1249619,5,0,338558,1,20220307,63.43,58.59,61.610001,37.5,Universal availability,SEARO,REPORTING,2022-03-01,345697245,190976834,126.387,69.820999,144505806,52.831001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Novavax - Covavax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",7,13Jan2021,2022-03-08,30148,5800253,401,150831,South-East Asia,5800253,2120.5681,211077,77.169998,30148,150831,55.144001,2171,0.79400003,401,2022-01-01,2.50%,96.6,5,All eligible groups are fully government-funded,5800253,30153.857,150831,310.14301,20987.898,109.089,109.11,545.77399,1.451,1.122,0.69999999,,,,,,,4328,63.43,276361788,145.72501,29.299999,5.3189998,3.053,11188.744,5.6999998,342.86401,6.3200002,2.8,76.099998,64.204002,1.04,71.720001,0.71799999,,08Mar2022,,,12847312,4.6500001,192068763,148021351,2952259,1897011,127.98,69.5,53.560001,Asia,1,Target reached,106.9988403,13725330,0.22830877,0.13046215,11.471388,8.0299711,4.5885549,89.21521,101.30276,3.5421405
Europe,Northern Europe,Isle of Man,IM,IMN,,,,Developed,Isle of Man,0,High Income Economies,Europe and Central Asia,,,,,,,,,,833,85.032,85032,,119574,,,,,,,,,,,,,,,,,,,EURO,OWID,2022-03-02,187694,69417,220.733,81.636002,66673,78.408997,"Moderna - mRNA-1273, AstraZeneca - AZD1222, Pfizer BioNTech - Comirnaty",3,,2022-03-08,85,23574,0,80,Europe,23574,27723.68,760,893.78101,85,80,94.082001,0,0,0,,,,,,23777,115.429,80,0,278386.59,2025.524,1351.464,936.65802,0,0,,,,,,,,784,,85410,147.87199,,,,,,,,,,,,81.400002,,,08Mar2022,,,51718,60.549999,69429,66697,2140,6039,219.92999,81.290001,78.089996,Europe,1,Target reached,,,,,,,,,,
Asia,Southern Asia,India,IN,IND,,,,Developing,India,1,Lower Middle Income Economies,South Asia,2833870000000,90.601,2116.44,356,20,77,131,0.645,Medium human development,356,1380004.385,1380004352,1965542748,1950772646,141.06,1691598587,4.6,Medium,0.31,1.6,55,63.74832153,5,1410000000,130205680,1,20220228,71.760002,67.970001,74.110001,25,Universal availability,SEARO,REPORTING,2022-02-28,1776718549,964234491,128.74699,69.872002,792399551,57.419998,"Bharat - Covaxin,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,SII - Covishield,Zydus - ZyCov-D",6,16Jan2021,2022-03-08,3993,42971308,108,515210,South-East Asia,42971308,3113.853,40263,2.918,3993,515210,37.334,1187,0.086000003,108,2022-01-01,2.50%,98.3,4,"Partial government funding for some eligible groups, full funding for others",42975883,5326.2861,515355,158.429,30842.26,3.283,3.822,369.85199,0.104,0.114,0.33000001,,,,,,,1450,71.760002,1393409033,450.41901,28.200001,5.9889998,3.414,6426.6738,21.200001,282.28,10.39,1.9,20.6,59.549999,0.52999997,69.660004,0.64499998,,08Mar2022,,,19497788,1.4,967460932,802358408,18627269,10037995,128.41,69.43,57.580002,Asia,1,Target reached,100.3886795,,0.45576534,0.26043734,21.616255,15.131379,8.6465025,90.39328,105.03192,
Africa,Sub-Saharan Africa,British Indian Ocean Territory,IO,IOT,,,,Developing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Europe,Northern Europe,Ireland,IE,IRL,,,,Developed,Ireland,0,High Income Economies,Europe and Central Asia,457515000000,57.35,102394.02,372,53,-8,2,0.955,High human development,372,4937.796,4937796,12363083,6976066,248.11,12363083,3,Low,,,76,5428.588867,5,12428000,19633914,1,20220308,14.81,46.880001,39.290001,100,Universal availability,EURO,REPORTING,2022-02-20,10418205,4018239,209.89999,80.940002,3926851,79.099998,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,2383,1322591,15,6570,Europe,1322591,26641.293,22258,448.349,2383,6570,132.341,73,1.47,15,2022-01-01,2.50%,92.2,5,All eligible groups are fully government-funded,1326946,3318,6571,9,266299.72,873.98798,665.87701,1318.709,0.20100001,1.806,0.94,48,9.6330004,603,121.014,18,3.6259999,985,14.81,4982904,69.874001,38.700001,13.928,8.6780005,67335.297,0.2,126.459,3.28,23,25.700001,,2.96,82.300003,0.95499998,6.2199998,08Mar2022,610,122.471,2840811,57.009998,4057788,3983568,135326,91553,213.59,81.43,79.940002,Europe,1,Target reached,314.4679871,,0.01810262,0.010344354,0.4877879,0.34145153,0.19511516,84.268661,84.268661,
Asia,Southern Asia,Iran (Islamic Republic of),IR,IRN,,,,Developing,Iran,0,Lower Middle Income Economies,Middle East and North Africa,651707000000,33.599,12725.04,364,32,53,70,0.783,High human development,364,83992.953,83992952,156793028,119040264,184.4,134370948,3.7,Medium,0.33,0.2,72,470.4346008,5,0,0,0,20220225,62.040001,58.330002,61.310001,37.5,Universal availability,EMRO,REPORTING,2022-03-06,142195819,63110540,169.295,75.138,55717367,66.335999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Bharat - Covaxin,Finlay - Soberana-02,Gamaleya - Gam-Covid-Vac,Shifa - COVIran Barakat",6,09Feb2021,2022-03-08,6426,7096318,168,138116,Eastern Mediterranean,7096318,8448.707,44889,53.444,6426,138116,164.438,1278,1.522,168,2020-11-01,3.00%,76,5,All eligible groups are fully government-funded,7102159,5916.8569,138260,170.85699,83526.547,68.694,69.586998,1626.038,1.694,2.0090001,0.50999999,,,,,,,2865,62.040001,85028760,49.831001,32.400002,5.4400001,3.1819999,19082.619,0.2,270.30801,9.5900002,0.80000001,21.1,,1.5,76.68,0.78299999,36.110001,08Mar2022,,,24188461,28.450001,63221401,55822245,1706088,1225502,168.45,74.349998,65.650002,Asia,1,Target reached,108.2359161,8929000,0.075803295,0.043316171,2.9292064,2.0504444,1.1716825,90.69014,105.82333,5.6947684
Asia,Western Asia,Iraq,IQ,IRQ,,,,Developing,Iraq,0,Upper Middle Income Economies,Middle East and North Africa,196269000000,59.405,4892.96,368,33,44,123,0.674,Medium human development,368,40222.503,40222504,18464821,57651091,44.84,16187603,4.9,Medium,0.04,0,61,253.3146362,5,0,0,0,20220228,64.809998,53.650002,61.310001,0,Universal availability,EMRO,REPORTING,2022-03-05,17014009,9992944,42.299999,24.844,6892020,17.135,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty",4,02Mar2021,2022-03-08,737,2308928,18,25068,Eastern Mediterranean,2308928,5740.3901,6135,15.253,737,25068,62.323002,79,0.19599999,18,2022-01-01,2.50%,85,5,All eligible groups are fully government-funded,2309816,857.14301,25076,11,56091.609,21.563999,20.815001,608.94598,0.19400001,0.26699999,0.58999997,,,,,,,791,64.809998,41179351,88.125,20,3.1860001,1.957,15663.986,2.5,218.612,8.8299999,,,94.575996,1.4,70.599998,0.67400002,,08Mar2022,,,,,9992944,6892020,9985,435337,41.32,24.27,16.74,Asia,0,Target not reached,34.5888176,750000,0.29585364,0.16905922,8.1637602,5.7146325,3.2655041,92.14283,105.10518,4.0617776
Europe,Northern Europe,Iceland,IS,ISL,,,,Developed,Iceland,0,High Income Economies,Europe and Central Asia,21580000000,75.81,68843.65,352,65,-18,4,0.949,High human development,352,341.25,341250,895929,480704,260.93,872031,2.5,Low,,,84,6274.959473,5,0,0,0,20220228,11.11,34.380001,25,100,Universal availability,EURO,REPORTING,2022-02-13,785791,305549,215.8,83.911003,294646,80.917,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,2011,147151,0,70,Europe,147151,40411.223,16827,4621.1011,2011,70,19.224001,8,2.197,0,2022-01-01,16.70%,96.4,5,All eligible groups are fully government-funded,150467,2465.1431,73,1.143,407999.63,8991.5176,6684.3721,197.944,5.4229999,3.099,1.13,,,54,146.424,0,0,849,11.11,368792,3.404,37.299999,14.431,9.2069998,46482.957,0.2,117.992,5.3099999,14.3,15.2,,2.9100001,82.989998,0.949,20.93,08Mar2022,82,222.446,249605,67.68,309518,289482,21266,7546,217.89999,83.93,78.489998,Europe,1,Target reached,153.5560303,,0.026924778,0.015385588,0.42199475,0.29539633,0.16879791,87.706841,90.110443,
Asia,Western Asia,Israel,IL,ISR,,,,Developed,Israel,0,High Income Economies,Middle East and North Africa,408513000000,73.246,49840.25,376,31.5,34.75,19,0.919,High human development,376,8655.541,8655541,18751229,12305686,213.33,18129791,2.7,Low,,,82,3456.386963,5,0,141155058.2,1,20220307,21.299999,45.310001,41.07,75,Universal availability,EURO,REPORTING,2022-02-13,13765678,7046983,159,81.416,6366185,73.550003,"AstraZeneca - Vaxzevria,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,16Dec2020,2022-03-08,4769,3682528,2,10322,Europe,3682528,42545.324,45739,528.43597,4769,10322,119.253,83,0.95899999,2,2022-01-01,2.50%,92.7,5,All eligible groups are fully government-funded,3688096,6485.8569,10322,14.857,396953.63,803.35797,698.08002,1110.968,0.53799999,1.599,0.56,247,26.584999,1237,133.14,77,8.2880001,125,21.299999,9291000,402.60599,30.6,11.733,7.3590002,33132.32,0.5,93.32,6.7399998,15.4,35.400002,,2.99,82.970001,0.91900003,14.87,08Mar2022,705,75.879997,5199065,55.959999,6700041,6122853,234338,185450,193.97,72.110001,65.900002,Asia,1,Target reached,222.9863434,,0.037190825,0.0212519,0.76611793,0.53628254,0.30644718,73.41214,75.928497,
Europe,Southern Europe,Italy,IT,ITA,,,,Developed,Italy,0,High Income Economies,Europe and Central Asia,2111650000000,154.753,35584.88,380,42.8333,12.8333,29,0.892,High human development,380,60461.828,60461828,138941773,84514459,230.16,134577199,3.2,Low,,,82,2905.5,5,0,5953246,1,20220305,63.889999,73.440002,73.209999,75,Universal availability,EURO,REPORTING,2022-02-20,131126289,50198378,219.89999,84.170998,46795578,78.460999,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,22662,13048774,130,156017,Europe,13048774,21878.686,264850,444.07001,22662,156017,261.591,1250,2.096,130,2022-01-01,2.50%,95.3,5,All eligible groups are fully government-funded,13109527,39936.43,156201,171.571,217162.11,1006.386,661.55499,2587.5029,3.0480001,2.842,0.81,610,10.105,9599,159.009,328,5.4330001,1252,63.889999,60367471,205.85899,47.900002,23.021,16.24,35220.086,2,113.151,4.7800002,19.799999,27.799999,,3.1800001,83.510002,0.89200002,13.96,08Mar2022,4413,73.101997,37905809,62.790001,50654119,47616443,725671,665588,223.08,83.910004,78.879997,Europe,1,Target reached,372.446228,,0.052089538,0.029765451,0.91137499,0.63796246,0.36454999,94.374992,97.435738,
Americas,Latin America and the Caribbean,Jamaica,JM,JAM,,,x,Developing,Jamaica,0,Upper Middle Income Economies,Latin America and the Caribben,15372000000,95.812,5421.64,388,18.25,-77.5,101,0.734,High human development,388,2961.161,2961161,3068018,4162847,103.18,2967812,4.1,Medium,0.86,0.4,65,327.4035339,5,1200000,6000000000,1,20220221,74.07,71.349998,81.550003,0,Universal availability,AMRO,REPORTING,2022-02-25,1353947,764769,45.723,25.827,648481,21.9,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",5,10Mar2021,2022-03-08,34,128213,3,2830,Americas,128213,4329.813,227,7.6659999,34,2830,95.57,17,0.574,3,2021-01-01,11.50%,53.5,5,All eligible groups are fully government-funded,128228,25,2831,2.4289999,43124.145,5.0450001,8.408,952.08899,0.336,0.81699997,0.51999998,,,,,,,440,74.07,2973462,266.879,31.4,9.684,6.3899999,8193.5713,,206.537,11.28,5.3000002,28.6,66.425003,1.7,74.470001,0.73400003,1.92,08Mar2022,,,29774,1,770737,656984,29318,13772,46.040001,25.92,22.09,North America,0,Target not reached,91.11867523,1398010,0.26700407,0.15257376,6.3163643,4.4214549,2.5265458,44.131001,45.621052,45.567204
Europe,Northern Europe,Jersey,JE,JEY,,,,Developed,Jersey,0,Unclassified Economies,Unclassified,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EURO,OWID,2022-02-27,222371,82645,206.289,76.667999,78935,73.225998,"Moderna - mRNA-1273, AstraZeneca - AZD1222, Pfizer BioNTech - Comirnaty",3,,2022-03-08,229,39490,1,115,Europe,39490,36634.012,1983,1839.5861,229,115,106.683,3,2.783,1,,,,,,,,,,,,,,,,,,,,,,,970,,101073,,,,,,,,,,,,,,,,27Feb2022,,,60791,60.150002,82645,78935,,1233,220.00999,81.769997,78.099998,Europe,1,Target reached,,,,,,,,,,
Asia,Western Asia,Jordan,JO,JOR,,,,Developing,Jordan,0,Upper Middle Income Economies,Middle East and North Africa,44863000000,90.888,4393.64,400,31,36,102,0.729,High human development,400,10203.14,10203140,10440514,14376631,101.67,9092192,4.3,Medium,0.85,0.5,76,334.04422,5,0,0,0,20220221,34.259998,38.02,39.880001,25,Universal availability,EMRO,REPORTING,2022-03-02,9649298,4694106,94.571999,46.007,4385036,42.977001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",6,13Jan2021,2022-03-08,0,1654677,0,13882,Eastern Mediterranean,1654677,16217.341,22969,225.117,0,13882,136.056,47,0.461,0,2022-01-01,2.50%,93.9,5,All eligible groups are fully government-funded,1654677,3281.2859,13882,6.7140002,161132.88,1601.808,319.53201,1351.833,3.214,0.65399998,0.41,,,,,,,2197,34.259998,10269022,109.285,23.200001,3.8099999,2.3610001,8337.4902,0.1,208.257,11.75,,,,1.4,74.529999,0.72899997,25.33,08Mar2022,,,,,4694106,4385036,185322,87729,93.970001,45.709999,42.700001,Asia,1,Target reached,64.1626358,1200000,0.32947624,0.18827213,6.1907973,4.3335581,2.4763188,92.421677,106.1273,11.493687
Asia,Eastern Asia,Japan,JP,JPN,,,,Developed,Japan,0,High Income Economies,East Asia and Pacific,5103180000000,256.86,40704.3,392,36,138,19,0.919,High human development,392,126476.458,126476456,293143728,176471114,232.56,258958758,2.3,Low,,,83,4360.473633,5,840442222757,8269849765,1,20220307,47.220001,56.25,50,100,Universal availability,WPRO,REPORTING,2022-02-24,223820819,101672246,176.966,80.388,100178635,79.207001,"AstraZeneca - Vaxzevria,Moderna - Spikevax,Novavax - Covavax,Pfizer BioNTech - Comirnaty",4,17Feb2021,2022-03-08,40575,5434108,114,25049,Western Pacific,5434108,4296.5371,428216,338.57401,40575,25049,19.805,1416,1.12,114,2022-01-01,2.50%,94,5,All eligible groups are fully government-funded,5486083,59262,25317,201.714,43522.797,427.90701,470.14401,200.84801,1.975,1.6,0.81999999,2017,16.000999,27492,218.103,,,8119,47.220001,126050796,347.77802,48.200001,27.049,18.493,39002.223,,79.370003,5.7199998,11.2,33.700001,,13.05,84.629997,0.91900003,2.0699999,08Mar2022,,,32749794,25.98,101824621,100351180,6586453,1997542,186.37,80.779999,79.610001,Asia,1,Target reached,275.2858582,,0.045538187,0.026021821,0.60727346,0.42509145,0.24290939,76.351906,86.431068,
Asia,Central Asia,Kazakhstan,KZ,KAZ,,x,,Developing,Kazakhstan,0,Upper Middle Income Economies,Europe and Central Asia,180716000000,25.176,10144.68,398,48,68,51,0.825,High human development,398,18776.707,18776708,23010492,26592941,121.14,21251558,3,Low,0.58,0.4,76,272.9652405,5,6000000,0,0,20220124,76.849998,54.169998,61.900002,0,Universal availability,EURO,REPORTING,2022-02-20,24149547,10110959,128.60001,53.848,8159841,43.457001,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty,RIBSP - QazVac,Sinovac - CoronaVac",5,07Apr2021,2022-03-08,81,1392250,1,18980,Europe,1392250,7414.772,1580,8.415,81,18980,101.083,33,0.176,1,2022-01-01,2.50%,84,5,All eligible groups are fully government-funded,1392338,196,18980,4.7140002,73300.398,8.8970003,10.319,999.21301,0.052999999,0.248,0.37,,,,,,,565,76.849998,18994958,6.6810002,30.6,6.9910002,4.625,24055.588,0.1,466.79199,7.1100001,7,43.099998,98.999001,6.6999998,73.599998,0.82499999,29.120001,08Mar2022,,,2514071,13.24,9394344,9010266,2118887,351158,110.13,49.459999,47.439999,Asia,1,Target reached,70,,0.14269549,0.081540272,7.576056,5.3032393,3.0304224,104.95016,113.6366,
Africa,Sub-Saharan Africa,Kenya,KE,KEN,,,,Developing,Kenya,1,Lower Middle Income Economies,Sub-Saharan Africa,105681000000,69.73,2198.59,404,1,38,143,0.601,Medium human development,404,53771.3,53771300,24650091,76979983,44.83,24650091,5.6,High,0.66,1.9,55,83.41162872,4,0,0,0,20220307,32.41,44.060001,50.360001,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-03-03,16786825,7858965,31.219,14.616,7662349,14.25,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",5,05Mar2021,2022-03-08,19,323094,0,5641,Africa,323094,600.867,148,0.27500001,19,5641,10.491,2,0.0040000002,0,2022-01-01,2.50%,90.9,5,All eligible groups are fully government-funded,323115,19.570999,5641,0.28600001,5876.3462,0.382,0.35600001,102.59,0,0.0049999999,0.66000003,,,,,,,1146,32.41,54985702,87.323997,20,2.6860001,1.528,2993.0281,36.799999,218.63699,2.9200001,1.2,20.4,24.650999,1.4,66.699997,0.60100001,,08Mar2022,,,255481,0.46000001,8816664,7667915,282646,236375,30.440001,16.030001,13.95,Africa,0,Target not reached,57.79537964,6236500,0.43873572,0.25070614,16.520479,11.564335,6.6081915,68.100456,68.100456,25.30011
Asia,Central Asia,Kyrgyzstan,KG,KGZ,,x,,Developing,Kyrgyzstan,1,Lower Middle Income Economies,Europe and Central Asia,8451000000,67.555,1224.75,417,41,75,120,0.697,Medium human development,417,6524.191,6524191,6017876,9279686,90.79,6017876,3.8,Medium,0.89,2.5,70,62.14477539,5,50861786,0,0,20220220,47.220001,54.689999,51.790001,75,Universal availability,EURO,REPORTING,2022-02-20,2492189,1320378,38.200001,20.238001,1110070,17.014999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,RIBSP - QazVac",6,31Mar2021,2022-03-08,17,200658,2,2968,Europe,200658,3075.6001,131,2.0079999,17,2968,45.492001,10,0.153,2,2022-01-01,3.10%,70.9,5,All eligible groups are fully government-funded,200658,18.714001,2968,1.429,30272.705,2.5650001,2.823,447.77399,0.30199999,0.21600001,0.5,,,,,,,945,47.220001,6628347,32.333,26.299999,4.4889998,2.882,3393.4741,1.4,436.362,7.1100001,3.5999999,50.5,89.220001,4.5,71.449997,0.69700003,20.200001,08Mar2022,,,,,1456004,1183841,34472,22900,41.98,21.969999,17.860001,Asia,0,Target not reached,77.90689087,1935200,0.78758931,0.45005104,22.174028,15.52182,8.8696117,41.413101,41.413101,32.157524
Asia,South-eastern Asia,Cambodia,KH,KHM,x,,,Developing,Cambodia,1,Lower Middle Income Economies,East Asia and Pacific,28547000000,36.961,1647.02,116,13,105,144,0.594,Medium human development,116,16718.971,16718971,39237800,23725024,231.54,38537913,4.9,Medium,,,60,113.3104401,5,0,0,0,20220221,16.67,32.810001,37.5,0,Universal availability,WPRO,REPORTING,2022-02-25,35067827,14524943,209.74899,86.876999,13841557,82.790001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",7,10Feb2021,2022-03-08,306,132708,1,3042,Western Pacific,132708,793.75702,2432,14.546,306,3042,18.195,10,0.059999999,1,2022-01-01,2.50%,98.3,,No availability,133065,353.71399,3043,1.571,7852.0889,21.066,20.872,179.56599,0.059,0.093000002,1.22,,,,,,,5774,16.67,16946446,90.671997,25.6,4.4120002,2.385,3645.0701,,270.892,4,2,33.700001,66.228996,0.80000001,69.82,0.59399998,,08Mar2022,,,8455724,49.900002,14693174,13866433,341978,289014,212.21001,86.699997,81.830002,Asia,1,Target reached,159.4291687,10101000,0.5856638,0.33466503,12.16128,8.5128965,4.864512,89.372559,90.995659,25.743034
Oceania,Micronesia,Kiribati,KI,KIR,x,,x,Developing,Kiribati,1,Lower Middle Income Economies,East Asia and Pacific,219000000,20.94,1927.08,296,1.4167,173,134,0.63,Medium human development,296,119.446,119446,207003,169943,170.53,207003,5.9,High,16.12,11.2,41,172.3057404,5,0,0,0,20220228,72.690002,69.010002,75.300003,25,Universal availability,WPRO,REPORTING,2022-02-19,127916,76491,107.088,64.037003,50428,42.216999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV",2,26May2021,2022-03-08,6,2991,1,12,Western Pacific,2991,2503.998,77,64.462997,6,12,10.046,1,0.83700001,1,,,,5,All eligible groups are fully government-funded,3000,8.5710001,13,0.28600001,24714.141,74.141998,70.612,107.095,8.2379999,2.3540001,0.47,,,,,,,1862,72.690002,121388,143.701,23.200001,3.895,2.21,1981.132,,434.65701,22.66,35.900002,58.900002,,1.9,68.370003,0.63,,08Mar2022,,,,,76491,50428,,1494,104.56,63.009998,41.540001,Oceania,1,Target reached,92.42594147,103000,0.50055003,0.28602859,7.9974122,5.5981884,3.1989648,61.794273,61.794273,49.757732
Americas,Latin America and the Caribbean,Saint Kitts and Nevis,KN,KNA,,,x,Developing,Saint Kitts and Nevis,0,High Income Economies,Latin America and the Caribben,952000000,61.704,16917.16,659,17.3333,-62.75,74,0.779,High human development,659,53.192,53192,69005,74964,128.87,69005,3.2,Low,,,,1087.801025,,,,,,,,,,,AMRO,REPORTING,2022-02-25,60467,31162,113.677,58.584,26294,49.431999,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty,SII - Covishield",3,22Feb2021,2022-03-08,0,5536,0,42,Americas,5536,10407.58,6,11.28,0,42,78.959,0,0,0,,,,,,5537,1,42,0,103406.41,18.676001,18.676001,784.37201,0,0,0.47999999,,,,,,,336,,53546,212.86501,,,,24654.385,,,12.84,,,,2.3,76.230003,0.77899998,,08Mar2022,,,3011,5.6199999,31162,26294,4024,894,112.93,58.200001,49.110001,North America,1,Target reached,64.43431854,41000,0.10956922,0.062610984,2.4342687,1.7039881,0.9737075,87.626984,87.626984,59.415985
Asia,Eastern Asia,Republic of Korea,KR,KOR,,,,Developing,South Korea,0,High Income Economies,East Asia and Pacific,1674110000000,51.297,35195.52,410,37,127.5,23,0.916,High human development,410,51269.183,51269184,131438752,71827258,256.19,118730456,2.9,Low,,,86,2624.533203,5,61600000,7698257367,1,20220306,40.740002,56.77,57.740002,50,Universal availability,WPRO,REPORTING,2022-02-27,118895241,44776711,231.90401,87.335999,44285420,86.377998,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Novavax - Covavax,Pfizer BioNTech - Comirnaty",5,26Feb2021,2022-03-08,202721,4869691,186,9282,Western Pacific,4869691,9498.2803,1596246,3113.4609,202721,9282,18.104,1112,2.1689999,186,2022-01-01,2.50%,95.6,5,All eligible groups are fully government-funded,5212118,245633.14,9440,167.714,101590.48,6674.3159,4787.687,183.99699,3.0799999,3.2690001,1.49,955,18.614,,,819,15.963,1131,40.740002,51305184,527.96698,43.400002,13.914,8.6219997,35938.375,0.2,85.998001,6.8000002,6.1999998,40.900002,,12.27,83.029999,0.91600001,8.2799997,08Mar2022,11957,233.056,31868296,62.119999,44880845,44400545,1381540,880612,233.17999,87.480003,86.540001,Asia,1,Target reached,220.620575,1413000,0.052665792,0.030094739,1.0089413,0.70625895,0.40357652,90.456764,100.13879,1.0750254
Asia,Western Asia,Kuwait,KW,KWT,,,,Developing,Kuwait,0,High Income Economies,Middle East and North Africa,116130000000,7.909,27927.16,414,29.3375,47.6581,64,0.806,High human development,414,4270.563,4270563,8324240,6059974,192.31,7831651,3.8,Medium,,,76,1758.674194,5,60000000,0,0,20220228,43.52,49.48,49.400002,50,Universal availability,EMRO,REPORTING,2022-03-06,7592265,3393521,177.78101,79.462997,3277287,76.740997,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",5,28Dec2020,2022-03-08,610,623769,1,2546,Eastern Mediterranean,623769,14606.22,3875,90.737,610,2546,59.617001,8,0.18700001,1,2022-01-01,2.70%,97.5,5,All eligible groups are fully government-funded,624205,536.14301,2548,1.286,144206.39,100.727,123.862,588.64899,0.46200001,0.29699999,0.44999999,,,,,,,817,43.52,4328553,232.12801,33.700001,2.345,1.114,65530.535,,132.235,15.84,2.7,37,,2,75.489998,0.80599999,14.51,08Mar2022,,,380911,8.8000002,3393521,3277287,19007,40778,175.39999,78.400002,75.709999,Asia,1,Target reached,96.15536499,,0.066372663,0.037927236,1.5056797,1.0539758,0.60227185,91.206703,96.943352,
Asia,South-eastern Asia,Lao People's Democratic Republic,LA,LAO,x,x,,Developing,Laos,1,Lower Middle Income Economies,East Asia and Pacific,19269000000,70.921,2625.61,418,18,105,137,0.613,Medium human development,418,7275.556,7275556,15881854,10331101,215.22,15287816,4.7,Medium,,,51,68.22131348,4,0,0,0,20220228,84.260002,79.480003,78.330002,87.5,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,WPRO,REPORTING,2022-02-17,8791236,4830440,120.832,66.392998,4255830,58.494999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Gamaleya - Sputnik-Light,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",8,25Nov2020,2022-03-08,165,144320,3,632,Western Pacific,144320,1983.627,1577,21.674999,165,632,8.6870003,11,0.15099999,3,2022-01-01,3.80%,98.2,5,All eligible groups are fully government-funded,144551,226.286,633,1.429,19588.561,31.304001,30.665001,85.779999,0.13600001,0.19400001,0.86000001,,,,,,,4642,84.260002,7379358,29.715,24.4,4.0289998,2.322,6397.3599,22.700001,368.11099,4,7.3000002,51.200001,49.839001,1.5,67.919998,0.61299998,,08Mar2022,,,,,5094724,4360273,662440,146235,128.13,69.040001,59.09,Asia,1,Target reached,112.6054459,9239760,0.3673813,0.20993216,20.198967,14.139277,8.079586,55.353966,57.504852,58.178093
Asia,Western Asia,Lebanon,LB,LBN,,,,Developing,Lebanon,0,Upper Middle Income Economies,Middle East and North Africa,,,,422,33.8333,35.8333,92,0.744,High human development,422,6825.442,6825442,5719933,9476811,84.5,5088371,5,High,,,73,663.0510864,5,34000000,0,0,20220214,35.189999,50,50,50,Universal availability,EMRO,REPORTING,2022-02-28,5452304,2641501,79.882004,38.701,2285770,33.488998,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty",4,14Feb2021,2022-03-08,1126,1079375,9,10161,Eastern Mediterranean,1079375,15813.987,10665,156.254,1126,10161,148.869,70,1.026,9,2022-01-01,2.50%,91.9,5,All eligible groups are fully government-funded,1080381,1383.571,10169,9.2860003,159603.63,148.61501,204.394,1502.256,1.182,1.372,0.58999997,,,,,,,700,35.189999,6769151,594.56097,31.1,8.5139999,5.4299998,13367.565,,266.591,12.71,26.9,40.700001,,2.9000001,78.93,0.74400002,6.8800001,08Mar2022,,,539250,7.9699998,2499496,2170547,285437,56153,76.959999,36.919998,32.07,Asia,0,Target not reached,48.63261414,817250,,,3.1189151,2.1832404,1.247566,95.321114,107.15225,14.287755
Africa,Sub-Saharan Africa,Liberia,LR,LBR,x,,,Developing,Liberia,1,Low Income Economies,Sub-Saharan Africa,3110000000,56.608,703.406,430,6.5,-9.5,175,0.48,Low human development,430,5057.677,5057677,1655594,7252291,31.96,1655594,6.2,High,1.82,17.1,39,52.56287003,1,57500000,0,0,20220307,29.629999,36.669998,41.900002,0,Availability for ONE or TWO of following: key workers/clinically vulnerable groups (non elderly)/elderly groups,AFRO,REPORTING,2022-02-10,1200630,1116709,23.739,22.079,1084591,21.444,SII - Covishield,1,01Apr2021,2022-03-08,0,7384,0,294,Africa,7384,145.996,0,0,0,294,5.8130002,0,0,0,2021-06-01,7.50%,57,5,All eligible groups are fully government-funded,7384,0,294,0,1425.425,0,0,56.754002,0,0,0.079999998,,,,,,,305,29.629999,5180208,49.126999,19.200001,3.0569999,1.756,752.78802,38.599998,272.509,2.4200001,1.5,18.1,1.188,0.80000001,64.099998,0.47999999,,08Mar2022,,,,,1116709,1084591,8242,39207,23.18,21.559999,20.940001,Africa,0,Target not reached,63.99068832,27000,1.1424412,0.65282357,21.840511,15.288359,8.7362051,72.519592,72.519592,1.6308346
Africa,Northern Africa,Libya,LY,LBY,,,,Developing,Libya,0,Upper Middle Income Economies,Middle East and North Africa,31757000000,,4068.61,434,25,17,105,0.724,High human development,434,6871.287,6871287,5753319,9741953,82.68,5753319,4.4,Medium,0.8,,64,,5,0,13408000,1,20220307,44.439999,42.189999,48.209999,0,Universal availability,EMRO,REPORTING,2022-03-06,3347763,2168808,48.721001,31.563,1100438,16.014999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",7,11Apr2021,2022-03-08,495,498453,9,6308,Eastern Mediterranean,498453,7254.1382,4007,58.314999,495,6308,91.802002,47,0.68400002,9,2022-01-01,2.50%,78.4,5,All eligible groups are fully government-funded,498839,532,6314,6.4289999,71687.328,55.471001,76.453003,907.375,0.86199999,0.92400002,0.52999997,,,,,,,748,44.439999,6958538,3.6229999,29,4.4239998,2.816,17881.51,,341.862,10.43,,,,3.7,72.910004,0.72399998,,08Mar2022,,,79418,1.14,2172442,1101751,48231,23862,48.189999,31.219999,15.83,Africa,0,Target not reached,68.13363647,731250,0.3557972,0.20331268,,,,58.188377,58.188377,12.710054
Americas,Latin America and the Caribbean,Saint Lucia,LC,LCA,,,x,Developing,Saint Lucia,1,Upper Middle Income Economies,Latin America and the Caribben,1937000000,95.645,9419.27,662,13.8833,-61.1333,86,0.759,High human development,662,183.629,183629,294083,258161,159.48,294083,3.8,Medium,5.22,2.4,68,502.1817017,,,,,,,,,,,AMRO,REPORTING,2022-02-25,116213,57622,63.287998,31.379999,51912,28.27,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty,SII - Covishield",3,17Feb2021,2022-03-08,0,22779,0,362,Americas,22779,12405.038,91,49.556999,0,362,197.13901,4,2.178,0,,,,,,22808,13.714,364,0.85699999,123686.97,70.499001,74.372002,1973.959,10.846,4.6479998,0.50999999,,,,,,,5217,,184401,293.18701,34.900002,9.7209997,6.4050002,12951.839,,204.62,11.62,,,87.202003,1.3,76.199997,0.759,,08Mar2022,,,6736,3.6500001,57622,51912,1798,1912,63.049999,31.25,28.15,North America,0,Target not reached,82.472435,96650,0.15368494,0.087819971,4.1180315,2.882622,1.6472125,39.517075,39.517075,32.864872
Europe,Western Europe,Liechtenstein,LI,LIE,,,,Developed,Liechtenstein,0,High Income Economies,Europe and Central Asia,,,,438,47.1667,9.5333,19,0.919,High human development,438,38.137,38137,,,,,1.9,Very Low,,,,,5,0,658643.4,1,20220305,31.48,50,50,50,Universal availability,OTHER,OWID,2022-03-03,70228,26707,181.248,68.927002,26354,68.015999,"Moderna - mRNA-1273, Pfizer BioNTech - Comirnaty",2,,2022-03-08,0,13222,0,75,Europe,13222,34123.934,1026,2647.947,0,75,193.563,0,0,0,,,,5,All eligible groups are fully government-funded,13222,167.14301,79,0.14300001,345637.06,705.80902,4369.291,2065.144,26.141001,3.734,1.33,,,,,,,0,31.48,38254,237.01199,,,,,,,7.77,,,,2.3970001,82.489998,0.91900003,10.62,08Mar2022,4,103.234,18167,47.490002,26707,26354,973,726,183.58,69.809998,68.889999,Europe,1,Target reached,,,,,,,,,,
Asia,Southern Asia,Sri Lanka,LK,LKA,,,,Developing,Sri Lanka,1,Lower Middle Income Economies,South Asia,86686000000,109.25,3665.77,144,7,81,72,0.782,High human development,144,21413.25,21413250,42229308,30096228,196.44,37682626,4.3,Medium,,,66,160.6969605,5,135448000,152500000,1,20220307,33.330002,47.400002,50.599998,25,Universal availability,SEARO,REPORTING,2022-02-28,38275280,16903964,178.746,78.942001,14177935,66.210999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",6,29Jan2021,2022-03-08,0,650802,0,16339,South-East Asia,650802,3039.249,3854,17.997999,0,16339,76.303001,95,0.44400001,0,2022-01-01,2.50%,97.5,5,All eligible groups are fully government-funded,653029,868.71399,16339,13.571,30377.248,103.594,40.41,760.04901,0,0.63099998,0.80000001,,,,,,,1667,33.330002,21497306,341.95499,34.099998,10.069,5.3309999,11669.077,0.69999999,197.093,10.68,0.30000001,27,,3.5999999,76.980003,0.78200001,,08Mar2022,,,7317106,34.040001,16928363,14208755,1085196,475620,178.88,78.75,66.099998,Asia,1,Target reached,129.5163269,3687200,0.26313707,0.15036404,8.5751467,6.0026026,3.4300587,90.636765,101.57275,8.7313766
Africa,Sub-Saharan Africa,Lesotho,LS,LSO,x,x,,Developing,Lesotho,1,Lower Middle Income Economies,Sub-Saharan Africa,2125000000,50.022,1187.51,426,-29.5,28.5,165,0.527,Low human development,426,2142.252,2142252,1617357,3022694,74.91,1617357,6,High,,,48,124.193634,5,0,0,0,20220306,37.959999,38.02,43.450001,0,Universal availability,AFRO,REPORTING,2022-03-04,926760,782175,43.261002,36.512001,727528,33.960999,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,SII - Covishield",3,10Mar2021,2022-03-08,0,32707,0,697,Africa,32707,1526.76,0,0,0,697,32.535999,0,0,0,,,,5,All eligible groups are fully government-funded,32716,14.857,697,0.14300001,15152.841,4.1680002,6.881,322.82501,0,0.066,0.85000002,,,,,,,1875,37.959999,2159067,73.561996,22.200001,4.506,2.6470001,2851.1531,59.599998,405.12601,3.9400001,0.40000001,53.900002,2.1170001,,54.330002,0.52700001,,08Mar2022,,,,,782175,727528,,17261,42.919998,36.23,33.700001,Africa,0,Target not reached,85.05992126,203340,0.81228787,0.46416453,11.095577,7.7669039,4.4382305,57.300892,57.300892,12.572364
Europe,Northern Europe,Lithuania,LT,LTU,,,,Developed,Lithuania,0,High Income Economies,Europe and Central Asia,62662000000,47.428,22411.65,440,56,24,34,0.882,High human development,440,2722.291,2722291,9126433,3765807,339.29,9104914,2.8,Low,,,73,1369.979492,5,331253.5,4732093.5,1,20220228,50.93,64.580002,59.52,100,Universal availability,EURO,REPORTING,2022-02-20,4432081,1944941,158.60001,69.763,1890524,67.662003,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,4740,938968,20,8548,Europe,938968,33605.504,31566,1129.7419,4740,8548,305.931,116,4.152,20,2022-01-01,8.30%,84.8,5,All eligible groups are fully government-funded,938968,4546.2861,8548,22,349076.66,1762.172,1690.156,3177.8579,7.4349999,8.1789999,0.81,,,1737,645.758,,,206,50.93,2689862,45.134998,43.5,19.002001,13.778,29524.266,0.69999999,342.98901,3.6700001,21.299999,38,,6.5599999,75.93,0.88200003,26.370001,08Mar2022,,,911886,33.900002,1946828,1870907,41196,27613,165.61,72.379997,69.550003,Europe,1,Target reached,314.4679871,,0.082706988,0.047261134,1.9328756,1.3530129,0.77315027,48.563126,48.677902,
Europe,Western Europe,Luxembourg,LU,LUX,,,,Developed,Luxembourg,0,High Income Economies,Europe and Central Asia,80387000000,26.258,131301.6,442,49.75,6.1667,23,0.916,High human development,442,625.976,625976,1617316,888740,254.77,1575862,3.1,Low,,,83,6220.741211,5,220507,0,0,20220307,46.299999,50,57.139999,0,Universal availability,EURO,REPORTING,2022-02-20,1214622,467216,194,74.622002,456085,72.844002,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,30,187971,3,999,Europe,187971,30022.137,4794,765.68298,30,999,159.55701,7,1.118,3,2022-01-01,10.30%,92.4,5,All eligible groups are fully government-funded,188748,706.57098,999,1,297328.03,1223.981,1113.037,1573.689,0,1.575,0.92000002,6,9.4519997,26,40.957001,,,863,46.299999,634814,231.44701,39.700001,14.312,9.842,94277.969,0.2,128.27499,4.4200001,20.9,26,,4.5100002,82.25,0.91600001,-10.2,08Mar2022,11,17.569,365154,57.52,479766,456085,9891,7216,200.56,75.580002,71.849998,Europe,1,Target reached,314.4679871,,0.014117117,0.0080669234,0.42567274,0.29797092,0.1702691,75.101097,77.076675,
Europe,Northern Europe,Latvia,LV,LVA,,,,Developed,Latvia,0,High Income Economies,Europe and Central Asia,38119000000,47.552,19538.9,428,57,25,37,0.866,High human development,428,1886.202,1886202,4610207,2613708,246.94,4447970,3.4,Low,,,71,1166.797852,5,0,0,0,20220228,48.150002,49.48,49.400002,50,Universal availability,EURO,REPORTING,2022-02-13,2766743,1295877,145,67.93,1258746,65.983002,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,2594,704134,9,5345,Europe,704134,36910.586,51014,2674.145,2594,5345,280.18399,121,6.3429999,9,2022-01-01,15.10%,82.2,5,All eligible groups are fully government-funded,712271,7089.5708,5369,16.143,381519.13,4358.4829,3797.4409,2875.8379,4.8210001,8.6470003,0.92000002,,,1114,596.70001,128,68.669998,491,48.150002,1866934,31.212,43.900002,19.754,14.136,25063.846,0.69999999,350.06,4.9099998,25.6,51,,5.5700002,75.290001,0.866,16.950001,08Mar2022,1054,564.56201,502703,26.93,1342593,1299881,24844,17038,153.19,71.910004,69.629997,Europe,1,Target reached,319.8575745,201240,0.094867162,0.054209806,2.269459,1.5886214,0.90778363,60.013424,62.202377,4.365097
Asia,Eastern Asia,"China, Macao Special Administrative Region",MO,MAC,,,,Developing,Macao,0,High Income Economies,East Asia and Pacific,33024000000,0,42106.56,,,,,,,446,649.342,649342,,921747,,,,,,,,,5,0,52610000,1,20220219,32.41,48.439999,48.209999,50,Universal availability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5,All eligible groups are fully government-funded,82,0.14300001,,,124.546,0,0.21699999,,,,,,,,,,,7710,32.41,658391,20546.766,39.200001,9.7980003,4.9910002,104861.85,,,,,,,,84.239998,,7.5900002,08Mar2022,,,130726,19.860001,543710,495159,7758,6788,174.10001,82.580002,75.209999,Asia,1,Target reached,,,0.044021644,0.025155226,,,,,,
Americas,Latin America and the Caribbean,Saint Martin (French Part),MF,MAF,,,,Developing,Saint Martin (French part),0,High Income Economies,Latin America and the Caribben,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2022-03-08,0,9870,0,44,Americas,9870,25530.924,28,72.428001,0,44,113.816,0,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Africa,Northern Africa,Morocco,MA,MAR,,,,Developing,Morocco,1,Lower Middle Income Economies,Middle East and North Africa,123776000000,75.788,3470.8,504,32,-5,121,0.686,Medium human development,504,36910.558,36910560,56323410,52282702,150.82,56323410,4.2,Medium,0.21,0.3,70,174.2237701,5,0,0,0,20220222,65.739998,60.419998,65.480003,25,Universal availability,EMRO,REPORTING,2022-03-06,53894957,24854067,146.015,67.335999,23308809,63.148998,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty",5,28Jan2021,2022-03-08,52,1161698,5,16022,Eastern Mediterranean,1161698,3147.332,723,1.959,52,16022,43.408001,34,0.092,5,2022-01-01,2.50%,91.7,5,All eligible groups are fully government-funded,1161776,92.142998,16029,5,31109.455,2.089,2.467,429.21701,0.18700001,0.134,0.25999999,,,,,,,610,65.739998,37344787,80.080002,29.6,6.7690001,4.2090001,7485.0132,1,419.146,7.1399999,0.80000001,47.099998,,1.1,76.68,0.68599999,,08Mar2022,,,5779158,15.48,24854067,23308809,898916,401310,144.32001,66.550003,62.419998,Africa,1,Target reached,130.8761444,,0.27791864,0.15881065,7.9093685,5.5365582,3.1637473,95.688377,95.688377,
Europe,Western Europe,Monaco,MC,MCO,,,,Developed,Monaco,0,High Income Economies,Europe and Central Asia,,,,,,,,,,492,39.244,39244,,,,,,,,,,2905.84375,5,0,1224000,1,20220228,40.740002,56.25,53.57,75,Universal availability,EURO,REPORTING,2021-12-21,65140,28875,166,73.578003,25667,65.403999,Pfizer BioNTech - Comirnaty,1,30Jun2021,2022-03-08,29,9568,0,51,Europe,9568,24380.797,157,400.061,29,51,129.95599,0,0,0,,,,5,All eligible groups are fully government-funded,9605,22.857,51,0,243041.5,1670.04,578.36902,1290.486,0,0,0.62,,,,,,,3998,40.740002,39520,19347.5,,,,,,,5.46,,,,13.8,86.75,,5.5900002,08Mar2022,,,10598,26.82,28875,25667,,313,164.83,73.059998,64.949997,Europe,1,Target reached,90.65663147,,,,0.91126716,0.637887,0.36450687,,,
Europe,Eastern Europe,Republic of Moldova,MD,MDA,,x,,Developed,Moldova,1,Upper Middle Income Economies,Europe and Central Asia,11712000000,38.14,4791.63,498,47,29,90,0.75,High human development,498,4033.963,4033963,2407172,5633635,59.82,2407172,4.4,Medium,,,69,284.3071289,5,584057000,14723949,1,20220228,42.59,49.48,51.189999,37.5,Universal availability,EURO,REPORTING,2022-02-20,2059291,1074332,51,26.632,1030133,25.537001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",7,03Mar2021,2022-03-08,352,505996,5,11298,Europe,505996,12543.397,3610,89.489998,352,11298,280.07199,70,1.735,5,2022-01-01,2.50%,77.8,5,All eligible groups are fully government-funded,505996,515.71399,11298,10,125743.75,87.474998,128.159,2807.637,1.243,2.4849999,0.47999999,,,,,,,697,42.59,4024025,123.655,37.599998,10.864,6.9549999,5189.9722,0.2,408.50201,5.7199998,5.9000001,44.599998,86.978996,5.8000002,71.900002,0.75,56.779999,08Mar2022,,,82869,2.0599999,989897,1044154,45233,16176,51.849998,24.6,25.950001,Europe,0,Target not reached,65.40677643,855920,0.30211014,0.17263436,7.2738237,5.0916767,2.9095297,85.548141,85.548141,35.557076
Africa,Sub-Saharan Africa,Madagascar,MG,MDG,x,,,Developing,Madagascar,1,Low Income Economies,Sub-Saharan Africa,15676000000,48.821,498.682,450,-20,47,164,0.528,Low human development,450,27691.019,27691020,4048052,39798266,14.24,4048052,6.2,High,0.79,10.9,28,19.84997559,5,0,0,0,20220308,37.5,44.529999,50.889999,0,Universal availability,AFRO,REPORTING,2022-02-28,1228391,1038325,4.4359999,3.75,987960,3.5680001,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,SII - Covishield",3,10May2021,2022-03-08,0,63791,0,1373,Africa,63791,230.367,132,0.477,0,1373,4.9580002,7,0.025,0,2022-01-01,3.70%,78.7,5,All eligible groups are fully government-funded,63791,18.857,1373,1,2244.002,4.6430001,0.66299999,48.299,0,0.035,0.63,,,,,,,116,37.5,28427333,43.951,19.6,2.9289999,1.686,1416.4399,77.599998,405.99399,3.9400001,,,50.540001,0.2,67.040001,0.528,,08Mar2022,,,,,1038325,987960,13544,10256,4.3200002,3.6500001,3.48,Africa,0,Target not reached,50.52766418,300000,1.6114478,0.92082733,57.833824,40.483677,23.13353,30.345238,30.345238,7.4109721
Asia,Southern Asia,Maldives,MV,MDV,,,x,Developing,Maldives,1,Upper Middle Income Economies,South Asia,5456000000,137.213,11899.09,462,3.25,73,95,0.74,High human development,462,540.542,540542,1213958,761068,223.31,1213958,3.9,Medium,,,62,854.3706055,,,,,,,,,,,SEARO,REPORTING,2022-02-28,902028,398214,166.87399,73.668999,371091,68.651001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",8,01Feb2021,2022-03-08,0,173064,0,297,South-East Asia,173064,32016.635,2409,445.66199,0,297,54.945,0,0,0,2021-03-01,13.90%,86.1,,,173337,383.14301,297,0,318856.94,502.189,704.79901,546.33801,0,0,0.67000002,,,,,,,2242,,543620,1454.433,30.6,4.1199999,2.875,15183.616,,164.905,9.1899996,2.0999999,55,95.803001,,78.919998,0.74000001,3.78,08Mar2022,,,137102,25.219999,398262,371224,11474,7843,166.77,73.260002,68.290001,Asia,1,Target reached,117.8920975,400000,0.12165636,0.069517918,2.4204953,1.6943467,0.96819812,74.30471,74.30471,32.950069
Americas,Latin America and the Caribbean,Mexico,MX,MEX,,,,Developing,Mexico,0,Upper Middle Income Economies,Latin America and the Caribben,1094530000000,59.773,9967.39,484,23,-102,74,0.779,High human development,484,128932.753,128932752,218189219,182367108,167.5,198871329,3.7,Medium,0.44,0.2,76,540.3723145,5,0,0,0,20220220,35.189999,41.93,44.349998,25,Universal availability,AMRO,REPORTING,2022-02-25,179274307,85083649,139.045,65.990997,78750047,61.077999,"AstraZeneca - Vaxzevria,CanSino - Convidecia,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",7,24Dec2020,2022-03-08,1905,5564985,35,319859,Americas,5564985,4316.1919,56356,43.709999,1905,319859,248.082,1710,1.326,35,2022-01-01,2.50%,97.6,5,All eligible groups are fully government-funded,5566669,8291.4287,319901,250.286,42734.332,12.928,63.652,2455.823,0.322,1.921,0.73000002,,,,,,,2053,35.189999,130262220,66.444,29.299999,6.8569999,4.3210001,17336.469,2.5,152.783,13.06,6.9000001,21.4,87.847,1.38,75.050003,0.77899998,3.97,08Mar2022,,,,,85340303,79110688,7246123,1648223,140.88,65.510002,60.73,North America,1,Target reached,118.0491333,13182900,0.1452336,0.082990631,3.8269911,2.6788938,1.5307964,82.164604,90.145882,6.0419574
Oceania,Micronesia,Marshall Islands,MH,MHL,,,x,Developing,Marshall Islands,1,Upper Middle Income Economies,East Asia and Pacific,228000000,14.442,4338.17,584,9,168,117,0.704,High human development,584,59.194,59194,64149,83465,107.6,64149,5.4,High,27.61,9.9,,664.3184815,,,,,,,,,,,WPRO,REPORTING,2022-02-16,51939,27833,87.744003,47.02,23644,39.943001,"Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,29Dec2020,2022-03-08,0,4,0,0,Western Pacific,4,6.757,0,0,0,0,0,0,0,0,,,,,,7,0,,,117.414,0,0,,,,,,,,,,,,,59618,295.14999,,,,3819.2019,,557.79303,30.530001,,,82.501999,2.7,73.699997,0.704,,08Mar2022,,,,,,,,,,,,Oceania,,Not available,50,,0.33368909,0.19067948,3.1129646,2.1790752,1.2451859,80.966187,80.966187,
Europe,Southern Europe,North Macedonia,MK,MKD,,x,,Developed,North Macedonia,0,Upper Middle Income Economies,Europe and Central Asia,14410000000,52.951,6711.73,807,41.8333,22,82,0.774,High human development,807,2083.38,2083380,2235528,2915725,107.34,2216993,3.7,Medium,0.93,0.4,72,436.8871765,,,,,,,,,,,EURO,REPORTING,2022-02-20,1823012,851356,87.5,41.004002,832608,40.101002,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac,Wuhan CNBG - Inactivated",6,17Feb2021,2022-03-08,124,299766,7,9086,Europe,299766,14388.446,2504,120.189,124,9086,436.11801,60,2.8800001,7,2021-08-01,13.70%,91.2,,,300106,338.28601,9097,10,144097.39,163.25301,162.42999,4367.9702,5.2820001,4.802,0.62,,,,,,,340,,2082661,82.599998,39.099998,13.26,8.1599998,13111.214,5,322.68799,10.08,,,,4.2800002,75.800003,0.77399999,41.43,08Mar2022,,,139048,6.6799998,851356,832608,39207,15497,87.529999,40.880001,39.98,Europe,0,Target not reached,103.9767838,558760,0.2156821,0.12324692,4.7334876,3.3134413,1.8933951,81.547264,82.229034,24.994543
Africa,Sub-Saharan Africa,Mali,ML,MLI,x,x,,Developing,Mali,1,Low Income Economies,Sub-Saharan Africa,20101000000,50.983,966.141,466,17,-4,184,0.434,Low human development,466,20250.834,20250834,3605955,29198014,17.29,3605955,5.8,High,0.82,9.1,38,34.28177643,5,0,0,0,20220308,40.740002,49.48,52.98,25,Universal availability,AFRO,REPORTING,2022-03-04,1735358,1227110,8.5690002,6.0599999,881628,4.3540001,SII - Covishield,1,31Mar2021,2022-03-08,0,30398,0,725,Africa,30398,150.10699,17,0.083999999,0,725,3.5799999,3,0.015,0,2022-01-01,4.00%,77.2,5,All eligible groups are fully government-funded,30401,2.5710001,725,0.42899999,1457.681,0.14399999,0.123,34.763,0,0.021,0.47999999,,,,,,,689,40.740002,20855724,15.196,16.4,2.5190001,1.4859999,2014.306,,268.02399,2.4200001,1.6,23,52.231998,0.1,59.310001,0.43399999,,08Mar2022,,,,,1227110,881628,,58966,8.3199997,5.8800001,4.23,Africa,0,Target not reached,61.67819595,700000,0.83176267,0.47529295,33.487179,23.441025,13.394872,48.124783,48.124783,19.412333
Europe,Southern Europe,Malta,MT,MLT,,,,Developed,Malta,0,High Income Economies,Middle East and North Africa,16338000000,63.016,31996.53,470,35.8333,14.5833,28,0.895,High human development,470,441.539,441539,1310800,720390,254.74,1303185,4.1,Medium,,,82,2531.910889,5,0,0,0,20220307,52.779999,61.459999,64.879997,37.5,Universal availability,EURO,REPORTING,2022-02-20,1192097,448134,231.7,87.089996,440866,85.678001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,72,71968,1,609,Europe,71968,13986.21,696,135.25999,72,609,118.353,4,0.77700001,1,2022-01-01,13.90%,84.1,5,All eligible groups are fully government-funded,72130,109.857,610,0.71399999,139759.73,308.07999,212.86,1181.941,1.938,1.3839999,1.01,3,5.8130002,35,67.816002,1,1.943,1064,52.779999,516100,1454.037,42.400002,19.426001,11.324,36513.324,0.2,168.711,8.8299999,20.9,30.200001,,4.4850001,82.529999,0.89499998,-12.81,08Mar2022,24,46.640999,344726,66.790001,471395,464006,10656,8191,241.44,91.339996,89.910004,Europe,1,Target reached,314.4679871,,0.057931282,0.033103589,1.0458504,0.7320953,0.41834015,90.944229,91.475655,
Asia,South-eastern Asia,Myanmar,MM,MMR,x,,,Developing,Myanmar,1,Lower Middle Income Economies,East Asia and Pacific,77172000000,58.356,1246.32,104,22,98,147,0.583,Medium human development,104,54409.794,54409792,49155515,76728420,89.69,42140344,4.8,Medium,0.74,8.6,61,60.01587296,4,194638.87,0,0,20220227,68.519997,70.099998,71.190002,62.5,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,SEARO,REPORTING,2022-02-26,45202278,23586822,83.077003,43.349998,20919933,38.449001,"Beijing CNBG - BBIBP-CorV,SII - Covishield",2,27Jan2021,2022-03-08,0,599619,0,19391,South-East Asia,599619,1102.042,9382,17.243,0,19391,35.639,19,0.035,0,2022-01-01,2.50%,91.8,5,All eligible groups are fully government-funded,601020,1540.429,19394,3.1429999,10966.315,25.563,28.107,353.866,0.055,0.057,1.04,,,,,,,2175,68.519997,54806014,81.721001,29.1,5.7319999,3.1199999,5591.5972,6.4000001,202.104,4.6100001,6.3000002,35.200001,79.287003,0.89999998,67.129997,0.583,,08Mar2022,,,,,24064085,21277241,3800,366806,82.730003,43.91,38.82,Asia,0,Target not reached,127.4550018,12436000,0.7739585,0.44226202,22.960592,16.072414,9.1842365,91.957695,107.26604,25.299297
Europe,Southern Europe,Montenegro,ME,MNE,,,,Developed,Montenegro,0,Upper Middle Income Economies,Europe and Central Asia,5706000000,93.404,8837.58,499,42,19,48,0.829,High human development,499,628.062,628062,1059208,879271,168.65,1059208,3.7,Medium,1.5,0.3,68,735.1588745,,,,,,,,,,,EURO,REPORTING,2022-02-13,526852,275260,83.900002,44.263,251592,40.457001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty",4,24Feb2021,2022-03-08,52,231006,0,2685,Europe,231006,36780.766,788,125.465,52,2685,427.50601,9,1.433,0,2022-01-01,15.80%,82.1,,,231115,107.429,2689,1,367987.63,165.592,171.05099,4281.499,4.777,1.592,0.56,,,,,,,333,,628051,46.279999,39.099998,14.762,9.3950005,16409.287,1,387.30499,10.08,44,47.900002,,3.8610001,76.879997,0.829,55.049999,08Mar2022,,,95417,15.19,288859,280519,69811,11277,105.85,45.990002,44.669998,Europe,1,Target reached,88.33677673,560000,0.16380049,0.093600281,2.8129973,1.9690982,1.125199,49.740185,49.740185,52.86969
Asia,Eastern Asia,Mongolia,MN,MNG,,x,,Developing,Mongolia,1,Lower Middle Income Economies,East Asia and Pacific,14123000000,77.709,4185.54,496,46,105,99,0.737,High human development,496,3278.292,3278292,6044312,4660995,181.55,6044312,3.8,Medium,,,62,163.441864,4,0,7827300,1,20220307,2.78,19.059999,18.209999,25,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,WPRO,REPORTING,2022-02-25,5568712,2271500,169.866,69.289001,2172842,66.279999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",6,23Feb2021,2022-03-08,189,913444,0,2104,Western Pacific,913444,27863.43,5287,161.27299,189,2104,64.18,8,0.244,0,2021-04-01,2.50%,71,5,All eligible groups are fully government-funded,913444,755.28601,2176,0.71399999,274366.66,56.769001,226.86099,653.59399,0,0.215,0.56,,,,,,,119,2.78,3329282,1.98,28.6,4.0310001,2.421,11840.846,0.5,460.043,4.8200002,5.5,46.5,71.18,7,69.870003,0.73699999,-12.19,08Mar2022,,,1026267,30.83,2271836,2173300,827202,125462,164.34,68.239998,65.279999,Asia,1,Target reached,126.8055115,450000,0.23046011,0.13169149,8.4311323,5.9017925,3.372453,92.131447,92.131447,7.4450159
Oceania,Micronesia,Northern Mariana Islands,MP,MNP,,,x,Developing,Northern Mariana Islands,0,High Income Economies,East Asia and Pacific,,,,,,,,,,580,57.557,57557,,,,,,,,,,,,,,,,,,,,,WPRO,REPORTING,2022-02-04,105295,44211,182.94,76.813004,42880,74.5,"Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,19Dec2020,2022-03-08,29,10155,0,30,Western Pacific,10155,17643.381,605,1051.132,29,30,52.122002,0,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Africa,Sub-Saharan Africa,Mozambique,MZ,MOZ,x,,,Developing,Mozambique,1,Low Income Economies,Sub-Saharan Africa,14142000000,133.568,492.273,508,-18.25,35,181,0.456,Low human development,508,31255.435,31255436,29615732,45028263,92.08,29615732,6.2,High,0.29,3.7,46,39.46094131,5,30000000,0,0,20220304,42.59,36.98,42.259998,0,Universal availability,AFRO,REPORTING,2022-03-05,23563858,12963020,75.390999,41.473999,11476420,36.717999,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,SII - Covishield",3,08Mar2021,2022-03-08,0,225140,0,2196,Africa,225140,720.323,93,0.29800001,0,2196,7.026,4,0.013,0,2022-01-01,2.90%,94.9,5,All eligible groups are fully government-funded,225150,12.429,2197,0.71399999,7000.27,0.31099999,0.38600001,68.307999,0.030999999,0.022,0.55000001,,,,,,,9781,42.59,32163045,37.728001,17.700001,3.158,1.87,1136.103,62.900002,329.94199,3.3,5.0999999,29.1,12.227,0.69999999,60.849998,0.456,,08Mar2022,,,138218,0.43000001,12963020,11476420,295812,318504,73.260002,40.299999,35.68,Africa,0,Target not reached,107.7058945,2357200,1.6324276,0.93281573,29.092058,20.364441,11.636824,79.565338,79.565338,7.9592834
Africa,Sub-Saharan Africa,Mauritania,MR,MRT,x,,,Developing,Mauritania,1,Lower Middle Income Economies,Sub-Saharan Africa,7554000000,55.361,2161.28,478,20,-12,157,0.546,Low human development,478,4649.66,4649660,3803853,6685154,79.66,3803853,5.8,High,,,41,57.88484573,4,0,0,0,20220307,43.52,40.419998,46.189999,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-02-28,2617442,1539645,56.292999,33.112999,1043548,22.444,"Beijing CNBG - BBIBP-CorV,SII - Covishield",2,26Mar2021,2022-03-08,3,58652,0,980,Africa,58652,1261.426,19,0.40900001,3,980,21.077,1,0.022,0,2022-01-01,5.40%,86.7,5,All eligible groups are fully government-funded,58654,2.286,980,0.14300001,12283.277,0.419,0.479,205.231,0,0.029999999,0.43000001,,,,,,,1265,43.52,4775110,4.289,20.299999,3.138,1.7920001,3597.6331,6,232.347,2.4200001,,,15.95,,64.919998,0.546,,08Mar2022,,,34249,0.72000003,1539645,1043548,10385,68628,54.810001,32.240002,21.85,Africa,0,Target not reached,50.95334625,335000,0.4463096,0.25503406,23.805885,16.66412,9.5223541,68.81028,68.81028,8.80686
Americas,Latin America and the Caribbean,Montserrat,MS,MSR,,,x,Developing,Montserrat,0,Unclassified Economies,Unclassified,,,,,,,,,,500,4.999,4999,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,4089,1869,81.795998,37.387001,1749,34.987,AstraZeneca - Vaxzevria,1,08Feb2021,2022-03-08,0,164,0,2,Americas,164,3280.656,1,20.004,0,2,40.007999,0,0,0,,,,,,164,0,2,0,32925.113,0,0,401.526,0,0,,,,,,,,602,,4981,,,,,,,,,,,,,74.160004,,,08Mar2022,,,,,1869,1749,,53,82.089996,37.52,35.110001,North America,0,Target not reached,,,,,,,,,,
Americas,Latin America and the Caribbean,Martinique,MQ,MTQ,,,,Developing,Martinique,0,Unclassified Economies,Unclassified,,,,,,,,,,474,375.265,375265,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,368725,146841,98.257004,39.130001,141027,37.581001,Pfizer BioNTech - Comirnaty,1,,2022-03-08,5098,122782,4,899,Americas,122782,32718.744,8314,2215.501,5098,899,239.564,5,1.332,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Africa,Sub-Saharan Africa,Mauritius,MU,MUS,,,x,Developing,Mauritius,0,Upper Middle Income Economies,Sub-Saharan Africa,12200000000,101.023,8681.61,480,-20.2833,57.55,66,0.804,High human development,480,1271.767,1271767,3490721,1782799,274.12,3490721,3.7,Medium,0.65,0.2,63,685.9456177,5,50000,0,0,20220220,47.220001,56.25,57.139999,50,Universal availability,AFRO,REPORTING,2022-02-15,2353567,993298,185.063,78.103996,947467,74.5,"Beijing CNBG - BBIBP-CorV,Bharat - Covaxin,SII - Covishield",3,26Jan2021,2022-03-08,0,169796,0,904,Africa,169796,13351.177,0,0,0,904,71.082001,0,0,0,2020-12-01,4.20%,81,5,All eligible groups are fully government-funded,169796,14133.429,904,16.857,133337.73,77691.086,11098.726,709.89502,92.663002,13.238,0.050000001,,,,,,,5075,47.220001,1273428,622.96198,37.400002,10.945,5.8839998,20292.744,0.5,224.644,22.02,3.2,40.700001,,3.4000001,74.989998,0.80400002,2.74,08Mar2022,,,491390,38.59,993298,947467,35153,20570,184.82001,78,74.400002,Africa,1,Target reached,212.6875,205000,0.16674326,0.095281869,3.0148163,2.1103714,1.2059265,67.423523,67.423523,5.8727121
Africa,Sub-Saharan Africa,Malawi,MW,MWI,x,x,,Developing,Malawi,1,Low Income Economies,Sub-Saharan Africa,8532000000,59.342,565.798,454,-13.5,34,174,0.483,Low human development,454,19129.955,19129956,4023845,27506753,20.48,4023845,5.8,High,2.27,24,46,30.40028763,5,40000000,37000000,1,20220307,37.959999,40.619999,46.43,0,Universal availability,AFRO,REPORTING,2022-02-27,1934835,1536112,10.114,8.0299997,811786,4.244,"Janssen - Ad26.COV 2-S,SII - Covishield",2,11Mar2021,2022-03-08,11,85440,0,2619,Africa,85440,446.629,101,0.528,11,2619,13.691,4,0.021,0,2021-06-01,7.50%,56,5,All eligible groups are fully government-funded,85452,15,2619,0.57099998,4349.2158,0.611,0.76300001,133.298,0,0.028999999,0.63999999,,,,,,,147,37.959999,19647681,197.519,18.1,2.9790001,1.783,1095.042,71.400002,227.349,3.9400001,4.4000001,24.700001,8.7040005,1.3,64.260002,0.48300001,,08Mar2022,,,,,1948930,820547,55787,21351,9.9200001,9.9200001,4.1799998,Africa,0,Target not reached,50.3868103,152000,1.4202949,0.81159705,37.762802,26.43396,15.105121,48.084232,48.084232,3.7774816
Asia,South-eastern Asia,Malaysia,MY,MYS,,,,Developing,Malaysia,0,Upper Middle Income Economies,East Asia and Pacific,380261000000,70.68,11124.67,458,2.5,112.5,62,0.81,High human development,458,32365.998,32365998,74438017,45886673,227.11,65749049,3.2,Low,,,73,436.61203,5,0,0,0,20220221,54.169998,60.16,58.040001,75,Universal availability,WPRO,REPORTING,2022-02-25,66872362,26873297,206.61301,83.028999,25748124,79.553001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,CanSino - Convidecia,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",8,24Feb2021,2022-03-08,26856,3649463,77,33305,Western Pacific,3649463,11275.607,206727,638.71698,26856,33305,102.901,556,1.7180001,77,2022-01-01,2.50%,98.9,5,All eligible groups are fully government-funded,3680953,30337.57,33384,79.570999,112305.69,960.758,925.59802,1018.544,2.4100001,2.428,1.13,368,11.228,7463,227.696,,,2503,54.169998,32776195,96.253998,29.9,6.2930002,3.4070001,26808.164,0.1,260.94199,16.74,1,42.400002,,1.9,76.160004,0.81,30.639999,08Mar2022,13275,405.01999,15064528,45.959999,27180031,25761043,582545,550127,206.85001,82.93,78.599998,Asia,1,Target reached,149.8899384,5915000,0.13012521,0.074357264,4.7364707,3.3155293,1.8945882,89.836304,101.70849,7.9462085
Africa,Sub-Saharan Africa,Mayotte,YT,MYT,,,,Developing,Mayotte,0,Unclassified Economies,Unclassified,,,,,,,,,,175,272.813,272813,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2022-03-08,0,36703,0,187,Africa,36703,13453.439,41,15.028,0,187,68.544998,0,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Europe,Northern Europe,Sark,,N/A,,,,Developed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Africa,Sub-Saharan Africa,Namibia,NA,NAM,,,,Developing,Namibia,0,Upper Middle Income Economies,Sub-Saharan Africa,11487000000,69.921,4693.46,516,-22,17,130,0.646,Medium human development,516,2540.916,2540916,1371551,3622282,53.01,1371551,5.1,High,0.78,0.4,62,427.2562256,5,0,1626240,1,20220307,28.700001,41.669998,47.619999,0,Universal availability,AFRO,REPORTING,2022-02-25,814463,440661,32.054001,17.343,373802,14.711,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",4,19Mar2021,2022-03-08,0,157284,0,4010,Africa,157284,6190.0781,32,1.2589999,0,4010,157.81799,1,0.039000001,0,2020-12-01,4.20%,46,5,All eligible groups are fully government-funded,157358,19,4014,1,60818.352,3.092,7.3429999,1551.3979,0,0.38600001,0.75,,,,,,,452,28.700001,2587344,3.0780001,22,3.552,2.085,9541.8076,13.4,243.811,3.9400001,9.6999998,34.200001,44.599998,,63.709999,0.64600003,,08Mar2022,,,,,440661,373802,9823,16348,31.48,17.030001,14.45,Africa,0,Target not reached,36.66527176,520000,0.30842918,0.17624524,4.8401871,3.3881309,1.9360747,59.382626,59.382626,37.91328
Oceania,Melanesia,New Caledonia,NC,NCL,,,x,Developing,New Caledonia,0,High Income Economies,East Asia and Pacific,,,,,,,,,,540,285.491,285491,403619,403504,140.04,395318,,,,,,,,,,,,,,,,,WPRO,REPORTING,2022-02-28,366995,187718,128.54601,65.750999,179277,62.793999,"Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty",2,20Jan2021,2022-03-08,1258,58227,0,302,Western Pacific,58227,20394.889,3914,1370.938,1258,302,105.78,3,1.051,0,,,,,,58733,553.85699,304,0.57099998,203780.48,2227.488,1921.667,1054.761,6.9390001,1.983,,,,,,,,180,,288217,15.342,33.400002,9.9540005,6.4889998,,,,23.360001,,,,,77.550003,,-4.3400002,08Mar2022,,,,,187823,179468,,5037,127.44,65.169998,62.27,Oceania,1,Target reached,,,,,,,,90.926094,92.835388,
Africa,Sub-Saharan Africa,Niger,NE,NER,x,x,,Developing,Niger,1,Low Income Economies,Sub-Saharan Africa,14259000000,48.558,622.23,562,16,8,189,0.394,Low human development,562,24206.636,24206636,4267211,35183134,16.98,4267211,6.2,High,1.07,11.9,37,31.39763641,5,0,0,0,20220228,16.67,25.780001,29.459999,0,Universal availability,AFRO,REPORTING,2022-02-26,1840055,1474560,7.6009998,6.092,1049867,4.3369999,"Beijing CNBG - BBIBP-CorV,SII - Covishield",2,29Mar2021,2022-03-08,1,8767,0,307,Africa,8767,36.216999,13,0.054000001,1,307,1.268,0,0,0,2021-01-01,2.90%,42,5,All eligible groups are fully government-funded,8769,1.857,307,0,348.93399,0.079999998,0.074000001,12.216,0,0,0.66000003,,,,,,,140,16.67,25130810,16.955,15.1,2.553,1.378,926,44.5,238.339,2.4200001,0.1,15.4,8.9779997,0.30000001,62.419998,0.39399999,,08Mar2022,,,,,1474560,1049867,,25351,7.3200002,5.8699999,4.1799998,Africa,0,Target not reached,65.45227051,425000,1.2914839,0.7379908,36.563263,25.594284,14.625305,43.120789,43.120789,9.9596672
Oceania,Australia and New Zealand,Norfolk Island,NF,NFK,,,,Developed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Africa,Sub-Saharan Africa,Nigeria,NG,NGA,,,,Developing,Nigeria,1,Lower Middle Income Economies,Sub-Saharan Africa,466879000000,35.709,2272.84,566,10,8,161,0.539,Low human development,566,206139.587,206139584,62574609,295960986,29.6,62574609,5.9,High,0.18,1.5,42,71.46572876,5,34000000000,298500000,1,20220221,37.959999,42.709999,48.810001,0,Universal availability,AFRO,REPORTING,2022-03-06,27583270,18404584,13.381,8.9280005,8464214,4.1059999,SII - Covishield,1,05Mar2021,2022-03-08,20,254657,0,3142,Africa,254657,123.536,97,0.046999998,20,3142,1.524,0,0,0,2022-01-01,2.50%,85.3,5,All eligible groups are fully government-funded,254777,29.570999,3142,0,1205.1851,0.55800003,0.14,14.863,0,0,0.70999998,,,,,,,721,37.959999,211400704,209.588,18.1,2.7509999,1.447,5338.4541,,181.013,2.4200001,0.60000002,10.8,41.949001,,54.689999,0.53899997,,08Mar2022,,,,,18404584,8464214,797209,286036,13.05,8.71,4,Africa,0,Target not reached,59.76818085,400000,0.42440295,0.24251597,19.281969,13.497378,7.7127876,44.080612,44.080612,0.63923693
Americas,Latin America and the Caribbean,Nicaragua,NI,NIC,,,,Developing,Nicaragua,1,Lower Middle Income Economies,Latin America and the Caribben,11966000000,49.53,2047.1,558,13,-85,128,0.66,Medium human development,558,6624.554,6624554,10424880,9383331,155.54,9556922,4.5,Medium,1.89,1.9,73,160.7587891,5,0,100000000,1,20220228,8.3299999,21.879999,21.43,25,Universal availability,AMRO,REPORTING,2022-02-25,9367505,5423137,141.40601,81.863998,3944368,59.542,"AstraZeneca - Vaxzevria,CIGB - CIGB-66,Finlay - Soberana Plus,Finlay - Soberana-02,Gamaleya - Gam-Covid-Vac,Gamaleya - Sputnik-Light,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",9,03Mar2021,2022-03-08,0,14035,0,225,Americas,14035,211.86301,77,1.1619999,0,225,3.3959999,1,0.015,0,2022-01-01,2.50%,95.4,5,All eligible groups are fully government-funded,18203,14,225,0.14300001,2715.9009,14.622,2.089,33.57,0,0.021,1.28,,,,,,,2340,8.3299999,6702379,51.667,27.299999,5.4450002,3.5190001,5321.4438,3.2,137.01601,11.47,,,,0.89999998,74.480003,0.66000003,61.060001,08Mar2022,,,,,5459763,4017542,,311302,141.39999,81.459999,59.939999,North America,1,Target reached,81.46007538,500000,0.47120318,0.26925895,8.5718489,6.0002942,3.4287395,89.857201,98.018013,4.7962184
Oceania,Polynesia,Niue,NU,NIU,,,x,Developing,Niue,0,Unclassified Economies,Unclassified,,,,,,,,,,570,1.618,1618,,,,,,,,,,1011.710754,,,,,,,,,,,WPRO,REPORTING,2021-11-24,2628,1340,162.423,82.818001,1288,79.603996,Pfizer BioNTech - Comirnaty,1,08Jun2021,2022-03-08,0,0,0,0,Western Pacific,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,,,,,,,,,,,,,1239,,1614,,,,,,,,,,,,,73.709999,,,24Nov2021,,,,,1340,1288,,87,162.83,83.019997,79.800003,Oceania,1,Target reached,,,,,,,,,,
Europe,Western Europe,Netherlands,NL,NLD,,,,Developed,Netherlands,0,High Income Economies,Europe and Central Asia,1005710000000,58.059,57714.88,528,52.5,5.75,8,0.944,High human development,528,17134.873,17134872,43004862,24042332,250.42,41232600,2.5,Low,,,86,5335.30127,5,540164027.7,261627134.6,1,20220227,34.259998,51.560001,51.790001,50,Universal availability,EURO,REPORTING,2022-02-20,33860098,13447203,194.5,77.249001,12351489,70.955002,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,06Jan2021,2022-03-08,64107,6771643,5,21612,Europe,6771643,38900.531,410075,2355.7261,64107,21612,124.153,60,0.345,5,2022-01-01,2.50%,87.3,5,All eligible groups are fully government-funded,6931584,62825.57,21730,7.7140002,403630.47,3856.8469,3658.3721,1265.351,0.699,0.449,1.27,161,9.375,1325,77.155998,85,4.9499998,176,34.259998,17173094,508.54401,43.200001,18.778999,11.881,48472.547,,109.361,5.29,24.4,27.299999,,3.3199999,82.279999,0.94400001,-3.6500001,08Mar2022,1094,63.703999,9003462,52.43,13450667,12356769,,271463,197.64999,78.32,71.949997,Europe,1,Target reached,314.4679871,,0.032116503,0.018352287,0.49631685,0.3474218,0.19852674,78.735512,82.119728,
Europe,Northern Europe,Norway,NO,NOR,,,,Developed,Norway,0,High Income Economies,Europe and Central Asia,414228000000,42.7,82244.23,578,62,10,1,0.957,High human development,578,5421.242,5421242,13680470,7651881,250.3,13189109,1.8,Very Low,,,87,8007.397949,5,233438898.7,694263420,1,20220227,13.89,27.6,26.190001,37.5,Universal availability,EURO,REPORTING,2022-02-13,11165064,4324308,208,80.563004,4016748,74.834,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,856,1308337,0,1664,Europe,1308337,24374.803,61305,1142.135,856,1664,31.000999,5,0.093000002,0,2022-01-01,2.50%,93.4,5,All eligible groups are fully government-funded,1325909,9832.8574,1664,9.4289999,242590.38,1869.318,1799.035,304.448,11.893,1.725,0.83999997,,,525,96.055,32,5.7750001,309,13.89,5465629,14.462,39.700001,16.820999,10.813,64800.059,0.2,114.316,5.3099999,19.6,20.700001,,3.5999999,82.400002,0.95700002,-1.49,08Mar2022,462,84.582001,2889840,52.869999,4329583,4022021,138639,69108,205.67999,79.209999,73.589996,Europe,1,Target reached,125.1479492,,0.022537751,0.012878715,0.3306942,0.23148593,0.13227768,81.613159,84.653664,
Asia,Southern Asia,Nepal,NP,NPL,x,x,,Developing,Nepal,1,Lower Middle Income Economies,South Asia,34046000000,46.669,1172.64,524,28,84,142,0.602,Medium human development,524,29136.808,29136808,44850674,41544888,151.14,44850674,5.2,High,0.38,2.8,48,53.24640274,5,1000000,0,0,20220307,46.299999,52.599998,51.189999,62.5,Universal availability,SEARO,REPORTING,2022-02-27,37129004,18491302,127.43,63.464001,17490473,60.028999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Bharat - Covaxin,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",8,27Jan2021,2022-03-08,74,977641,1,11949,South-East Asia,977641,3355.3469,565,1.939,74,11949,41.009998,11,0.037999999,1,2022-01-01,2.50%,97.9,5,All eligible groups are fully government-funded,977641,80.713997,11949,1.571,32945.027,2.494,2.72,402.66299,0.034000002,0.052999999,0.31999999,,,,,,,3772,46.299999,29674920,204.42999,25,5.809,3.2119999,2442.804,15,260.797,7.2600002,9.5,37.799999,47.782001,0.30000001,70.779999,0.602,,08Mar2022,,,1312118,4.4200001,21645983,17843980,312874,387959,126.99,72.940002,60.130001,Asia,1,Target reached,99.95318604,5585420,0.82258832,0.47005048,25.879683,18.115778,10.351873,82.7836,82.7836,12.453369
Oceania,Micronesia,Nauru,NR,NRU,,,x,Developing,Nauru,0,High Income Economies,East Asia and Pacific,130000000,28.236,10138.2,,,,,,,520,10.834,10834,14050,15168,129.68,14050,5,High,,,,1049.447021,,,,,,,,,,,WPRO,REPORTING,2021-12-31,15128,7764,139.634,71.663002,7364,67.971001,"AstraZeneca - Vaxzevria,SII - Covishield",2,09Apr2021,2022-03-08,0,0,0,0,Western Pacific,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,,,,,,,,,,,,,0,,10873,682.45001,,,,12895.635,,,24.07,43,36.900002,,5,59.959999,,,18Jan2022,,,,,7764,7364,168,560,139.13,71.410004,67.730003,Oceania,1,Target reached,79.09500885,10000,0.18283324,0.10447614,2.5232337,1.7662635,1.0092934,107.6726,107.6726,71.174377
Oceania,Australia and New Zealand,New Zealand,NZ,NZL,,,,Developed,New Zealand,0,High Income Economies,East Asia and Pacific,211653000000,51.966,48348.99,554,-41,174,14,0.931,High human development,554,4822.233,4822233,11189684,6804899,230.21,8859978,2.1,Low,,,87,4211.046387,5,0,23870000,1,20220228,61.110001,66.150002,72.019997,25,Universal availability,WPRO,REPORTING,2022-02-25,10554287,4255126,218.867,88.239998,3960755,82.135002,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Novavax - Covavax,Pfizer BioNTech - Comirnaty",4,19Feb2021,2022-03-08,23913,263449,0,65,Western Pacific,263449,5463.2158,143288,2971.4031,23913,65,1.348,9,0.18700001,0,2022-01-01,2.50%,93.9,5,All eligible groups are fully government-funded,286750,20547.43,65,1.286,55937.031,4388.1548,4008.238,12.68,0,0.25099999,2.4000001,,,,,,,3239,61.110001,5126300,18.205999,37.900002,15.322,9.7200003,36085.844,,128.797,8.0799999,14.8,17.200001,,2.6099999,82.290001,0.93099999,-2.6500001,08Mar2022,,,2504298,48.849998,4271879,3970210,131487,81494,209.63,83.330002,77.449997,Oceania,1,Target reached,361.2755127,,0.038337927,0.021907385,0.62882233,0.44017562,0.25152892,94.321579,119.12318,
Asia,Western Asia,Oman,OM,OMN,,,,Developing,Oman,0,High Income Economies,Middle East and North Africa,65303000000,68.196,17632.65,512,21,57,60,0.813,High human development,512,5106.622,5106622,7504946,7312726,143.68,6729797,3,Low,,,69,624.7444458,4,0,0,0,20220307,21.299999,34.169998,39.049999,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,EMRO,REPORTING,2022-02-28,6878593,3220696,134.69901,63.069,3004483,58.834999,"AstraZeneca - Vaxzevria,Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",5,29Dec2020,2022-03-08,335,385153,0,4249,Eastern Mediterranean,385153,7542.2212,2909,56.965,335,4249,83.206001,5,0.097999997,0,2022-01-01,3.80%,99.1,5,All eligible groups are fully government-funded,385513,467,4249,0.71399999,73805.328,68.920998,89.405998,813.45898,0,0.13699999,0.75,,,,,,,1530,26.85,5223376,14.98,30.700001,2.355,1.53,37960.711,,266.34201,12.61,0.5,15.6,97.400002,1.6,77.860001,0.81300002,4.7399998,08Mar2022,,,32412,0.62,3220696,3004483,6747,61172,131.69,61.66,57.52,Asia,1,Target reached,71.83960724,200000,0.10512317,0.060070381,4.238533,2.9669731,1.6954132,91.654129,102.21101,2.6649094
Asia,Southern Asia,Pakistan,PK,PAK,,,,Developing,Pakistan,1,Lower Middle Income Economies,South Asia,,83.416,,586,30,70,154,0.557,Medium human development,586,220892.331,220892336,238621843,315279901,105.96,231235288,5.3,High,0.34,2.4,45,39.49928665,5,363749935.5,300000000,1,20220223,54.169998,70.050003,69.349998,75,Universal availability,EMRO,REPORTING,2022-02-28,213532343,124309711,96.667999,56.276001,100096471,45.314999,"Beijing CNBG - BBIBP-CorV,Bharat - Covaxin,CanSino - Convidecia,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",8,03Feb2021,2022-03-08,756,1515014,7,30272,Eastern Mediterranean,1515014,685.86102,5654,2.5599999,756,30272,13.704,94,0.043000001,7,2022-01-01,2.50%,98,4,"Partial government funding for some eligible groups, full funding for others",1516150,737.71399,30287,9.8570004,6732.4619,3.3659999,3.276,134.489,0.027000001,0.044,0.55000001,,,,,,,1766,54.169998,225199929,255.573,23.5,4.4949999,2.78,5034.708,4,423.03101,8.3500004,2.8,36.700001,59.606998,0.60000002,67.269997,0.55699998,,08Mar2022,,,4704755,2.0899999,127697360,100463513,2339218,2175773,96.559998,56.700001,44.610001,Asia,1,Target reached,59.52050018,3220000,,,34.886707,24.420694,13.954682,89.485664,92.344185,1.3494154
Americas,Latin America and the Caribbean,Panama,PA,PAN,,,,Developing,Panama,0,Upper Middle Income Economies,Latin America and the Caribben,62799000000,62.19,13861.06,591,9,-80,57,0.815,High human development,591,4314.768,4314768,7687926,6134216,175.46,7494698,3.8,Medium,0.11,0,79,1192.820801,5,0,0,0,20220305,31.48,42.709999,48.810001,25,Universal availability,AMRO,REPORTING,2022-02-25,7544898,3331140,174.862,77.203003,2923513,67.755997,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty",2,20Jan2021,2022-03-08,81,757568,3,8114,Americas,757568,17557.564,2306,53.444,81,8114,188.052,35,0.81099999,3,2022-01-01,2.50%,95.6,5,All eligible groups are fully government-funded,758312,351.28601,8122,4.1430001,173068.05,87.182999,80.172997,1853.668,0.91299999,0.94599998,0.44999999,,,,,,,2379,31.48,4381583,55.132999,29.700001,7.9180002,5.0300002,22267.037,2.2,128.34599,8.3299999,2.4000001,9.8999996,,2.3,78.510002,0.815,-1.22,08Mar2022,,,1190009,27.16,3238331,2577397,164331,75396,159.89,73.910004,58.82,North America,1,Target reached,144.5493622,503100,0.10443646,0.059677977,1.7337055,1.2135938,0.69348222,98.13958,100.66981,6.5440278
Oceania,Polynesia,Pitcairn,PN,PCN,,,,Developing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,WPRO,REPORTING,2021-11-11,74,37,148,74,37,74,AstraZeneca - Vaxzevria,1,17May2021,2022-03-08,0,0,0,0,Western Pacific,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,,,,,,,,,,,,,0,,47,,,,,,,,,,,,,,,,07Sep2021,,,,,47,47,,1,200,100,100,Oceania,1,Target reached,,,,,,,,,,
Americas,Latin America and the Caribbean,Peru,PE,PER,,,,Developing,Peru,0,Upper Middle Income Economies,Latin America and the Caribben,210733000000,35.002,6676.52,604,-10,-76,79,0.777,High human development,604,32971.846,32971846,68056541,46703181,204.01,74334785,4.3,Medium,0.16,0.1,77,370.1099548,5,0,23757005,1,20220214,66.669998,65.620003,67.860001,50,Universal availability,AMRO,REPORTING,2022-02-25,61695372,27499335,187.11501,83.402,24113780,73.134003,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Pfizer BioNTech - Comirnaty",3,09Feb2021,2022-03-08,1609,3527549,76,211108,Americas,3527549,10698.667,11285,34.226002,1609,211108,640.26703,570,1.729,76,2022-01-01,2.50%,97,5,All eligible groups are fully government-funded,3528038,1539.714,211155,69,105758.39,14.659,46.154999,6329.6968,1.409,2.0680001,0.58999997,,,,,,,4101,66.669998,33359415,25.129,29.1,7.151,4.4549999,12236.706,3.5,85.754997,5.9499998,4.8000002,,,1.6,76.739998,0.77700001,18.73,08Mar2022,,,10279707,30.82,27709199,24443197,602960,389374,187.14999,83.059998,73.269997,South America,1,Target reached,235.8245087,3035100,0.21681954,0.12389688,5.5875287,3.9112701,2.2350116,90.653114,82.996635,4.4596744
Asia,South-eastern Asia,Philippines,PH,PHL,,,,Developing,Philippines,1,Lower Middle Income Economies,East Asia and Pacific,398332000000,59.114,3492.07,608,13,122,107,0.718,High human development,608,109581.085,109581088,219661890,155465674,197.81,212876923,4.7,Medium,0.41,1,61,142.0787659,5,0,1857847000,1,20220214,78.239998,72.139999,82.440002,0,Universal availability,WPRO,REPORTING,2022-02-24,135251295,68661595,123.426,62.658001,63016833,57.507,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Bharat - Covaxin,Gamaleya - Gam-Covid-Vac,Gamaleya - Sputnik-Light,Janssen - Ad26.COV 2-S,Julphar - Hayat-Vax,Moderna - Spikevax,Novavax - Covavax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",11,01Mar2021,2022-03-08,733,3668268,43,57066,Western Pacific,3668268,3347.5381,6276,5.7270002,733,57066,52.077,615,0.56099999,43,2022-01-01,2.50%,97.1,5,All eligible groups are fully government-funded,3668710,807.28601,57072,88.713997,33037.48,3.98,7.27,513.94501,0.054000001,0.79900002,0.47,,,,,,,10165,78.239998,111046910,351.87299,25.200001,4.803,2.661,7599.188,,370.43701,7.0700002,7.8000002,40.799999,78.462997,1,71.230003,0.71799999,1.76,08Mar2022,,,10137875,9.1300001,56110301,63091847,2648872,1629125,127.84,50.529999,56.82,Asia,1,Target reached,144.1558838,27623770,0.27622584,0.15784334,9.6988459,6.7891917,3.8795383,61.572491,63.534973,12.575586
Oceania,Micronesia,Palau,PW,PLW,,,x,Developing,Palau,0,High Income Economies,East Asia and Pacific,235000000,,11835.18,585,7.5,134.5,50,0.826,High human development,585,18.092,18092,6171,25329,34.11,6171,3.8,Medium,,,,2355.695801,,,,,,,,,,,WPRO,REPORTING,2022-02-16,45692,19923,252.554,110.12,17430,96.341003,"Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,03Jan2021,2022-03-08,20,3864,0,6,Western Pacific,3864,21357.506,83,458.76599,20,6,33.164001,0,0,0,,,,,,3864,11.857,6,0,212611.42,0,652.42297,330.142,0,0,0.56,,,,,,,,,18174,47.237,,,,13240.405,,,15.89,7.6999998,22.700001,,4.8000002,73.699997,0.82599998,,08Mar2022,,,,,,,,,,,,Oceania,,Not available,128.2216339,6200,0.15661781,0.08949589,1.124084,0.7868588,0.4496336,740.43103,740.43103,100.46994
Oceania,Melanesia,Papua New Guinea,PG,PNG,,,x,Developing,Papua New Guinea,1,Lower Middle Income Economies,East Asia and Pacific,23267000000,45.482,2951.98,598,-6,147,155,0.555,Medium human development,598,8947.027,8947027,1071483,12766607,11.75,1071483,5.7,High,,,40,65.08071899,5,0,0,0,20220221,46.759998,51.82,55.650002,25,Universal availability,WPRO,REPORTING,2022-02-28,412501,310659,4.6100001,3.4719999,250256,2.7969999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,SII - Covishield",4,30Mar2021,2022-03-08,0,41533,0,638,Western Pacific,41533,464.20999,231,2.582,0,638,7.131,0,0,0,2021-07-01,9.70%,18.4,5,All eligible groups are fully government-funded,41533,34.714001,639,0.14300001,4554.5542,12.282,3.8069999,70.072998,0,0.016000001,1.01,,,,,,,205,46.759998,9119005,18.219999,22.6,3.8080001,2.142,3823.1941,,561.49402,17.65,23.5,48.799999,,,64.5,0.55500001,,08Mar2022,,,,,310659,250256,,5196,6.1500001,3.4100001,2.74,Oceania,0,Target not reached,51.19793701,218480,0.32676372,0.18672213,21.173706,14.821594,8.4694824,38.498138,38.498138,20.39043
Europe,Eastern Europe,Poland,PL,POL,,,,Developed,Poland,0,High Income Economies,Europe and Central Asia,634899000000,55.507,17318.5,616,52,20,35,0.88,High human development,616,37846.605,37846604,105449847,52915800,278.99,105449847,3.1,Low,,,75,1014.038208,5,0,518361020,1,20220304,24.07,38.540001,36.900002,50,Universal availability,EURO,REPORTING,2022-02-20,53029684,22587330,139.7,59.506001,22130915,58.303001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,13176,5760498,217,112768,Europe,5760498,15175.924,80464,211.981,13176,112768,297.08499,1182,3.1140001,217,2022-01-01,2.50%,84.7,5,All eligible groups are fully government-funded,5760498,11494.857,112768,168.85699,152406.22,348.599,304.121,2983.5171,5.7410002,4.467,0.68000001,,,12886,340.927,,,656,24.07,37797000,124.027,41.799999,16.763,10.202,27216.445,,227.33099,5.9099998,23.299999,33.099998,,6.6199999,78.730003,0.88,3.03,08Mar2022,,,11439017,30.26,22542001,22250993,638504,341329,141.62,59.639999,58.869999,Europe,1,Target reached,314.4679871,,0.10703006,0.061160032,2.6113415,1.827939,1.0445366,50.289009,50.289009,
Americas,Latin America and the Caribbean,Puerto Rico,PR,PRI,,,x,Developing,Puerto Rico,0,High Income Economies,Latin America and the Caribben,95913000000,52.361,34143.27,,,,,,,630,2860.84,2860840,,,,,,,,,,,5,0,0,0,20220305,46.299999,49.48,56.549999,0,Universal availability,AMRO,REPORTING,2022-02-25,6895098,3098101,241.015,108.293,2596222,90.75,"Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,,2022-03-08,146,474907,1,4135,Americas,474907,16600.189,1410,49.285999,146,4135,144.537,25,0.87400001,1,,,,5,All eligible groups are fully government-funded,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.054288883,0.031022219,,,,,,
Asia,Eastern Asia,Democratic People's Republic of Korea,KP,PRK,,,,Developing,North Korea,1,Low Income Economies,East Asia and Pacific,,,,,,,,,,408,25778.815,25778816,,,,,4.8,Medium,3.11,,71,,,,,,,,,,,,,,,,,,,,,,,,2022-03-08,0,0,0,0,South-East Asia,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,49.99999619,,,,,,,,,
Europe,Southern Europe,Portugal,PT,PRT,,,,Developed,Portugal,0,High Income Economies,Europe and Central Asia,257055000000,130.787,24457.14,620,39.5,-8,38,0.864,High human development,620,10196.707,10196707,30924723,14235092,304.14,29433087,2.8,Low,,,82,2221.439209,5,0,242461000,1,20220307,13.89,35.419998,40.48,0,Universal availability,EURO,REPORTING,2022-02-20,23288435,9651664,226.2,93.810997,8660752,84.117996,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,5606,3337806,17,21216,Europe,3337806,32418.76,75188,730.271,5606,21216,206.062,153,1.4859999,17,2022-01-01,2.50%,96.3,5,All eligible groups are fully government-funded,3352874,11321.429,21248,23.143,329750.13,1481.915,1113.446,2089.709,3.1470001,2.276,0.77999997,81,7.9660001,1250,122.936,,,1040,13.89,10167923,112.371,46.200001,21.502001,14.924,27936.896,0.5,127.842,9.8500004,16.299999,30,,3.3900001,82.050003,0.86400002,-2.21,08Mar2022,,,6200217,60.98,9661714,9412251,168320,150867,225.28999,95.019997,92.57,Europe,1,Target reached,314.4679871,,0.075789727,0.043308415,1.1920201,0.83441401,0.47680801,75.306854,79.123322,
Americas,Latin America and the Caribbean,Paraguay,PY,PRY,,x,,Developing,Paraguay,0,Upper Middle Income Economies,Latin America and the Caribben,38287000000,38.415,5028.22,600,-23,-58,103,0.728,High human development,600,7132.53,7132530,9002171,10107497,124.69,7983479,3.6,Medium,0.43,0.3,69,388.3932495,5,0,7000000,1,20220214,35.189999,39.580002,45.240002,0,Universal availability,AMRO,REPORTING,2022-02-25,8070750,3786974,113.154,53.094002,3185645,44.664001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Bharat - Covaxin,Gamaleya - Gam-Covid-Vac,Julphar - Hayat-Vax,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",8,22Feb2021,2022-03-08,260,643879,11,18471,Americas,643879,9027.3477,2558,35.863998,260,18471,258.96799,112,1.5700001,11,2022-01-01,2.50%,91.6,5,All eligible groups are fully government-funded,644609,346.42899,18494,14.571,89285.461,56.790001,47.984001,2561.623,1.6619999,2.0179999,0.67000002,,,,,,,2231,35.189999,7219641,17.143999,26.5,6.3779998,3.8329999,8827.0098,1.7,199.12801,8.2700005,5,21.6,79.601997,1.3,74.25,0.72799999,54.220001,08Mar2022,,,1144903,15.86,3821093,3217516,141096,90584,113.35,52.93,44.57,South America,1,Target reached,80.12288666,2732000,0.28789511,0.1645115,5.3245006,3.7271502,2.1298001,89.653374,101.09315,30.348234
Asia,Western Asia,State of Palestine,PS,PSE,,,,Developing,Palestine,1,Lower Middle Income Economies,Middle East and North Africa,,,,275,32,35.25,115,0.708,High human development,275,5101.416,5101416,5090098,7311858,97.46,5090098,5,High,0.94,,,,5,1000000,0,0,20220307,16.67,31.25,35.709999,0,Universal availability,EMRO,REPORTING,2022-03-06,3609984,1979151,70.764,38.796001,1716216,33.641998,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Gamaleya - Sputnik-Light,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",8,02Feb2021,2022-03-08,598,652298,2,5583,Eastern Mediterranean,652298,12786.612,5095,99.874001,598,5583,109.44,70,1.372,2,2022-01-01,2.50%,83.4,5,All eligible groups are fully government-funded,652298,727.85699,5583,10,124895.36,114.499,139.36301,1068.976,0.38299999,1.915,0.66000003,,,,,,,721,16.67,5222756,778.20203,20.4,3.043,1.726,4449.8979,1,265.91,10.59,,,,,74.050003,0.708,58.860001,08Mar2022,,,2779,0.050000001,1979151,1716216,58442,41850,69.120003,37.889999,32.860001,Asia,0,Target not reached,125.3433609,1644500,,,,,,70.9217,70.9217,32.307827
Oceania,Polynesia,French Polynesia,PF,PYF,,,x,Developing,French Polynesia,0,High Income Economies,East Asia and Pacific,,,,,,,,,,258,280.904,280904,,,,,,,,,,,,,,,,,,,,,WPRO,REPORTING,2022-02-22,414137,183676,147.42799,65.387001,180364,64.207001,"Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty",2,18Jan2021,2022-03-08,0,68975,0,643,Western Pacific,68975,24554.303,1324,471.32901,0,643,228.901,2,0.71200001,0,,,,,,68975,325.14301,643,0.28600001,244129.91,1946.668,1150.8101,2275.832,0,1.011,,,,,,,,453,,282534,77.323997,32.700001,7.7750001,4.5929999,,,,22.629999,,,,,77.660004,,144.46001,08Mar2022,,,,,183990,180807,450,3216,129.12,65.120003,63.990002,Oceania,1,Target reached,,,,,,,,,,
Asia,Western Asia,Qatar,QA,QAT,,,,Developing,Qatar,0,High Income Economies,Middle East and North Africa,155571000000,59.012,61790.57,634,25.5,51.25,45,0.848,High human development,634,2881.06,2881060,7036774,4102734,240.12,5849033,3.3,Low,,,68,1807.153931,5,0,0,0,20220306,55.560001,59.380001,60.709999,50,Universal availability,EMRO,REPORTING,2022-03-03,6398889,2575934,222.10201,89.408997,2575934,89.408997,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,165,358418,0,670,Eastern Mediterranean,358418,12440.521,1436,49.842999,165,670,23.254999,0,0,0,2022-01-01,2.50%,97.9,5,All eligible groups are fully government-funded,358564,181.714,671,0.14300001,122354.91,49.82,62.007,228.96899,0.34099999,0.048999999,0.52999997,,,,,,,4304,55.560001,2930524,227.32201,31.9,1.307,0.61699998,116935.6,,176.69,16.52,0.80000001,26.9,,1.2,80.230003,0.84799999,54.169998,08Mar2022,,,1297264,44.27,2360308,2218292,43974,37344,218.87,80.540001,75.699997,Asia,1,Target reached,119.0167389,,0.029998105,0.017141774,1.4652874,1.0257012,0.586115,90.934982,109.4008,
Africa,Sub-Saharan Africa,Réunion,RE,REU,,,,Developing,Reunion,0,Unclassified Economies,Unclassified,,,,,,,,,,638,895.308,895308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2022-03-08,8019,310181,14,680,Africa,310181,34645.02,8019,895.66498,8019,680,75.950996,14,1.564,14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Europe,Eastern Europe,Romania,RO,ROU,,,,Developed,Romania,0,Upper Middle Income Economies,Europe and Central Asia,289408000000,51.121,14863.89,642,46,25,49,0.828,High human development,642,19237.682,19237682,26859217,26778881,140.42,26042460,3.6,Medium,,,74,738.5581665,5,0,808365.18,1,20220214,47.220001,59.900002,59.52,62.5,Universal availability,EURO,REPORTING,2022-02-20,15831189,8147081,81.900002,42.150002,8056216,41.68,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,27Jan2021,2022-03-08,3188,2771449,32,63993,Europe,2771449,14338.415,37965,196.416,3188,63993,331.07501,579,2.9960001,32,2022-01-01,2.50%,81.1,5,All eligible groups are fully government-funded,2776910,4995,64094,73.713997,145176.86,285.50101,261.13901,3350.835,5.2800002,3.8540001,0.54000002,924,48.306999,8269,432.30301,,,208,47.220001,19127772,85.128998,43,17.85,11.69,23313.199,5.6999998,370.94601,9.7399998,22.9,37.099998,,6.8920002,76.050003,0.82800001,6.8899999,08Mar2022,,,,,8147081,8070200,150935,131697,87.309998,42.59,42.189999,Europe,1,Target reached,314.4679871,,0.097390383,0.05565165,2.8000503,1.9600352,1.1200202,58.941364,60.789913,
Europe,Eastern Europe,Russian Federation,RU,RUS,,,,Developed,Russia,0,Upper Middle Income Economies,Europe and Central Asia,1584220000000,17.935,11273.24,643,60,100,52,0.824,High human development,643,145934.46,145934464,177312284,204276831,121.52,163144228,3.2,Low,,,75,653.4172363,5,1000000,312789295,1,20220307,40.279999,50.779999,49.110001,62.5,Universal availability,EURO,OWID,2022-02-17,160816996,78284278,110.2,53.643002,71601909,49.063999,"SRCVB - EpiVacCorona, Gamaleya - Sputnik V",2,,2022-03-08,66576,17081394,652,357601,Europe,17081394,11704.839,586025,401.56699,66576,357601,245.04201,5155,3.5320001,652,2022-01-01,2.50%,75.1,4,"Partial government funding for some eligible groups, full funding for others",16835844,82593.711,350490,723.28601,115383.53,449.37399,566.05103,2402.064,4.3660002,4.9569998,0.73000002,,,,,,,341,40.279999,145912022,8.823,39.599998,14.178,9.3929996,24765.953,0.1,431.297,6.1799998,23.4,58.299999,,8.0500002,72.580002,0.824,19.23,08Mar2022,66317,454.5,12491700,8.5600004,78770001,72124064,2389472,1020075,110.51,53.98,49.43,Europe,1,Target reached,100,,0.12841029,0.073377311,3.1648996,2.2154298,1.2659599,90.697044,98.573509,
Africa,Sub-Saharan Africa,Rwanda,RW,RWA,x,x,,Developing,Rwanda,1,Low Income Economies,Sub-Saharan Africa,10621000000,74.834,802.264,646,-2,30,160,0.543,Low human development,646,12952.209,12952209,26063130,18587124,196.31,26063130,5.1,High,1.12,6.6,57,51.39912415,5,0,0,0,20220228,45.369999,53.119999,60.709999,0,Universal availability,AFRO,REPORTING,2022-02-24,18038703,8811796,139.271,68.032997,7808436,60.285999,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",7,05Mar2021,2022-03-08,9,129560,1,1459,Africa,129560,1000.292,58,0.44800001,9,1459,11.264,2,0.015,1,2021-06-01,9.30%,91.9,5,All eligible groups are fully government-funded,129567,7.2859998,1459,0.28600001,9759.1113,0.52700001,0.54900002,109.893,0.075000003,0.022,0.55000001,,,,,,,12410,45.369999,13276517,494.86899,20.299999,2.974,1.642,1854.2111,56,191.375,4.2800002,4.6999998,21,4.6170001,,69.019997,0.54299998,,08Mar2022,,,1676522,12.63,8811796,7808436,211071,164763,135.87,66.370003,58.810001,Africa,1,Target reached,92.03700256,2907000,1.0016652,0.57238019,22.335011,15.634507,8.9340048,69.211578,69.211578,11.153687
Asia,Western Asia,Saudi Arabia,SA,SAU,,,,Developing,Saudi Arabia,0,High Income Economies,Middle East and North Africa,735483000000,29.681,23762.42,682,25,45,40,0.854,High human development,682,34813.867,34813868,65627642,49476952,185.7,58407543,2.8,Low,,,74,1316.260254,5,525000000,510000000,1,20220308,63.889999,59.900002,68.449997,0,Universal availability,EMRO,REPORTING,2022-03-06,61384936,26026203,176.323,74.758003,24286609,69.761002,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,06Jan2021,2022-03-08,279,747715,1,9009,Eastern Mediterranean,747715,2147.75,2688,7.7210002,279,9009,25.878,11,0.032000002,1,2022-01-01,2.50%,98.2,5,All eligible groups are fully government-funded,747934,334.85699,9011,1.429,21163.543,6.197,9.4750004,254.97501,0.057,0.039999999,0.5,,,,,,,3181,63.889999,35340680,15.322,31.9,3.2950001,1.845,49045.41,,259.53799,17.719999,1.8,25.4,,2.7,75.129997,0.85399997,,08Mar2022,,,9904609,28.030001,25792668,23964566,608460,402957,168.82001,72.980003,67.809998,Asia,1,Target reached,92.85054779,,0.078005522,0.044574585,2.0117602,1.4082321,0.80470407,93.535187,105.09762,
Africa,Northern Africa,Sudan,SD,SDN,x,,,Developing,Sudan,1,Low Income Economies,Sub-Saharan Africa,32476000000,209.93,789.448,729,15,30,170,0.51,Low human development,729,43849.269,43849268,7064241,62873091,15.73,7064241,5.8,High,1.49,11.6,44,46.92884064,4,0,100000000,1,20220221,16.67,28.440001,32.5,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,EMRO,REPORTING,2022-02-15,5711034,5126250,13.024,11.691,2333416,5.3210001,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",5,09Mar2021,2022-03-08,6,61631,0,4865,Eastern Mediterranean,61631,140.552,143,0.32600001,6,4865,11.095,956,2.1800001,0,2022-01-01,2.50%,79.5,5,All eligible groups are fully government-funded,61631,20.429001,4865,136.714,1372.342,0.134,0.45500001,108.329,21.221001,3.0439999,0.46000001,,,,,,,1233,16.67,44909351,23.257999,19.700001,3.5480001,2.0339999,4466.5068,,431.388,15.67,,,23.437,0.80000001,65.309998,0.50999999,,08Mar2022,,,,,5126250,2333416,20715,159116,12.72,11.41,5.1999998,Africa,0,Target not reached,66.21622467,250000,1.0179265,0.58167225,24.462568,17.123798,9.7850275,80.844269,80.844269,3.5389507
Africa,Sub-Saharan Africa,Senegal,SN,SEN,x,,,Developing,Senegal,1,Lower Middle Income Economies,Sub-Saharan Africa,28103000000,71.873,1602.9,686,14,-14,168,0.512,Low human development,686,16743.93,16743930,5980876,24074831,34.78,5980876,5.2,High,,,45,59.09758377,4,0,3800000,1,20220307,21.299999,34.169998,39.049999,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-03-01,2493984,1448125,14.895,8.6490002,1031849,6.1630001,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,SII - Covishield",3,23Feb2021,2022-03-08,11,85768,1,1962,Africa,85768,512.23297,75,0.44800001,11,1962,11.718,2,0.012,1,2022-01-01,3.60%,75.7,5,All eligible groups are fully government-funded,85772,10.429,1962,0.28600001,4987.8149,0.233,0.60600001,114.094,0,0.017000001,0.64999998,,,,,,,170,21.299999,17196308,82.328003,18.700001,3.0079999,1.796,2470.5801,38,241.21899,2.4200001,0.40000001,16.6,20.858999,,67.940002,0.51200002,,08Mar2022,,,,,1448125,1031849,17437,59731,14.5,8.4200001,6,Africa,0,Target not reached,63.79853058,325000,0.60178429,0.34387672,23.317366,16.322157,9.3269463,41.69931,41.69931,5.4339867
Asia,South-eastern Asia,Singapore,SG,SGP,,,x,Developing,Singapore,0,High Income Economies,East Asia and Pacific,362524000000,137.859,66263.42,702,1.3667,103.8,11,0.938,High human development,702,5850.343,5850343,16142763,8255358,273.76,14429776,2.5,Low,,,86,2632.713867,5,0,0,0,20220307,60.189999,77.599998,74.400002,100,Universal availability,WPRO,REPORTING,2022-02-21,13452417,4977864,229.942,85.086998,4898322,83.726997,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,30Dec2020,2022-03-08,13520,846341,6,1084,Western Pacific,846341,14466.522,121917,2083.929,13520,1084,18.528999,65,1.1109999,6,2022-01-01,2.50%,98.8,5,All eligible groups are fully government-funded,846341,17416.715,1084,7.7140002,155189.42,2479.0959,3193.6179,198.76801,0,1.415,1.03,33,6.0510001,1444,264.77899,84,15.403,2254,60.189999,5453600,7915.731,42.400002,12.922,7.0489998,85535.383,,92.242996,10.99,5.1999998,28.299999,,2.4000001,83.620003,0.93800002,10.31,08Mar2022,2007,368.01401,3723755,68.279999,4994166,4933358,82816,78931,250.32001,91.580002,90.459999,Asia,1,Target reached,126.5959854,,0.027973201,0.015984686,1.0058062,0.70406437,0.4023225,83.334045,93.226791,
Americas,Latin America and the Caribbean,South Georgia and the South Sandwich Islands,GS,SGS,,,,Developing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Africa,Sub-Saharan Africa,Saint Helena,SH,SHN,,,,Developing,Saint Helena,0,Unclassified Economies,Unclassified,,,,,,,,,,654,6.071,6071,,,,,,,,,,,,,,,,,,,,,AFRO,OWID,2021-05-05,7892,4361,129.995,71.833,3531,58.161999,AstraZeneca - AZD1222,1,,2022-03-08,0,0,0,0,Africa,0,0,0,0,0,0,0,0,0,0,,,,,,4,0,,,656.276,0,0,,,,,,,,,,,15915,,6095,,,,,,,,,,,,,80.559998,,,08Mar2022,,,,,4361,3531,,165,129.48,71.550003,57.93,Africa,1,Target reached,,,,,,,,,,
Europe,Northern Europe,Svalbard and Jan Mayen Islands,SJ,SJM,,,,Developed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Oceania,Melanesia,Solomon Islands,SB,SLB,x,,x,Developing,Solomon Islands,1,Lower Middle Income Economies,East Asia and Pacific,1675000000,20.38,2356.51,90,-8,159,151,0.567,Medium human development,90,686.878,686878,510185,985593,72.47,510185,5.7,High,2.49,3.6,47,111.9044876,5,0,0,0,20220228,87.5,64.580002,73.809998,0,Universal availability,WPRO,REPORTING,2022-02-27,315423,214939,45.921001,31.292,100347,14.609,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Pfizer BioNTech - Comirnaty,SII - Covishield",4,23Mar2021,2022-03-08,124,8150,2,118,Western Pacific,8150,1186.5179,1101,160.289,124,118,17.179001,19,2.766,2,2021-11-01,8.70%,54,5,All eligible groups are fully government-funded,8150,157.286,118,1.714,11576.787,176.138,223.41901,167.61501,0,2.4349999,0.68000001,,,,,,,2855,87.5,703995,21.841,20.799999,3.507,2.043,2205.9231,25.1,459.78,18.68,,,35.889999,1.4,73,0.56699997,,08Mar2022,,,,,214939,100347,,2317,44.790001,30.530001,14.25,Oceania,0,Target not reached,71.36378479,300800,0.40933415,0.23390523,12.314073,8.6198511,4.9256291,61.825222,61.825222,58.959003
Africa,Sub-Saharan Africa,Sierra Leone,SL,SLE,x,,,Developing,Sierra Leone,1,Low Income Economies,Sub-Saharan Africa,3842000000,71.072,541.063,694,8.5,-11.5,182,0.452,Low human development,694,7976.985,7976985,2308071,11397880,28.35,2308071,6.2,High,1.75,22.4,39,46.15795517,4,0,0,0,20220307,48.150002,46.150002,52.740002,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-03-04,1859571,1516460,23.312,19.01,964902,12.096,"Beijing CNBG - BBIBP-CorV,SII - Covishield",2,15Mar2021,2022-03-08,0,7665,0,125,Africa,7665,96.088997,0,0,0,125,1.567,0,0,0,2021-01-01,5.10%,87.9,5,All eligible groups are fully government-funded,7666,0.14300001,125,0,941.61401,0,0.017999999,15.354,0,0,0.17,,,,,,,805,48.150002,8141343,104.7,19.1,2.5380001,1.285,1390.3,52.200001,325.72101,2.4200001,8.8000002,41.299999,19.275,,54.700001,0.45199999,,08Mar2022,,,,,1516460,964902,6053,32362,22.84,18.629999,11.85,Africa,0,Target not reached,56.0186615,410000,1.4852245,0.84869969,24.871119,17.409782,9.9484472,80.568192,80.568192,17.763752
Americas,Latin America and the Caribbean,El Salvador,SV,SLV,,,,Developing,El Salvador,1,Lower Middle Income Economies,Latin America and the Caribben,26224000000,84.235,4244.3,222,13.8333,-88.9167,124,0.673,Medium human development,222,6486.201,6486201,13016793,9125900,199.69,13016793,4.2,Medium,,,76,300.0532837,5,0,0,0,20220220,32.41,36.98,42.259998,0,Universal availability,AMRO,REPORTING,2022-02-25,10174711,4540530,156.867,70.002998,4262971,65.723999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",6,17Feb2021,2022-03-08,0,156364,3,4091,Americas,156364,2410.7161,8578,132.25,0,4091,63.071999,20,0.308,3,2022-01-01,2.50%,96.8,5,All eligible groups are fully government-funded,156364,0,4092,2.5710001,23987.727,0,0,627.75201,0.153,0.39399999,0.19,,,,,,,1679,32.41,6518500,307.811,27.6,8.2729998,5.4169998,7292.458,2.2,167.295,8.8699999,2.5,18.799999,90.650002,1.3,73.32,0.67299998,49.240002,08Mar2022,,,1406719,21.58,4569063,4258480,102028,72435,157,70.089996,65.330002,North America,1,Target reached,126.6058121,850800,0.22726952,0.1298683,4.5925179,3.2147624,1.837007,78.166039,78.166039,6.5361724
Europe,Southern Europe,San Marino,SM,SMR,,,,Developed,San Marino,0,High Income Economies,Europe and Central Asia,1515000000,94.567,50934.19,,,,,,,674,33.938,33938,70928,47614,208.55,62480,,,,,,3050.918213,5,0,0,0,20220307,52.779999,59.380001,57.139999,75,Universal availability,EURO,REPORTING,2022-02-20,64480,24583,190,71.351997,21841,63.394001,"Gamaleya - Gam-Covid-Vac,Pfizer BioNTech - Comirnaty",2,24Feb2021,2022-03-08,57,14581,0,112,Europe,14581,42963.641,161,474.39401,57,112,330.01401,0,0,0,,,,5,All eligible groups are fully government-funded,14581,23.857,112,0,428726.84,1705.381,701.474,3293.1489,0,0,0.72000003,,,,,,,1823,52.779999,34010,556.66699,,,,56861.469,,,5.6399999,,,,3.8,84.970001,,33.060001,08Mar2022,,,13152,38.669998,24583,21841,990,725,189.59,72.279999,64.220001,Europe,1,Target reached,104.2752151,,0.036392059,0.020795463,0.86793542,0.60755479,0.34717417,90.909088,103.20103,
Africa,Sub-Saharan Africa,Somalia,SO,SOM,x,,,Developing,Somalia,1,Low Income Economies,Sub-Saharan Africa,5365000000,,350.361,,,,,,,706,15893.219,15893219,5796171,22903300,35.43,5796171,7.3,Very High,1.68,,25,,3,0,0,0,20220228,40.740002,42.810001,48.93,0,Availability for ALL of following: key workers/ clinically vulnerable groups (non elderly)/elderly groups,EMRO,REPORTING,2022-02-28,1838348,1479158,11.567,9.3070002,937617,5.8990002,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,SII - Covishield,Sinovac - CoronaVac",4,16Mar2021,2022-03-08,0,26400,0,1359,Eastern Mediterranean,26400,166.10899,87,0.54699999,0,1359,8.5509996,11,0.068999998,0,2021-04-01,12.80%,61.5,5,All eligible groups are fully government-funded,26400,7,1359,1.571,1613.741,0,0.428,83.070999,0.67199999,0.096000001,0.46000001,,,,,,,751,40.740002,16359500,23.5,16.799999,2.7309999,1.4960001,,,365.76901,6.0500002,,,9.8310003,0.89999998,57.400002,,,08Mar2022,,,,,1479158,937617,17966,34098,11.24,9.04,5.73,Africa,0,Target not reached,62.75069427,700000,2.2936342,1.3106482,,,,31.716593,31.716593,12.076939
Americas,Northern America,Saint Pierre and Miquelon,PM,SPM,,,,Developed,Saint Pierre and Miquelon,0,Unclassified Economies,Unclassified,,,,,,,,,,666,5.795,5795,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2022-03-08,0,995,0,1,Americas,995,17169.975,0,0,0,1,17.256001,0,0,0,,,,,,1125,5.4289999,1,0,194940.22,0,940.664,173.28,0,0,,,,,,,,,,5771,,,,,,,,,,,,,81.07,,,08Mar2022,,,,,,,,,,,,North America,,Not available,,,,,,,,,,
Europe,Southern Europe,Serbia,RS,SRB,,,,Developed,Serbia,0,Upper Middle Income Economies,Europe and Central Asia,58333000000,59.854,8793.84,688,44,21,64,0.806,High human development,688,8737.37,8737370,9371005,9671514,135.65,9228006,3.6,Medium,0.7,0.2,65,641.0250244,5,0,0,0,20220307,36.110001,48.959999,48.810001,50,Universal availability,EURO,REPORTING,2022-01-23,6612050,3356512,95.5,48.458,3255538,47,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",5,23Dec2020,2022-03-08,2231,1927849,26,15463,Europe,1927849,27832.121,16874,243.608,2231,15463,223.237,222,3.2049999,26,2022-01-01,2.50%,75.8,5,All eligible groups are fully government-funded,1930437,2368,15488,29.714001,280931.94,376.62601,344.60901,2253.9319,3.638,4.3239999,0.56,83,12.079,1797,261.513,,,193,36.110001,6871547,80.291,41.200001,17.365999,,14048.881,,439.41501,10.08,37.700001,40.200001,97.719002,5.6090002,76,0.80599999,10.28,08Mar2022,,,1869580,27.209999,3344962,3265654,69995,64449,123.41,48.68,47.52,Europe,1,Target reached,53.57585144,463270,0.16461523,0.094065845,3.226083,2.2582581,1.2904333,70.558601,71.651993,4.9436531
Africa,Sub-Saharan Africa,South Sudan,SS,SSD,x,x,,Developing,South Sudan,1,Low Income Economies,Sub-Saharan Africa,4575000000,64.375,230.132,728,8,30,185,0.433,Low human development,728,11193.729,11193729,929859,15933928,8.17,929859,7.3,Very High,0.3,10.8,31,22.63818741,4,0,0,0,20220228,36.110001,39.380001,45,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-02-20,518428,469694,4.631,4.1960001,426227,3.8080001,"Janssen - Ad26.COV 2-S,SII - Covishield",2,06Apr2021,2022-03-08,0,17015,0,137,Africa,17015,152.005,37,0.331,0,137,1.224,0,0,0,2022-01-01,14.40%,72.3,5,All eligible groups are fully government-funded,17025,6.7140002,137,0,1495.865,0.87900001,0.58999997,12.037,0,0,0.97000003,,,,,,,854,36.110001,11381377,,19.200001,3.441,2.0320001,1569.8879,,280.77499,10.43,,,,,57.849998,0.433,,08Mar2022,,,,,469694,426227,4158,9720,4.5599999,4.1300001,3.74,Africa,0,Target not reached,60.69850922,59000,3.491909,1.9953766,50.710773,35.497543,20.284309,55.753399,55.753399,6.345048
Africa,Sub-Saharan Africa,Sao Tome and Principe,ST,STP,x,,x,Developing,Sao Tome and Principe,1,Lower Middle Income Economies,Sub-Saharan Africa,476000000,60.738,2392.89,678,1,7,135,0.625,Medium human development,678,219.161,219161,394327,312710,176.54,394327,5.1,High,,,55,108.4464035,,,,,,,,,,,AFRO,REPORTING,2022-03-01,193775,111775,88.417999,51.001999,77969,35.576,"AstraZeneca - Vaxzevria,SII - Covishield",2,15Mar2021,2022-03-08,0,5939,0,72,Africa,5939,2709.905,5,2.2809999,0,72,32.853001,0,0,0,,,,,,5939,0.71399999,72,0,26588.887,0,3.198,322.34399,0,0,0.23,,,,,,,1200,,223364,212.841,18.700001,2.8859999,2.1619999,3052.7141,32.299999,270.11301,2.4200001,,,41.34,2.9000001,70.389999,0.625,,08Mar2022,,,4031,1.8,111775,77969,,2448,86.75,50.040001,34.91,Africa,0,Target not reached,90.590065,74000,0.40311089,0.23034908,12.706738,8.8947163,5.082695,49.140686,49.140686,18.766151
Americas,Latin America and the Caribbean,Suriname,SR,SUR,,,x,Developing,Suriname,0,Upper Middle Income Economies,Latin America and the Caribben,3010000000,140.553,4620.4,740,4,-56,97,0.738,High human development,740,586.634,586634,588898,828517,99.51,588898,3.6,Medium,1.83,0.6,71,619.2471314,5,0,0,0,20220301,50,45.830002,52.380001,0,Universal availability,AMRO,REPORTING,2022-02-25,545058,265860,92.913002,45.32,234910,40.043999,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield",5,23Feb2021,2022-03-08,24,78511,0,1318,Americas,78511,13383.348,388,66.139999,24,1318,224.672,2,0.34099999,0,,,,5,All eligible groups are fully government-funded,78623,47,1319,0.28600001,132854.45,74.349998,79.418999,2228.801,0,0.48300001,0.62,,,,,,,171,50,591798,3.612,29.6,6.9330001,4.2290001,13767.119,,258.314,12.54,7.4000001,42.900002,67.778999,3.0999999,71.68,0.73799998,,08Mar2022,,,46313,7.8299999,266637,236131,9775,6238,84.959999,45.060001,39.900002,South America,0,Target not reached,70.58151245,441400,0.31330621,0.17903212,3.3395391,2.3376775,1.3358157,92.555588,92.555588,74.95356
Europe,Eastern Europe,Slovakia,SK,SVK,,,,Developed,Slovakia,0,High Income Economies,Europe and Central Asia,118079000000,61.361,21383.29,703,48.6667,19.5,39,0.86,High human development,703,5459.643,5459643,9318183,7645016,170.64,9318183,3.3,Low,,,77,1342.074829,5,0,0,0,20220221,42.59,57.290001,52.98,87.5,Universal availability,EURO,REPORTING,2022-02-20,7008272,2816259,128.39999,51.599998,2754644,50.471001,"AstraZeneca - Vaxzevria,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",5,06Jan2021,2022-03-08,0,1512913,46,18750,Europe,1512913,27719.828,54784,1003.761,0,18750,343.54001,220,4.0310001,46,2022-01-01,2.50%,78.3,5,All eligible groups are fully government-funded,2216994,11742.714,18750,31.429001,406842.38,2542.175,2154.915,3440.8279,8.441,5.7670002,0.83999997,235,43.125,2757,505.939,,,21,42.59,5449270,113.128,41.200001,15.07,9.1669998,30155.152,0.69999999,287.95901,7.29,23.1,37.700001,,5.8200002,77.540001,0.86000001,-8.0100002,08Mar2022,,,1625854,29.84,2817878,2753673,,35899,129.10001,51.709999,50.529999,Europe,1,Target reached,332.9179382,15000,0.08668451,0.049534004,1.9730643,1.381145,0.78922576,75.210716,75.210716,0.16097559
Europe,Southern Europe,Slovenia,SI,SVN,,,,Developed,Slovenia,0,High Income Economies,Europe and Central Asia,59475000000,77.181,28939.27,705,46,15,22,0.917,High human development,705,2078.932,2078932,5198055,2910212,250.06,5017206,2.6,Low,,,79,2219.100586,4,0,16367576.52,1,20220228,48.150002,60.209999,59.880001,62.5,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,EURO,REPORTING,2022-02-20,2957432,1252953,141.10001,59.782001,1217641,58.097,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",4,23Dec2020,2022-03-08,754,904492,1,7128,Europe,904492,43156.105,11693,557.909,754,7128,340.099,28,1.336,1,2022-01-01,2.50%,79.1,5,All eligible groups are fully government-funded,907630,1779.429,6374,8,436628.66,1525.4561,856.02002,3066.3059,3.3670001,3.849,0.56,108,51.955002,526,253.03999,59,28.150999,218,48.150002,2078723,102.619,44.5,19.062,12.93,31400.84,,153.493,7.25,20.1,25,,4.5,81.32,0.917,-15.08,08Mar2022,349,167.95,630482,30.33,1264048,1218885,36494,19122,142.69,60.810001,58.639999,Europe,1,Target reached,314.4679871,,0.064051375,0.036600783,1.1932763,0.83529335,0.47731051,56.894974,58.945797,
Europe,Northern Europe,Sweden,SE,SWE,,,,Developed,Sweden,0,High Income Economies,Europe and Central Asia,611970000000,39.635,58639.19,752,62,15,7,0.945,High human development,752,10099.27,10099270,25094577,14224223,246.99,24287860,2.2,Low,,,86,5671.385742,5,143528042.2,9900000,1,20220308,19.440001,28.65,29.17,25,Universal availability,EURO,REPORTING,2022-02-20,19694254,7526952,190.7,72.882004,7334879,71.022003,"AstraZeneca - Vaxzevria,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,23Dec2020,2022-03-08,0,2455966,0,17512,Europe,2455966,23780.633,9002,87.165001,0,17512,169.565,40,0.38699999,0,2022-01-01,2.50%,94.1,5,All eligible groups are fully government-funded,2460783,1800.1429,17549,43.856998,242199.27,474.10699,177.177,1727.2371,3.642,4.3169999,0.50999999,44,4.3309999,1152,113.384,,,2823,19.440001,10160159,24.718,41,19.985001,13.433,46949.281,0.5,133.98199,4.79,18.799999,18.9,,2.22,82.800003,0.94499999,3.6900001,08Mar2022,,,4989399,49.110001,7808159,7593465,96699,110593,202.98,76.849998,74.739998,Europe,1,Target reached,314.4679871,,0.031610258,0.018063005,0.4669053,0.3268337,0.18676211,78.480118,81.086823,
Africa,Sub-Saharan Africa,Eswatini,SZ,SWZ,,x,,Developing,Eswatini,1,Lower Middle Income Economies,Sub-Saharan Africa,4211000000,46.036,3965.43,748,-26.5,31.5,138,0.611,Medium human development,748,1160.164,1160164,755592,1641317,64.45,755592,5.3,High,,,63,264.0551453,5,40000000,13640045.16,1,20220307,60.189999,58.849998,67.260002,0,Universal availability,AFRO,REPORTING,2022-02-21,490899,380363,42.313,32.785,336066,28.966999,"Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",3,19Mar2021,2022-03-08,9,69307,0,1391,Africa,69307,5973.897,147,12.671,9,1391,119.897,1,0.086000003,0,2021-06-01,7.50%,45,5,All eligible groups are fully government-funded,69331,20,1391,0.14300001,59137.523,20.471001,17.059,1186.4871,0,0.122,1.16,,,,,,,449,49.07,1172369,79.491997,21.5,3.1630001,1.845,7738.9751,,333.436,3.9400001,1.7,16.5,24.097,2.0999999,60.189999,0.611,,08Mar2022,,,,,380363,336066,17170,11049,41.869999,32.439999,28.67,Africa,0,Target not reached,40.85297394,20000,0.24325231,0.13900132,5.2186069,3.6530249,2.0874426,64.968796,64.968796,2.6469312
Americas,Latin America and the Caribbean,Sint Maarten (Dutch part),SX,SXM,,,x,Developing,Sint Maarten (Dutch part),0,High Income Economies,Latin America and the Caribben,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,61545,27857,143.522,64.961998,25848,60.277,"AstraZeneca - Vaxzevria,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,22Feb2021,2022-03-08,3,9573,0,85,Americas,9573,22324.053,25,58.299999,3,85,198.218,0,0,0,,,,,,,,,,,,,,,,,,,,,,,760,,43421,1209.088,,,,36327.23,,,,,,,,78.949997,,,25Feb2022,,,,,27857,25848,,892,141.74001,64.160004,59.529999,North America,1,Target reached,,,,,,,,,,
Africa,Sub-Saharan Africa,Seychelles,SC,SYC,,,x,Developing,Seychelles,0,High Income Economies,Sub-Saharan Africa,1240000000,81.881,13140.37,690,-4.5833,55.6667,67,0.796,High human development,690,98.34,98340,305998,138474,309.37,305998,4,Medium,,,71,839.7733154,5,0,0,0,20220307,56.48,52.080002,59.52,0,Universal availability,AFRO,REPORTING,2022-03-01,198120,84141,201.45,85.555,79921,81.264,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Julphar - Hayat-Vax,SII - Covishield",4,10Jan2021,2022-03-08,0,39427,0,163,Africa,39427,40089.684,50,50.84,0,163,165.74001,0,0,0,,,,5,All eligible groups are fully government-funded,39605,28.857,163,0,400414.53,1799.616,291.75201,1647.963,0,0,0.64999998,,,,,,,1678,56.48,98910,208.354,36.200001,8.6059999,5.586,26382.287,1.1,242.64799,10.55,7.0999999,35.700001,,3.5999999,73.400002,0.796,50.759998,08Mar2022,,,27744,28.049999,84141,79921,3758,2401,200.3,85.07,80.800003,Africa,1,Target reached,141.7652435,126000,0.14106147,0.080606557,3.1532319,2.2072623,1.2612928,64.745522,64.745522,41.176739
Asia,Western Asia,Syrian Arab Republic,SY,SYR,,,,Developing,Syria,1,Low Income Economies,Middle East and North Africa,,,,760,35,38,151,0.567,Medium human development,760,17500.657,17500656,12358032,25585986,67.62,10406186,4.7,Medium,1.15,,60,,5,0,-0.2,0,20220207,55.09,44.009998,50.299999,0,Universal availability,EMRO,REPORTING,2022-03-01,3264756,2239981,18.655001,12.799,1269123,7.2519999,"Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Gamaleya - Sputnik-Light,Janssen - Ad26.COV 2-S,SII - Covishield,Sinovac - CoronaVac",6,01Apr2021,2022-03-08,59,55085,4,3099,Eastern Mediterranean,55085,314.76001,510,2.914,59,3099,17.708,24,0.13699999,4,,,,5,All eligible groups are fully government-funded,55140,68,3102,3.286,3017.1201,3.0090001,3.721,169.73399,0.164,0.18000001,0.81999999,,,,,,,528,55.09,18275704,,21.700001,,2.5769999,,,376.26401,,,,70.598,1.5,72.699997,0.56699997,,08Mar2022,,,3046,0.02,2239981,1269123,,90157,17.860001,12.26,6.9400001,Asia,0,Target not reached,64.92456818,1805000,,,,,,26.418091,31.373224,14.605886
Americas,Latin America and the Caribbean,Turks and Caicos Islands,TC,TCA,,,,Developing,Turks and Caicos Islands,0,High Income Economies,Latin America and the Caribben,,,,,,,,,,796,38.718,38718,74992,54916,191.18,61977,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,68176,31165,176.08299,80.491997,29160,75.314003,Pfizer BioNTech - Comirnaty,1,11Jan2021,2022-03-08,0,5867,0,36,Americas,5867,15153.159,0,0,0,36,92.980003,0,0,0,,,,,,5867,0,36,0,149569.16,0,0,917.75897,0,0,,,,,,,,765,,39226,37.312,,,,,,,,,,,,80.220001,,,08Mar2022,,,,,31165,29160,,517,173.8,79.449997,74.339996,North America,1,Target reached,,,,,,,,90.911034,110.0021,
Africa,Sub-Saharan Africa,Chad,TD,TCD,x,x,,Developing,Chad,1,Low Income Economies,Sub-Saharan Africa,12013000000,44.003,729.844,148,15,19,187,0.398,Low human development,148,16425.859,16425859,1544338,23680979,9.13,1544338,7.2,Very High,0.76,16.8,28,29.85083008,4,0,0,0,20220220,32.41,34.169998,39.049999,0,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-02-18,403992,271031,2.4590001,1.65,142452,0.86699998,Beijing CNBG - BBIBP-CorV,1,04Jun2021,2022-03-08,1,7258,0,190,Africa,7258,44.186001,1,0.0060000001,1,190,1.1569999,0,0,0,2021-06-01,7.50%,69,,No availability,7258,0.14300001,190,0,429.08701,0,0.0080000004,11.233,0,0,0.38999999,,,,,,,23,32.41,16914985,11.833,16.700001,2.4860001,1.446,1768.153,38.400002,280.995,6.0999999,,,5.8179998,,54.240002,0.398,,08Mar2022,,,,,271031,142452,,4722,2.3900001,1.6,0.83999997,Africa,0,Target not reached,60.59119034,200000,1.1010572,0.62917554,38.457893,26.920525,15.383157,26.159559,26.159559,12.950533
Africa,Sub-Saharan Africa,Togo,TG,TGO,x,,,Developing,Togo,1,Low Income Economies,Sub-Saharan Africa,6442000000,62.883,1000.44,768,8,1.1667,167,0.515,Low human development,768,8278.737,8278737,5948335,11869539,70.16,5948335,5.9,High,0.3,4.5,43,51.1550293,5,0,0,0,20220219,43.52,56.77,54.169998,75,Universal availability,AFRO,REPORTING,2022-03-04,2734547,1549440,33.030998,18.716,1145453,13.836,SII - Covishield,1,10Mar2021,2022-03-08,12,36833,0,272,Africa,36833,444.91199,27,0.32600001,12,272,3.286,0,0,0,2021-01-01,2.90%,50,5,All eligible groups are fully government-funded,36838,4.5710001,272,0,4345.0049,0.58999997,0.53899997,32.082001,0,0,0.57999998,,,,,,,616,43.52,8478242,143.366,19.4,2.839,1.525,1429.813,49.200001,280.03299,6.1500001,0.89999998,14.2,10.475,0.69999999,61.040001,0.51499999,,08Mar2022,,,,,1549440,1145453,,37978,32.25,18.280001,13.51,Africa,0,Target not reached,76.2141571,445000,0.80324656,0.45899805,22.441586,15.70911,8.976634,45.971638,45.971638,7.4810848
Asia,South-eastern Asia,Thailand,TH,THA,,,,Developing,Thailand,0,Upper Middle Income Economies,East Asia and Pacific,536841000000,58.043,7808.66,764,15,100,79,0.777,High human development,764,69799.978,69799976,136760891,97931182,195.51,113747068,3.8,Medium,0.36,0.2,80,296.1651001,5,0,1888198190,1,20220304,47.220001,55.209999,52.380001,75,Universal availability,SEARO,REPORTING,2022-02-28,123738218,53584958,177.27499,76.768997,49673251,71.165001,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",7,28Feb2021,2022-03-08,18943,3066800,69,23369,South-East Asia,3066800,4393.6982,154453,221.27901,18943,23369,33.48,393,0.56300002,69,2022-01-01,2.50%,97.7,5,All eligible groups are fully government-funded,3088873,22047,23438,59.570999,44157.766,315.54999,315.17801,335.064,0.986,0.852,1.15,,,,,,,996,47.220001,69950844,135.132,40.099998,11.373,6.8899999,16277.671,0.1,109.861,7.04,1.9,38.799999,90.669998,2.0999999,77.150002,0.77700001,3.71,08Mar2022,,,20803580,29.74,53788628,49735847,1063719,846179,177.74001,76.889999,71.099998,Asia,1,Target reached,166.5505066,7560870,0.18538392,0.10593367,6.9825916,4.887814,2.7930367,90.477783,108.78365,5.5285325
Asia,Central Asia,Tajikistan,TJ,TJK,,x,,Developing,Tajikistan,1,Lower Middle Income Economies,Europe and Central Asia,8220000000,49.343,839.18,762,39,71,125,0.668,Medium human development,762,9537.642,9537642,13169794,13649475,135.08,12668663,4.3,Medium,1.44,9.5,68,61.87225342,5,0,0,0,20220224,14.81,21.35,24.4,0,Universal availability,EURO,REPORTING,2022-02-20,9279471,4916961,97.300003,51.553001,4107682,43.068001,"AstraZeneca - Vaxzevria,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",6,24Mar2021,2022-03-08,0,17786,0,125,Europe,17786,186.48199,0,0,0,125,1.311,0,0,0,2021-03-01,3.20%,76.7,5,All eligible groups are fully government-funded,17786,0,125,0,1824.275,0,0,12.821,0,0,0.02,,,,,,,4973,14.81,9749625,64.280998,23.299999,3.4660001,2.155,2896.9131,4.8000002,427.698,7.1100001,,,72.704002,4.8000002,71.099998,0.66799998,0.38,08Mar2022,,,2386,0.02,4916961,4107682,113265,88171,95.18,50.43,42.130001,Asia,1,Target reached,71.28530884,390000,1.1494554,0.65683168,22.271696,15.590187,8.9086781,70.460258,73.247437,2.9613218
Oceania,Polynesia,Tokelau,TK,TKL,,,,Developing,Tokelau,0,Unclassified Economies,Unclassified,,,,,,,,,,772,1.35,1350,,,,,,,,,,,,,,,,,,,,,WPRO,REPORTING,2021-09-28,1936,968,143.407,71.704002,968,71.704002,Pfizer BioNTech - Comirnaty,1,20Jul2021,2022-03-08,0,0,0,0,Western Pacific,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,,,,,,,,,,,,,12427,,1368,,,,,,,,,,,,,81.860001,,,12Oct2021,,,,,968,968,,23,141.52,70.760002,70.760002,Oceania,1,Target reached,,,,,,,,,,
Asia,Central Asia,Turkmenistan,TM,TKM,,x,,Developing,Turkmenistan,0,Upper Middle Income Economies,Europe and Central Asia,53269000000,27.029,8843.87,795,40,60,111,0.715,High human development,795,6031.187,6031187,,,,,3.3,Low,1.85,2.3,70,500.0064392,5,0,0,0,20220208,69.440002,54.169998,61.900002,0,Universal availability,EURO,REPORTING,2021-08-29,7580976,4374694,125.7,72.535004,3206282,53.161999,"Anhui ZL - Recombinant,AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,RIBSP - QazVac,SRCVB - EpiVacCorona",6,24Feb2021,2022-03-08,0,0,0,0,Europe,0,0,0,0,0,0,0,0,0,0,,,,5,All eligible groups are fully government-funded,,,,,,,,,,,,,,,,,,6762,62.5,6117933,12.253,26.9,4.277,2.5409999,16389.023,,536.78302,7.1100001,,,100,7.4000001,68.190002,0.71499997,,29Aug2021,,,,,4374694,3206282,,41369,123.91,71.510002,52.41,Asia,1,Target reached,131.5803833,,0.163684,0.09353371,4.1359468,2.8951628,1.6543787,,,
Asia,South-eastern Asia,Timor-Leste,TL,TLS,x,,x,Developing,Timor,1,Lower Middle Income Economies,East Asia and Pacific,1711000000,16.461,1262.72,626,-8.55,125.5167,141,0.606,Medium human development,626,1318.442,1318442,1462002,1881425,108.79,1431630,5.5,High,0.36,0.7,52,92.67004395,5,15500000,0,0,20220221,36.110001,37.5,42.860001,0,Universal availability,SEARO,REPORTING,2022-03-01,1265017,679946,95.947998,51.571999,573462,43.494999,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",4,07Apr2021,2022-03-08,6,22768,0,129,South-East Asia,22768,1726.8831,52,3.944,6,129,9.7840004,1,0.075999998,0,2022-01-01,26.70%,80.2,5,All eligible groups are fully government-funded,22768,10.714,129,0.14300001,16942.053,4.4650002,7.973,95.990997,0,0.106,0.5,,,,,,,638,36.110001,1343875,87.176003,18,3.556,1.897,6570.1021,30.299999,335.34601,6.8600001,6.3000002,78.099998,28.177999,5.9000001,69.5,0.60600001,,08Mar2022,,,,,679946,573462,7881,11248,94.129997,50.599998,42.669998,Asia,1,Target reached,61.60822296,312000,0.76390648,0.43651798,14.869962,10.408973,5.9479847,86.526352,88.362007,21.340601
Oceania,Polynesia,Tonga,TO,TON,,,x,Developing,Tonga,1,Upper Middle Income Economies,East Asia and Pacific,495000000,45.58,5009.78,776,-20,-175,104,0.725,High human development,776,105.697,105697,160300,147976,151.66,157383,4,Medium,,,58,242.3727722,5,0,0,0,20220306,79.169998,65.620003,75,0,Universal availability,WPRO,REPORTING,2022-02-18,157483,75868,148.998,71.779999,69092,65.369003,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty",2,14Apr2021,2022-03-08,57,1059,0,0,Western Pacific,1059,1001.94,704,666.06702,57,0,0,0,0,0,,,,5,All eligible groups are fully government-funded,1059,100.571,,,9919.5381,1508.0699,942.04199,,,,,,,,,,,2988,79.169998,106759,150.028,22.299999,5.8200002,4.0320001,5425.6211,,227.49001,15.42,11.8,44.400002,,2.5999999,70.910004,0.72500002,,08Mar2022,,,,,76910,70283,,2026,137.87,72.040001,65.830002,Oceania,1,Target reached,77.46419525,50600,0.28895479,0.16511703,8.5323114,5.9726181,3.4129245,98.242668,100.06354,31.565815
Americas,Latin America and the Caribbean,Trinidad and Tobago,TT,TTO,,,x,Developing,Trinidad and Tobago,0,High Income Economies,Latin America and the Caribben,23441000000,70.429,15352.72,780,11,-61,67,0.796,High human development,780,1399.491,1399491,2313041,1964724,164.82,2313041,3.8,Medium,,,74,1167.933105,5,0,0,0,20220220,50.93,55.209999,59.52,25,Universal availability,AMRO,REPORTING,2022-02-25,1520535,740765,108.649,52.931,701881,50.153,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty,SII - Covishield",5,17Feb2021,2022-03-08,0,130400,0,3659,Americas,130400,9317.6934,2633,188.14,0,3659,261.453,31,2.2149999,0,2021-01-01,13.10%,59.8,5,All eligible groups are fully government-funded,130964,402.71399,3667,5,93320.813,307.82999,286.961,2612.988,1.425,3.563,0.80000001,,,,,,,472,50.93,1403374,266.88599,36.200001,10.014,5.8189998,28763.07,,228.467,10.97,,,89.443001,3,73.510002,0.796,,08Mar2022,,,138063,9.8400002,742525,704144,22019,17908,108.97,52.91,50.18,North America,1,Target reached,143.4624634,869080,0.1207343,0.068991035,2.2672532,1.5870771,0.90690124,65.737488,65.737488,37.573048
Africa,Northern Africa,Tunisia,TN,TUN,,,,Developing,Tunisia,1,Lower Middle Income Economies,Middle East and North Africa,40624000000,90.199,3555.59,788,34,9,95,0.74,High human development,788,11818.618,11818618,16713650,16710070,140.03,16713650,3.8,Medium,,,70,233.0593109,4,0,0,0,20220221,43.52,48.75,52.139999,25,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,EMRO,REPORTING,2022-02-27,14629647,8830044,123.785,74.712997,6330350,53.563,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Gamaleya - Gam-Covid-Vac,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",7,13Mar2021,2022-03-08,11090,1016894,16,27959,Eastern Mediterranean,1016894,8604.1689,18664,157.92,11090,27959,236.567,175,1.4809999,16,2022-01-01,2.50%,95.3,5,All eligible groups are fully government-funded,1016894,2666.2859,27959,25,85197.227,929.14001,223.386,2342.4561,1.341,2.095,0.60000002,,,,,,,237,43.52,11935764,74.227997,32.700001,8.0010004,5.0749998,10849.297,2,318.991,8.5200005,1.1,65.800003,78.686996,2.3,76.699997,0.74000001,28.16,08Mar2022,,,1150919,9.6400003,7164186,6336607,428453,167388,109,60.02,53.09,Africa,1,Target reached,87.32427979,4378000,0.27129114,0.1550235,5.9126582,4.1388607,2.3650632,87.531128,87.531128,26.194159
Asia,Western Asia,Turkey,TR,TUR,,,,Developing,Turkey,0,Upper Middle Income Economies,Europe and Central Asia,652408000000,37.769,9406.58,792,39,35,54,0.82,High human development,792,84339.067,84339064,160569188,119059830,188.81,151171963,3.9,Medium,0.11,0,74,396.4668274,5,5000000,0,0,20220307,26.85,28.120001,32.139999,0,Universal availability,EURO,OWID,2022-02-23,144850157,57623451,171.7,69.295998,52715583,63.394001,"Pfizer BioNTech - Comirnaty, Sinovac - CoronaVac, Turkovac",3,,2022-03-08,34343,14387340,132,95681,Europe,14387340,17058.928,298775,354.255,34343,95681,113.448,1236,1.466,132,2022-01-01,2.50%,92,5,All eligible groups are fully government-funded,14425638,39471,95811,166.14301,169628.11,439.86099,464.13101,1126.6219,1.529,1.954,0.63999999,,,,,,,700,26.85,85042736,104.914,31.6,8.1529999,5.0609999,25129.342,0.2,171.285,12.13,14.1,41.099998,,2.8099999,77.690002,0.81999999,,08Mar2022,,,35464345,41.700001,57717026,52866807,1796891,1264431,171.74001,67.870003,62.16,Asia,1,Target reached,141.1055298,,0.15389228,0.087938443,5.216073,3.6512513,2.0864294,90.210434,95.818138,
Oceania,Polynesia,Tuvalu,TV,TUV,x,,x,Developing,Tuvalu,1,Upper Middle Income Economies,East Asia and Pacific,48000000,6.046,6004.1,,,,,,,798,11.792,11792,23000,16509,195.05,23000,5.1,High,,,,972.6124268,,,,,,,,,,,WPRO,REPORTING,2021-10-22,12114,6230,102.731,52.832001,5884,49.897999,AstraZeneca - Vaxzevria,1,13Apr2021,2022-03-08,0,0,0,0,Western Pacific,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,,,,,,,,,,,,,2516,,11925,373.06699,,,,3575.104,3.3,,27.25,,,,,67.57,,,22Oct2021,,,,,6230,5884,,240,101.58,52.240002,49.34,Oceania,1,Target reached,99.7903595,7000,0.24110192,0.13777252,2.1262324,1.4883627,0.85049295,52.669567,52.669567,30.434782
,,,,TWN,,,,,Taiwan,0,High Income Economies,East Asia and Pacific,682702000000,27.224,33401.71,,,,,,,158,23816.775,23816776,,,,,,,,,,,5,-0.18,1733514,1,20220226,27.780001,51.560001,48.209999,75,Universal availability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2022-01-01,2.50%,96.8,5,All eligible groups are fully government-funded,20922,55.570999,853,0,877.04901,2.2219999,2.3299999,35.757999,0,0,0.99000001,,,,,,,5511,27.780001,23855008,,42.200001,,8.3529997,,,103.957,,,,,,80.459999,,-0.38999999,08Mar2022,,,10661825,44.689999,19375913,18031096,500423,585216,201.5,81.220001,75.589996,Asia,1,Target reached,157.3462067,22386100,0.055494163,0.031710953,,,,,,
Africa,Sub-Saharan Africa,United Republic of Tanzania,TZ,TZA,x,,,Developing,Tanzania,1,Lower Middle Income Economies,Sub-Saharan Africa,67622000000,39.688,1159.19,834,-6,35,163,0.529,Low human development,834,59734.213,59734212,8019396,86097813,13.04,8019396,5.6,High,1.54,10.7,43,40.34330368,5,0,0,0,20220228,13.89,28.120001,25,50,Universal availability,AFRO,REPORTING,2022-02-23,4440797,3223953,7.434,5.3969998,2493984,4.1750002,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty",3,28Jul2021,2022-03-08,0,33620,0,798,Africa,33620,56.283001,0,0,0,798,1.336,0,0,0,2022-01-01,3.20%,75.3,5,All eligible groups are fully government-funded,33620,0,798,0,546.68103,0,0,12.976,0,0,0.46000001,,,,,,,598,13.89,61498438,64.698997,17.700001,3.108,1.874,2683.304,49.099998,217.28799,5.75,3.3,26.700001,47.952999,0.69999999,65.459999,0.52899998,,08Mar2022,,,,,3223953,2493984,,36789,7.2199998,5.2399998,4.0599999,Africa,0,Target not reached,41.21954346,1500000,0.83213276,0.47550446,34.156845,23.909792,13.662738,55.375706,55.375706,18.704651
Africa,Sub-Saharan Africa,Uganda,UG,UGA,x,x,,Developing,Uganda,1,Low Income Economies,Sub-Saharan Africa,41241000000,49.077,1018.44,800,1,32,159,0.544,Low human development,800,45741,45741000,36610274,65972946,77.69,36610274,6.1,High,1.29,20.9,45,32.40844345,5,0,5000000,1,20220307,43.52,46.349998,49.400002,25,Universal availability,AFRO,REPORTING,2022-02-28,16672943,13809794,36.451,30.191,7679657,16.789,"Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",5,10Mar2021,2022-03-08,0,163383,0,3588,Africa,163383,357.19199,15,0.033,0,3588,7.8439999,0,0,0,2022-01-01,11.00%,78.6,5,All eligible groups are fully government-funded,163416,10.571,3592,0.57099998,3467.821,0.29699999,0.22400001,76.224998,0,0.012,0.56999999,,,,,,,1269,43.52,47123533,213.759,16.4,2.168,1.308,1697.707,41.599998,213.33299,2.5,3.4000001,16.700001,21.222,0.5,63.369999,0.54400003,,08Mar2022,,,,,13809794,7679657,134275,294514,35.380001,29.309999,16.299999,Africa,0,Target not reached,63.42195129,1589400,0.78904992,0.45088565,35.422867,24.796007,14.169147,45.541706,45.541706,4.3414044
Europe,Eastern Europe,Ukraine,UA,UKR,,,,Developed,Ukraine,1,Lower Middle Income Economies,Europe and Central Asia,149537000000,54.391,4384.24,804,49,32,74,0.779,High human development,804,43733.759,43733760,46609475,60853551,107.23,46205233,4,Medium,,,68,248.1334839,5,0,233711205,1,20220214,75,68.75,71.43,50,Universal availability,EURO,REPORTING,2022-02-20,31455954,15718610,71.900002,35.942001,15062320,34.441002,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",6,24Feb2021,2022-03-08,4332,4879339,60,106739,Europe,4879339,11156.917,37196,85.051003,4332,106739,244.065,610,1.395,60,2022-01-01,2.50%,82.8,5,All eligible groups are fully government-funded,5040518,0,112459,0,115962.42,0,0,2587.238,0,0,-0.1,,,,,,,1201,75,43466822,77.389999,41.400002,16.462,11.133,7894.3931,0.1,539.849,7.1100001,13.5,47.400002,,8.8000002,72.059998,0.77899998,29.08,08Mar2022,,,752581,1.73,15729617,15221792,317209,255007,72.889999,36.189999,35.02,Europe,0,Target not reached,152.7536926,3342200,0.22001533,0.12572305,5.5534625,3.8874238,2.221385,67.488327,68.078766,7.1706452
Oceania,Micronesia,United States Minor Outlying Islands,UM,UMI,,,,Developing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Americas,Latin America and the Caribbean,Uruguay,UY,URY,,,,Developing,Uruguay,0,High Income Economies,Latin America and the Caribben,57742000000,67.471,16965.08,858,-33,-56,55,0.817,High human development,858,3473.727,3473727,6957757,4879213,199.64,6872022,3.2,Low,,,80,1660.952881,5,0,2500000,1,20220307,20.370001,27.6,29.76,12.5,Universal availability,AMRO,REPORTING,2022-02-25,7612199,2964083,219.136,85.329002,2728709,78.553001,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty,Sinovac - CoronaVac",3,27Feb2021,2022-03-08,1205,854375,6,7046,Americas,854375,24595.32,13864,399.10999,1205,7046,202.83701,69,1.9859999,6,2022-01-01,2.50%,94.8,5,All eligible groups are fully government-funded,857635,1890.714,7059,9.7139997,246082.53,502.70401,542.50598,2025.45,2.2950001,2.7869999,0.55000001,,,,,,,2283,20.370001,3485152,19.750999,35.599998,14.655,10.361,20551.408,0.1,160.70799,6.9299998,14,19.9,,2.8,77.910004,0.81699997,3.1800001,08Mar2022,,,1925982,55.259998,2964816,2731639,63763,49489,218.71001,85.07,78.379997,South America,1,Target reached,99.35842133,500000,0.10925972,0.062434129,1.5942656,1.1159859,0.63770622,109.40594,110.77087,7.186224
Americas,Northern America,United States of America,US,USA,,,,Developed,United States,0,High Income Economies,North America,21921600000000,133.284,69375.38,840,38,-97,17,0.926,High human development,840,331002.647,331002656,688202045,466081104,206.72,676649888,2.5,Low,,,84,10921.0127,5,2170950000,16179000000,1,20220208,39.810001,43.23,49.400002,0,Universal availability,AMRO,REPORTING,2022-02-25,537567013,253157102,162.40601,76.482002,210172612,63.495998,"Janssen - Ad26.COV 2-S,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",3,14Dec2020,2022-03-08,5937,78545019,94,951348,Americas,78545019,23729.424,332439,100.434,5937,951348,287.414,10236,3.092,94,2021-08-01,2.50%,71,5,All eligible groups are fully government-funded,79369007,39663.715,961843,1345.714,238406.17,89.527,119.141,2889.1541,4.6020002,4.0419998,0.61000001,5932,17.818001,28851,86.662003,,,426,58.799999,332915074,35.608002,38.299999,15.413,9.7320004,54225.445,1.2,151.089,10.79,19.1,24.6,,2.77,78.860001,0.926,19.780001,08Mar2022,27165,81.597,95120699,28.65,254132442,215398091,4546922,3503102,167.25999,76.540001,64.879997,North America,1,Target reached,232.792099,,0.026718412,0.015267665,0.24246836,0.16972785,0.096987344,78.111801,79.445374,
Asia,Central Asia,Uzbekistan,UZ,UZB,,x,,Developing,Uzbekistan,1,Lower Middle Income Economies,Europe and Central Asia,63303000000,38.876,1901.49,860,41,64,106,0.72,High human development,860,33469.199,33469200,47004426,47510071,138.51,46766877,4.1,Medium,0.51,1.7,73,98.57316589,5,0,410000,1,20220301,45.369999,52.080002,48.810001,75,Universal availability,EURO,REPORTING,2022-02-20,42121870,18446210,125.9,55.113998,13160671,39.321999,"Anhui ZL - Recombinant,Gamaleya - Gam-Covid-Vac,Gamaleya - Sputnik-Light,Moderna - Spikevax,Pfizer BioNTech - Comirnaty,SII - Covishield,Sinovac - CoronaVac",7,28Apr2021,2022-03-08,27,236994,0,1637,Europe,236994,708.09601,493,1.473,27,1637,4.8909998,1,0.003,0,2022-01-01,2.50%,77.3,4,"Partial government funding for some eligible groups, full funding for others",236994,70.429001,1637,0.14300001,6983.606,0.796,2.075,48.237999,0,0.0040000002,0.47,,,,,,,2385,45.369999,33935765,76.134003,28.200001,4.4689999,2.8729999,6253.104,,724.41699,7.5700002,1.3,24.700001,,4,71.720001,0.72000003,-16.459999,08Mar2022,,,,,18446210,13160671,720866,426314,124.12,54.360001,38.779999,Asia,0,Target not reached,93.78102112,502000,0.50728637,0.28987795,13.979464,9.7856245,5.5917854,89.612564,90.067741,1.0679846
Europe,Southern Europe,Holy See,VA,VAT,,,,Developed,Vatican,0,High Income Economies,Unclassified,,,,,,,,,,336,0.809,809,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2022-03-08,0,26,0,0,Europe,26,3213.844,0,0,0,0,0,0,0,0,,,,,,29,0,,,35714.285,0,0,,,,,,,,,,,,,812,,,,,,,,,,,,,75.120003,,,08Mar2022,,,,,,,,,,,,Europe,,Not available,,,,,,,,,,
Americas,Latin America and the Caribbean,Saint Vincent and the Grenadines,VC,VCT,,,x,Developing,Saint Vincent and the Grenadines,1,Upper Middle Income Economies,Latin America and the Caribben,819000000,101.002,6952.24,670,13.25,-61.2,97,0.738,High human development,670,110.947,110947,235901,155777,212.01,235901,4.1,Medium,7.05,3.2,71,354.8086548,,,,,,,,,,,AMRO,REPORTING,2022-02-25,67378,35207,60.734001,31.735001,29118,26.247,"AstraZeneca - Vaxzevria,Gamaleya - Gam-Covid-Vac,Gamaleya - Sputnik-Light,Pfizer BioNTech - Comirnaty,SII - Covishield",5,01Feb2021,2022-03-08,1,8321,0,106,Americas,8321,7500.4512,10,9.0139999,1,106,95.546997,0,0,0,2021-03-01,18.10%,35.8,,,8321,1.429,106,0,74782.734,8.9870005,12.839,952.646,0,0,0.40000001,,,,,,,827,,111269,281.78699,31.799999,7.724,4.8319998,10727.146,,252.675,11.62,,,,2.5999999,72.529999,0.73799998,,08Mar2022,,,3234,2.9100001,35411,29403,4258,889,61.16,31.82,26.43,North America,0,Target not reached,110.5339279,120100,0.20822066,0.11898323,5.8284936,4.0799456,2.3313975,28.561981,28.561981,50.911186
Americas,Latin America and the Caribbean,Venezuela (Bolivarian Republic of),VE,VEN,,,,Developing,Venezuela,0,Upper Middle Income Economies,Latin America and the Caribben,43749000000,,1627.35,862,8,-66,113,0.711,High human development,862,28435.943,28435944,41648007,40186926,145.09,40273042,4.4,Medium,0.5,0.4,74,338.8253784,5,0,200000000,1,20220307,28.700001,31.25,35.709999,0,Universal availability,AMRO,REPORTING,2022-02-25,37860994,22157232,133.145,77.919998,14287370,50.243999,"Beijing CNBG - BBIBP-CorV,CIGB - CIGB-66,Finlay - Soberana-02,Gamaleya - Gam-Covid-Vac,Gamaleya - Sputnik-Light,Sinovac - CoronaVac",6,22Feb2021,2022-03-08,581,516817,4,5649,Americas,516817,1817.478,2022,7.1110001,581,5649,19.865999,16,0.056000002,4,2022-01-01,2.50%,94.5,5,All eligible groups are fully government-funded,516966,263.14301,5650,2,18009.648,5.191,9.1669998,196.83,0.035,0.07,0.64999998,,,,,,,0,28.700001,28704947,36.252998,29,6.6139998,3.915,16745.021,,204.85001,6.4699998,,,,0.80000001,72.059998,0.71100003,,08Mar2022,,,410887,1.4299999,22157232,14287370,,466473,131.89999,77.190002,49.77,South America,1,Target reached,77.18959045,500000,0.88954437,0.50831103,6.1034389,4.2724071,2.4413755,90.907097,94.010765,1.2005377
Americas,Latin America and the Caribbean,British Virgin Islands,VG,VGB,,,x,Developing,British Virgin Islands,0,High Income Economies,Latin America and the Caribben,,,,,,,,,,92,30.237,30237,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,36610,18923,121.077,62.582001,17325,57.297001,"AstraZeneca - Vaxzevria,Janssen - Ad26.COV 2-S",2,11Feb2021,2022-03-08,0,6091,0,62,Americas,6091,20144.193,6,19.843,0,62,205.047,0,0,0,,,,,,6091,0.85699999,62,0,200210.36,0,28.174,2037.932,0,0,,,,,,,,197,,30423,207.97301,,,,,,,13.67,,,,,79.07,,,08Mar2022,,,,,18923,17325,,343,120.34,62.200001,56.950001,North America,1,Target reached,,,,,,,,,,
Americas,Latin America and the Caribbean,United States Virgin Islands,VI,VIR,,,x,Developing,United States Virgin Islands,0,High Income Economies,Latin America and the Caribben,,,,,,,,,,850,104.423,104423,,,,,,,,,,,5,0,0,0,20220228,38.889999,56.25,57.139999,50,Universal availability,,,,,,,,,,,,,2022-03-08,0,15426,0,109,Americas,15426,14772.325,31,29.686001,0,109,104.381,0,0,0,,,,5,All eligible groups are fully government-funded,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Asia,South-eastern Asia,Viet Nam,VN,VNM,,,,Developing,Vietnam,1,Lower Middle Income Economies,East Asia and Pacific,369494000000,47.904,3742.86,704,16,106,117,0.704,High human development,704,97338.583,97338584,215294056,137436361,219.31,179256288,3.8,Medium,0.28,0.4,75,180.7181854,5,400050,53966,1,20220307,66.669998,64.059998,73.209999,0,Universal availability,WPRO,REPORTING,2022-02-24,192865986,79469390,198.13901,81.641998,75322542,77.382004,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,CIGB - CIGB-66,Gamaleya - Gam-Covid-Vac,Moderna - Spikevax,Pfizer BioNTech - Comirnaty",6,08Mar2021,2022-03-08,147358,4582058,78,40891,Western Pacific,4582058,4707.3398,1138573,1169.704,147358,40891,42.008999,639,0.65600002,78,2022-01-01,2.50%,99.3,5,All eligible groups are fully government-funded,4776873,174177.72,40977,91.286003,48659.773,1984.489,1774.267,417.414,0.87599999,0.93000001,1.7,,,,,,,6236,66.669998,98168829,308.12701,32.599998,7.1500001,4.7179999,6171.8838,2,245.465,6,1,45.900002,85.847,2.5999999,75.400002,0.704,,08Mar2022,,,40851505,41.610001,79603926,77454922,2091069,1675471,201.60001,81.089996,78.900002,Asia,1,Target reached,148.0363159,16767560,0.25771737,0.14726706,7.6251321,5.3375921,3.0500526,89.582588,107.59232,7.7882133
Oceania,Melanesia,Vanuatu,VU,VUT,,,x,Developing,Vanuatu,1,Lower Middle Income Economies,East Asia and Pacific,912000000,46.074,3235.21,548,-16,167,140,0.609,Medium human development,548,307.15,307150,325942,440250,103.65,325942,5.3,High,,,48,104.2496109,5,0,0,0,20220306,22.219999,27.08,30.950001,0,Universal availability,WPRO,REPORTING,2022-02-20,197335,114284,64.248001,37.208,85180,27.733,"AstraZeneca - Vaxzevria,Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S",3,02Jun2021,2022-03-08,30,49,0,0,Western Pacific,49,15.953,31,10.093,30,0,0,0,0,0,,,,5,All eligible groups are fully government-funded,52,4.8569999,1,0,165.36099,31.799999,15.446,3.1800001,0,0,,,,,,,,4691,22.219999,314464,22.662001,23.1,4.3940001,2.6199999,2921.9089,13.2,546.29999,12.02,2.8,34.5,25.209,,70.470001,0.60900003,,08Mar2022,,,,,114284,85180,,1977,63.43,36.34,27.09,Oceania,0,Target not reached,76.57015991,230000,0.29815686,0.17037533,13.218275,9.2527924,5.2873101,60.54298,60.54298,70.564705
,,West Bank and Gaza,,WBG,,,,,,,,,,44.74,3320.85,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Oceania,Polynesia,Wallis and Futuna Islands,WF,WLF,,,,Developing,Wallis and Futuna,0,Unclassified Economies,Unclassified,,,,,,,,,,876,11.246,11246,,,,,,,,,,,,,,,,,,,,,WPRO,REPORTING,2022-02-18,15633,6450,139.009,57.354,6399,56.900002,Moderna - Spikevax,1,19Mar2021,2022-03-08,0,453,0,7,Western Pacific,453,4028.0991,0,0,0,7,62.243999,0,0,0,,,,,,454,0,7,0,40923.02,0,0,630.97198,0,0,,,,,,,,1262,,11094,,,,,,,,,,,,,79.940002,,,08Mar2022,,,,,6450,6399,,343,115.82,58.139999,57.68,Oceania,1,Target reached,,,,,,,,,,
Oceania,Polynesia,Samoa,WS,WSM,,,x,Developing,Samoa,1,Lower Middle Income Economies,East Asia and Pacific,830000000,47.621,3906.41,882,-13.5833,-172.3333,111,0.715,High human development,882,198.41,198410,303899,280202,151.84,290889,3.4,Low,,,58,271.9157715,,,,,,,,,,,WPRO,REPORTING,2022-02-16,276278,145989,139.243,73.578003,130289,65.665001,"AstraZeneca - Vaxzevria,Pfizer BioNTech - Comirnaty",2,18Apr2021,2022-03-08,8,41,0,0,Western Pacific,41,20.664,8,4.0320001,8,0,0,0,0,0,,,,,,41,1.143,,,204.853,0,5.71,,,,,,,,,,,600,,200144,69.413002,22,5.6059999,3.5639999,6021.5571,,348.97699,9.21,16.700001,38.099998,,,73.32,0.71499997,,08Mar2022,,,,,145989,130289,,3269,138.03999,72.940002,65.099998,Oceania,1,Target reached,75.92183685,50000,0.24692748,0.14110142,5.0677457,3.5474219,2.0270984,90.911125,94.977119,16.452835
,,Bonaire,,XAA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,33014,17366,157.84801,83.030998,15648,74.817001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,Sint Eustatius,,XBA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,3110,1588,99.075996,50.589001,1522,48.487,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,Saba,,XCA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AMRO,REPORTING,2022-02-25,3148,1582,162.856,81.842003,1566,81.014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,Kosovo (as per UNSCR 1244)',,XKX,,,,,,1,,,,25.77,4986.26,,,,,,,,,,,,,,,,,,,,5,0,0,0,20220221,66.669998,52.599998,60.119999,0,Universal availability,EURO,REPORTING,2022-02-20,1808756,899560,100.7,50.096001,813185,45.285999,"AstraZeneca - AZD1222, Pfizer BioNTech - Comirnaty",2,,2022-03-08,23,226605,1,3109,Europe,226605,12619.552,400,22.275999,23,3109,173.13901,5,0.278,1,2020-12-01,4.20%,32,5,All eligible groups are fully government-funded,226680,53,3120,0.71399999,127197.18,17.955999,29.74,1750.729,0.56099999,0.40099999,0.31,,,,,,,244,66.669998,1782115,168.155,,,,9795.834,0.60000002,,,,,,,,,8.6899996,08Mar2022,,,98304,5.52,900417,817608,22668,19287,101.92,50.529999,45.880001,Europe,1,Target reached,93.65599823,187580,,,,,,,,
Asia,Western Asia,Yemen,YE,YEM,x,,,Developing,Yemen,1,Low Income Economies,Middle East and North Africa,19056000000,73.482,585.003,887,15,48,179,0.47,Low human development,887,29825.968,29825968,2277651,42686895,7.47,2277651,6.4,High,0.64,,42,,3,0,0,0,20220307,12.04,14.17,16.190001,0,Availability for ALL of following: key workers/ clinically vulnerable groups (non elderly)/elderly groups,EMRO,REPORTING,2022-03-06,784792,624837,2.631,2.095,384655,1.29,"Janssen - Ad26.COV 2-S,SII - Covishield,Sinovac - CoronaVac",3,20Apr2021,2022-03-08,4,11781,0,2138,Eastern Mediterranean,11781,39.499001,10,0.034000002,4,2138,7.1680002,3,0.0099999998,0,2022-01-01,3.00%,61.3,,No availability,11781,1.429,2138,0.42899999,386.38101,0,0.046999998,70.120003,0,0.014,0.40000001,,,,,,,24,12.04,30490639,53.507999,20.299999,2.9219999,1.5829999,1479.147,18.799999,495.00299,5.3499999,7.5999999,29.200001,49.542,0.69999999,66.120003,0.47,,08Mar2022,,,,,624837,384655,,10240,2.5699999,2.05,1.26,Asia,0,Target not reached,60.00000381,,1.3736682,0.78495324,,,,34.4562,34.4562,
Africa,Sub-Saharan Africa,South Africa,ZA,ZAF,,,,Developing,South Africa,0,Upper Middle Income Economies,Sub-Saharan Africa,317191000000,68.828,6861.17,710,-29,24,114,0.709,High human development,710,59308.69,59308688,31347926,84058794,52.21,31347926,4.7,Medium,0.47,0.2,69,546.6884155,5,0,0,0,20220228,37.959999,51.040001,51.189999,50,Universal availability,AFRO,REPORTING,2022-03-06,32027146,21107042,54.000999,35.588001,18003550,30.356001,"Janssen - Ad26.COV 2-S,Pfizer BioNTech - Comirnaty",2,17Feb2021,2022-03-08,801,3685120,66,99609,Africa,3685120,6213.457,11078,18.679001,801,99609,167.95,197,0.33199999,66,2022-01-01,2.50%,84.8,5,All eligible groups are fully government-funded,3686556,1552.1429,99625,27.857,61399.625,23.917,25.851,1659.255,0.266,0.46399999,0.81,,,,,,,1381,37.959999,60041996,46.754002,27.299999,5.3439999,3.053,12294.876,18.9,200.38,5.52,8.1000004,33.200001,43.993,2.3199999,64.129997,0.70899999,7.8699999,08Mar2022,708,11.792,1417569,2.3599999,20529787,17423434,484564,241230,53.509998,34.189999,29.02,Africa,0,Target not reached,58.51730347,,0.21098442,0.12056253,3.7827764,2.6479435,1.5131105,102.16672,102.16672,
Africa,Sub-Saharan Africa,Zambia,ZM,ZMB,x,x,,Developing,Zambia,1,Lower Middle Income Economies,Sub-Saharan Africa,19564000000,101.011,1115.27,894,-15,30,146,0.584,Medium human development,894,18383.956,18383956,6357340,26488920,33.6,6357340,6.1,High,0.44,1.6,53,69.32437897,4,24000000,0,0,20220214,27.780001,36.25,36.07,37.5,Availability for key workers/ clinically vulnerable groups (non elderly) / elderly groups plus partial additional availability,AFRO,REPORTING,2022-03-03,2858338,2510296,15.548,13.655,1883799,10.247,"Beijing CNBG - BBIBP-CorV,Janssen - Ad26.COV 2-S,SII - Covishield",3,14Apr2021,2022-03-08,89,313910,0,3959,Africa,313910,1707.522,1160,6.3099999,89,3959,21.535,7,0.037999999,0,2022-01-01,13.00%,86.4,5,All eligible groups are fully government-funded,314159,169.85699,3959,0.85699999,16604.021,13.16,8.9770002,209.242,0,0.045000002,0.77999997,,,,,,,1643,27.780001,18920657,22.995001,17.700001,2.48,1.5420001,3689.251,57.5,234.49899,3.9400001,3.0999999,24.700001,13.938,2,63.889999,0.58399999,,08Mar2022,,,33684,0.18000001,2510296,1983053,50201,36338,16,13.27,10.48,Africa,0,Target not reached,54.66651154,550000,0.86490268,0.49423009,19.877567,13.914297,7.9510269,44.961227,44.961227,8.6514168
Africa,Sub-Saharan Africa,Zimbabwe,ZW,ZWE,,x,,Developing,Zimbabwe,1,Lower Middle Income Economies,Sub-Saharan Africa,7997000000,54.013,1664.76,716,-20,30,150,0.571,Medium human development,716,14862.927,14862927,22398292,21129039,148.41,22398292,5.3,High,0.72,1.9,54,103.0282722,5,3800000,100000001.1,1,20220228,50,52.599998,60.119999,0,Universal availability,AFRO,REPORTING,2022-03-04,7904719,4368633,53.183998,29.393,3403501,22.899,"Beijing CNBG - BBIBP-CorV,Bharat - Covaxin,Gamaleya - Gam-Covid-Vac,Sinovac - CoronaVac",4,18Feb2021,2022-03-08,501,239710,0,5399,Africa,239710,1612.8051,3330,22.405001,501,5399,36.325001,4,0.027000001,0,2022-01-01,8.80%,83.2,5,All eligible groups are fully government-funded,240343,496,5400,0.71399999,15925.012,41.942001,32.865002,357.80099,0.066,0.046999998,1.48,,,,,,,496,50,15092171,42.729,19.6,2.822,1.882,1899.775,21.4,307.84601,1.8200001,1.6,30.700001,36.791,1.7,61.490002,0.57099998,,08Mar2022,,,150894,1,4379875,3412556,180005,75000,52.630001,29.02,22.610001,Africa,0,Target not reached,133.0066223,2040000,0.57942283,0.33109877,13.374969,9.3624783,5.349988,35.291615,35.291615,9.1078377